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ABSTRACT 
Pain signaling involves transmission of nociceptive stimuli in the spinal cord 
where a critical balance between excitatory and inhibitory inputs determines the response 
to noxious stimuli. The neuropeptide, substance P (SP), mediates transmission of pain in 
part by binding to the tachykinin receptor (NK-1R) in the dorsal horn (DH) of the spinal 
cord. One of SP’s downstream effects is to modulate N-type Ca2+ (N-) channels. While 
phospholipid breakdown is a part of the inflammatory process that accompanies tissue 
damage, the role of this metabolic pathway has not been completely described with 
respect to N-channel modulation during pain signaling. Despite the incomplete 
understanding of this modulation, pharmacological antagonists of both NK-1R and N-
channels have been used to treat pain.  
In Chapter II, using whole-cell patch clamp recording techniques, the SP 
signaling cascade that mediates inhibition of recombinant N-channel activity was 
characterized. By adopting a pharmacological approach, I show that this pathway 
resembles the slow pathway that was earlier described for modulation of N-current by the 
M1 muscarinic receptor (M1R). M1R couples to Gq to stimulate phospholipid breakdown. 
Together with previous observations, the data presented in this chapter provide evidence 
for involvement of the extracellular receptor kinase (ERK1/2), phospholipase A2 and 
release of phospholipid metabolites in the modulation of N-current by SP. Overall, this 
chapter shows that phospholipid metabolism involved in modulation of N-currents is not 
specific to M1Rs but that other Gq-coupled receptors may also modulate N-currents via 
the same signal transduction pathway. 
 v
In Chapter III, enhancement of N-current by SP was studied as part of a 
collaborative project to understand current enhancement that occurs when a palmitoylated 
accessory CaVβ2a subunit is co-expressed with the pore-forming subunit CaV2.2 and the 
accessory subunit α2δ-1.  When CaVβ3 is present, SP inhibits N-current as described in 
Chapter II. However, when palmitoylated CaVβ2a is co-expressed with CaV2.2 (and α2δ-
1), current enhancement is observed at negative test potentials, demonstrating that both 
M1Rs and NK-1Rs exhibit the same profile of N-current modulation. This change in 
modulation by muscarinic agonists is not observed in the presence of a depalmitoylated 
CaVβ2a. However a chimeric CaVβ2aβ1b subunit that contains the palmitoylated N-
terminus from CaVβ2a confers enhancement. Normally expression of the β1b subunit 
resulted in current inhibition. These findings indicated that the palmitoylated CaVβ2a 
participates in enhancement of current. Our data support a model where inhibition 
dominates over enhancement; when inhibition is blocked, enhancement may be observed. 
Lastly, we show that N-current inhibition by SP is minimized when exogenous palmitic 
acid is applied to cells co-expressing CaVβ3 subunits with N-channels. These results 
indicate that the presence of palmitic acid can prevent N-current inhibition when SP is 
applied most likely by interacting with CaV2.2. We propose a model where palmitic acid 
occupies the inhibitory site and serves to antagonize inhibition by a lipid metabolite, 
which is most likely arachidonic acid. The CaVβ2a protein seems to have a role in 
positioning the palmitoyl groups near CaV2.2. This chapter provides a new role for 
protein palmitoylation where the palmitoyl groups of CaVβ2a are both necessary and 
sufficient to block inhibition of another protein: CaV2.2. 
 vi
 In Chapter IV, I probe the role of the relative orientation of CaVβ2a and the pore-
forming subunit of the N-channel in N-current modulation. Evidence is presented that 
shows that not just the presence of a palmitoylated CaVβ2a is necessary, but the relative 
orientation of CaVβ2a to CaV2.2 is critical for blocking inhibition. Using N-channel 
mutants that cause a change in the orientation of CaVβ2a relative to CaV2.2, I show that 
the block of inhibition is disrupted; inhibition by the slow pathway is rescued. These 
findings further support my model that the palmitoyl groups of CaVβ2a normally reside in 
a specific location that overlaps with the slow pathway inhibitory site on CaV2.2. Lastly I 
present data showing that the enhancement of N-current, observed when palmitoylated 
CaVβ2a is present, occurs via the slow pathway. 
 In Chapter V the effect of CaVβ’s orientation on N-channel modulation by the 
dopamine D2 receptor is tested. In this form of modulation, inhibition is rapid and 
voltage-dependent. The signaling pathway is membrane-delimited since Gβγ, released 
after receptor stimulation, directly interacts with the N-channel at a site that overlaps with 
a high affinity binding site for CaVβs. While N-currents are modulated by this pathway, 
the deletion mutants show aberrant membrane-delimited modulation.  The findings in this 
chapter further underscore the importance of proper positioning of CaVβ to CaV2.2 for 
eliciting proper N-current modulation after GPCR stimulation. 
Overall, the data presented in this dissertation provides a mechanistic approach 
into examining modulation of N-current by different GPCRs via two different signaling 
pathways as well as the role CaVβ subunits serve in each modulatory pathway. 
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CHAPTER I: 
 
BACKGROUND 
 
A. Introduction 
One in five people worldwide suffer from pain at any given time (Lewis, 2005). 
The American Pain Foundation estimates that 1 in 4 patients with pain are undertreated. 
In spite of intense research directed towards understanding the mechanisms underlying 
pain and analgesia, much remains unclear. My research aims at understanding the basic 
mechanism by which an ion channel is modulated by a neuropeptide with possible 
implications in pain perception. The N-type calcium channel (N-channel), which when 
pharmacologically blocked, relieves pain and its modulation by the neuropeptide 
substance P (SP) which mediates transmission of pain, are the key players of my thesis. 
During the course of my research, I have found that modulation of N-channel activity not 
only involves physical interactions between the channel and its accessory subunit, but the 
relative orientation between the two interacting subunits is also important for channel 
modulation.  
B. Brief overview of pain perception 
Pain is caused by intense stimuli (thermal, mechanical or chemical) from the 
environment, which generates signals at the site of insult in the periphery and visceral 
 
 2
organs that travel to the brain. These noxious signals are transmitted by small diameter, 
Aδ and C nerve fibres: the Aδ fibres are myelinated whereas the C fibres are 
unmyelinated (Kandel et al., 2000). These primary afferent nociceptive neurons have 
their cell bodies in the dorsal root ganglion (DRG), contain the neuropeptide SP (Lawson, 
2002), and terminate predominantly in laminae I and II of the dorsal horn of the spinal 
cord (Todd, 2002) (Fig 1.1). Thus, the synapse between the DRG and the dorsal horn of 
the spinal cord forms the first synapse in the pain pathway. 
 Pain may be described as chronic, “neuropathic” pain or nociceptive, 
“inflammatory” pain. Chronic pain following traumatic nerve injury or associated with 
diabetes or with neuropathies is characterized by hyperalgesia (increase in the pain 
elicited by a noxious stimulus) (Abdulla et al., 2003). Nociceptive pain is an acute 
response generated by the activation of nociceptors by painful stimuli (Millan, 1999). 
Both types of pain are characterized by hypersensitivity at the site of damage and in 
adjacent normal tissue. Hypersensitivity due to inflammatory pain usually diminishes 
once the disease process is controlled. In contrast, neuropathic pain persists long after the 
initiating event has healed; it is considered a pathological state of the nervous system. 
Stimulation of G-protein coupled receptors (GPCRs) and tyrosine-kinase receptors cause 
parallel activation of numerous intracellular kinases such as protein kinase A, protein 
kinase C and mitogen activated protein kinase (MAPK). These kinases in turn cause 
altered modulation of ion channels ultimately leading to facilitation in excitatory synaptic 
output of dorsal horn neurons (Woolf and Salter, 2000; Abdulla et al., 2003).   
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C. Substance P mediates pain signaling 
SP was the first peptide identified in the mammalian tachykinin family. Originally 
identified in 1931 by Von Euler and Gaddum and later purified (Chang and Leeman, 
1970; Chang et al., 1971), its peptide structure was identified as H-Arg-Pro-Lys-Pro-Gln-
Gln-Phe-Phe-Gly-Leu-Met-NH2 (Carraway and Leeman, 1979). Neurokinin A (NKA) 
and Neurokinin B (NKB) are two additional tachykinin family members that were 
identified more recently (Kangawa et al., 1983; Kimura et al., 1984; Nawa et al., 1984).  
SP and NKA are encoded by the preprotachykinin-A (PPT-A) gene (Almeida et al., 
2004). NKB is the only known sequence encoded by PPT-B. The three tachykinin 
receptors, NK-1R, NK-2R and NK-3R, recognize all three tachykinins, although SP, 
NKA and NKB exhibit preferential binding to NK-1R, NK-2R and NK-3R respectively 
(Mussap et al., 1993). SP serves as the principal neurotransmitter that mediates pain 
signaling. In response to nociceptive stimulation, SP is released from nociceptive DRG 
neurons onto dorsal horn neurons (Fig 1.2) which express NK-1R (Cheunsuang et al., 
2002) as well as N-channels (Yaksh, 2006) .  
 NK-1R has seven transmembrane domains and is Gq-coupled (Macdonald et al., 
1996). It was considered a putative drug target for pain, emesis and wound healing 
because its activation by SP is involved in diverse functions such as transmission of 
painful stimuli, neurogenic inflammation, smooth muscle contraction, secretion and 
activation of the immune system (Ulfers et al., 2002). Activation of NK-1R is associated 
with depression and anxiety; blocking NK-1R, either pharmacologically or by generating 
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knock-out mice, causes behavioral and physiological effects associated with anti-
depressant and anxiolytic behavior (Santarelli et al., 2002). 
D. Voltage-gated calcium channels 
Voltage-gated Ca2+ channels are the fastest Ca2+ signaling proteins (Clapham, 
2007) regulating numerous cellular processes in every organism (Hille, 2001). Ca2+ 
currents were first identified by Paul Fatt and Bernard Katz in crustacean muscle where 
they observed generation of action potentials in Na+-free medium (Fatt and Katz, 1953). 
The first evidence that cells express more than one type of Ca2+ channel came from 
electrophysiological studies on starfish eggs (Hagiwara et al., 1975). Subsequently, 
currents in mammalian sensory neurons were divided into two categories. Carbone and 
Lux first used the term low- and high-voltage activated (LVA and HVA) channels to 
describe these two components (Carbone and Lux, 1984, 1987). The HVA are further 
classified into L-type  for “Long lasting”, N-type for “Non-L and non-T” (Nowycky et 
al., 1985), P-type for “Purkinje cell” (Llinas et al., 1989)/Q-type for “cerebellar granule 
cells” and R-type for channels giving rise to a “Residual” current (Randall and Tsien, 
1995). The T-type calcium channels for “Transient” and “Tiny” were identified as LVA 
since they activated at negative voltages (Nowycky et al., 1985). We now know that at 
least 10 different genes encode Ca2+ channels (Catterall et al., 2005), which are classified 
into three subfamilies, CaV1, CaV2 and CaV3, based on their amino acid sequence 
homologies (Fig 1.3).  
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E. Structure of the α1 subunit 
Initial purification studies and later biochemical analyses identified α1, β, γ and 
α2δ subunits as part of the Ca2+ channel complex (Fig 1.4) (Yang et al., 1993; Catterall et 
al., 2005). The α1 subunit forms the pore of the channel and is found in association with 
auxillary subunits- intracellular β, a disulfide-linked α2δ and a transmembrane γ subunit 
(Catterall, 2000; Arikkath and Campbell, 2003). The α1 subunit CaV1.1 was first cloned 
from rabbit skeletal muscle (Tanabe et al., 1987). Analysis of hydrophobic and 
hydrophilic amino acids suggest that similar to the Na+ channel, the α1 subunit of the 
Ca2+ channel is organized in four internal repeat domains (I-IV) (Noda et al., 1984) that 
are connected by intracellular loops (Fig 1.4). The domains are equivalent to one subunit 
of K+ channels. The intracellular loops or linker regions are targets for phosphorylation as 
well as binding sites for regulatory proteins discussed later.  
Each domain or subunit consists of six hydrophobic transmembrane segments (S1 
- S6). The bacterial K+ channel Kcsa has been crystallized providing insight into the 
organization of how the four subunit regions form the selectivity pore (Doyle et al., 
1998). The membrane-associated loop between segments S5 and S6 consist of four 
highly conserved glutamate residues that form the selectivity filter of the channel. The 
pore region determines ion conductance and selectivity. S6 segments span the membrane 
at an angle in such a way that they are separated from one another at the outer pore 
region, but cross one another as they emerge from the inner membrane leaflet forming the 
helix cross bundle (Doyle et al., 1998).  
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Extensive mutagenesis studies (MacKinnon, 1991) as well as crystal structures of 
a chimeric voltage-gated K+ channel (Long et al., 2005) have provided a general picture 
of how voltage-gated ion channels are topologically organized and suggest what regions 
of the channel give rise to the “gates” for opening and inactivation.  The S4 segment 
consists of positively charged residues that appear to serve as the voltage sensor. S4 
appears to move during depolarization allowing the channel to transition from the closed 
to the open state (Liman et al., 1991; Jiang et al., 2003). The movements of S4 appear 
coupled to flexing of S6. Slow forms of inactivation also involve S6 though are not well 
understood. While few of these details have been confirmed in CaV channels, their 
sequence homology indicates that their biophysical properties arise due to a similar 
structural organization.     
F. Structure of the β subunit 
The CaVβ subunit is a 55 kDa cytosolic accessory subunit of the Ca2+ channel (Fig 
1.4). There are four different CaVβ subunit genes: β1- β4 and alternative splicing gives 
rise to additional variants (Pragnell et al., 1991; Perez-Reyes et al., 1992; Castellano et 
al., 1993a, 1993b; Birnbaumer et al., 1998). All CaVβ subunits are found in the brain 
(Birnbaumer et al., 1998). Among the different β subunits, β2a is uniquely palmitoylated 
on its N-terminus at residues Cys3 and Cys4 (Chien et al., 1996). Palmitoylation occurs 
post-translationally and is achieved by reversible esterification of cysteine-thiol groups 
with a 16-carbon palmitate (Mumby, 1997; Chien et al., 1998). Addition of palmitate 
groups to protein substrates is catalyzed by palmitoyl acyl transferases (Resh, 2006). 
Although palmitoylation of proteins usually serves to influence membrane targeting or 
 
 7
subcellular localization of the modified proteins (Resh, 2006), both palmitoylated as well 
as non-palmitoylated CaVβs show plasma membrane association (Chien et al., 1998). 
Whether palmitoylation serves additional roles involving either the CaVβ2a or the α1 
subunit will be discussed later. 
The amino acid structure of CaVβ subunits contains five domains (D1-D5). The 
N-terminal D1, middle D3 and C-terminal D5 regions are highly variable while D2 and 
D4 are highly conserved (Birnbaumer et al., 1998). The D2 and D4 regions are 
homologous to src homology 3 (SH3) and guanylate kinase (GK)-like motifs 
respectively. These two domains establish a resemblance between CaVβs and the 
membrane-associated guanylate kinase (MAGUK) family of proteins raising the 
possibility that these domains could interact with other proteins, including calcium 
channel α1 subunits. Unlike canonical SH3 domains, CaVβ’s SH3 domain contains a long 
and flexible HOOK region which is also known to mediate protein-protein interactions 
with similar sites on the PSD95 family of proteins. Except for the 13- amino terminal 
residues, this HOOK region is variable in both length and amino acid sequence between 
different CaVβ family members (Chien et al., 1998; Hanlon et al., 1999; Chen et al., 
2004; Opatowsky et al., 2004; Van Petegem et al., 2004). 
CaVβs bind the α1 subunit between domains I and II (I-II linker) at a sequence of 
residues called the α-interacting domain (AID) (Pragnell et al., 1994) thereby masking an 
endoplasmic retention site. This interaction enhances membrane expression of Ca2+ 
channels (Bichet et al., 2000) and was earlier proposed to occur via the amino terminus of 
CaVβ’s D4 domain, referred to as β-interaction domain (BID) (De Waard et al., 1994). 
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However, crystallography studies later showed that the BID is crucial for the association 
of the SH3 with the GK domains, but the AID binds to the CaVβ at a hydrophobic pocket 
in the GK domain near to but distinct from the BID (Chen et al., 2004; Opatowsky et al., 
2004; Van Petegem et al., 2004). A key point here is that the crystallography studies were 
performed using a CaVβ core protein that did not include the N-terminal amino acid 
residues, hence information regarding positioning of the palmitoyl groups is lacking. 
Depending on the CaVβ subunit co-expressed with the channel protein, CaVβ also affects 
the cellular distribution of channels (Brice and Dolphin, 1999) as well as their sensitivity 
to pharmacological antagonists (Hering, 2002). To understand the clinical importance of 
CaVβ subunits in affecting the binding of drugs to channels, it is important to know how 
CaVβ affects the channel’s activity. CaVβ subunits modify the channel’s biophysical 
properties such as channel opening, inactivation and inhibition by Gβγ proteins 
(Birnbaumer et al., 1998). Besides these known functions, the role of CaVβ in modulation 
of CaV2.2 currents via two different pathways will be discussed in Chapters III, IV, and V 
of my thesis. 
G. Structure of the α2δ subunit 
Four known genes that undergo splicing encode α2δ subunits. α2 and δ proteins 
arise from the same gene where the gene product undergoes post-translational proteolytic 
cleavage that separates α2 from the δ subunit. Molecular weight of α2δ subunits varies 
between 160 to 200 kDa. While both α2 and δ are highly glycosylated, α2 is located 
extracellularly and linked by disulfide bonds to the δ subunit located in the plasma 
membrane (Fig 1.4). α2δ-1 subunit is ubiquitously expressed; α2δ-2 and α2δ-3 are found 
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in neurons in the brain and α2δ-4 is found in non-neuronal cells (Klugbauer et al., 2003; 
Davies et al., 2007). All calcium channels have an α2δ co-expressed with them. The α2δ 
subunit increases current amplitude by an undefined mechanism and is a target for 
binding by analgesic drugs such as gabapentin (Davies et al., 2007). 
H. Structure of the γ subunit 
 The γ subunit is a 33 kDa transmembrane subunit. Unlike the other subunits, it 
does not affect membrane expression of channels nor does it affect the structural or 
functional integrity of the channels. This subunit has also been found associated with 
AMPA receptors (Sharp et al., 2001). The status of this protein serving as a calcium 
channel subunit rather than some other, more general function remains unresolved. 
Hence, this subunit was not included in our expression system and will not be further 
discussed. 
I. N-type (CaV2.2) calcium channel 
N-type calcium channels or N-channels belong to the high voltage-activated class 
of calcium channels. N-currents were first identified in chick dorsal root ganglion using 
whole-cell and single-channel recording techniques (Nowycky et al., 1985). N-channels 
are blocked by a toxin, ω-conotoxin GVIA, isolated from the cone shell mollusc Conus 
geographus (McCleskey et al., 1987; Plummer et al., 1989). This pharmacological tool 
aided in cloning N-channels from rat brain tissue and cell lines (Dubel et al., 1992).  
CaV2.2 undergoes alternative splicing in the I-II linker, II-III linker, S3-S4 extracellular 
linker and carboxy terminus giving rise to multiple tissue- and developmentally specific 
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variants. These variants differ in their activation and inactivation kinetics (Lin et al., 
1996; Ghasemzadeh et al., 1999; Lin et al., 1999; Lu and Dunlap, 1999; Pan and 
Lipscombe, 2000; Bell et al., 2004; Lin et al., 2004; Gray et al., 2007). One splice variant 
is associated with pain transmission since it is specifically expressed in nociceptive DRG 
neurons that respond to capsaicin (Bell et al., 2004). Hence N-channel antagonists such as 
ω-conotoxin GV1A and ω-conotoxin-MVIIA have been used therapeutically for pain 
relief (Snutch, 2005). 
 Calcium influx through N-channels regulates closely associated ion channels, 
such as calcium-activated K+ channels (Wisgirda and Dryer, 1994), activates specific 
enzymes (Rittenhouse and Zigmond, 1999), initiates neurotransmitter release from nerve 
endings (Hirning et al., 1988) and triggers gene transcription (Brosenitsch and Katz, 
2001; Zhao et al., 2007). In turn, a number of GPCRs modulate N-channels via different 
pathways. Multiple GPCRs couple neurotransmitter release to membrane excitability by 
regulating the opening and closing of N-channels. Different modulatory pathways 
activate different classes of G-proteins. While all G proteins involve α, β and γ subunits, 
they are distinguished on the basis of their sensitivity to pertussis toxin (PTX) or cholera 
toxin (Hille, 1994; Zhu and Ikeda, 1994). While cholera toxin prevents the Gα-bound 
GTP from converting into GDP so that the G protein remains in the active state, PTX 
prevents release of GDP from the Gα so that the G protein remains in the inactive state. 
Following receptor coupling to specific G proteins, signaling can then diverge; some 
pathways are well characterized while some remain incompletely understood and will be 
discussed in this thesis. 
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J. Modulation of N-channels by GPCRs via the membrane-delimited pathway 
Inhibition of voltage-gated Ca2+ currents by GPCRs in neurons (Reuter, 1974) 
was first described by Dunlap and Fischbach where application of norepinephrine on 
chick DRG neurons reduced the contribution of Ca2+ currents to the action potentials 
(Dunlap and Fischbach, 1978, 1981). Numerous other studies showed similar inhibition 
of native Ca2+ currents by other GPCRs (Tedford and Zamponi, 2006). Transmitter-
mediated inhibition of Ca2+ was blocked by pre-treatment of DRG cultures with PTX or 
dialyzing cells with GDP-β-S. GDP-β-S competes with GTP for binding to the guanine-
nucleotide site on G-proteins thus antagonizing their activation following transmitter 
binding to receptor. These initial experiments implicated PTX-sensitive Gi/o-proteins in 
this form of Ca2+ current inhibition (Holz et al., 1986). 
Subsequently, this form of inhibition was defined as membrane-delimited. This 
nomenclature was adopted because current inhibition did not occur when the Ca2+ 
channels were isolated in a cell-attached patch and the agonist applied to the bath. This 
observation indicated that inhibition must occur due to tight receptor-channel coupling 
rather than by indirect diffusible mediators (Forscher et al., 1986; Hille, 1994). Activation 
of GPCRs causes dissociation of the heterotrimeric complexes of Gαβγ subunits into Gα-
GTP and Gβγ both of which serve as rapid signaling components. Isoprenylation of Gγ’s 
C-terminus facilitates membrane association of Gβγ (Resh, 2006; Tedford and Zamponi, 
2006).  
During membrane-delimited inhibition of Ca2+ currents, application of neuro-
transmitters shifts the channels’ voltage-sensitivity whereby the channels require a more 
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positive membrane voltage before opening (Dunlap and Fischbach, 1978; Bean, 1989). 
There is no obvious change in the number of functional channels. Bean (1989) presented 
a model of membrane-delimited inhibition where N-channels exist in “willing” or 
“reluctant” modes in the absence or presence respectively of a neurotransmitter. The 
“willing” mode describes channels that are willing to open in response to moderate 
depolarizations. The “reluctant” mode describes channels that are reluctant to open; 
larger depolarizations are required for the channels to open. In the presence of 
neurotransmitters, activation of GPCRs shifts most N-channels to the “reluctant” mode 
while a large depolarization is required for channel opening. The voltage-dependence of 
this modulation, elicited by membrane-delimited inhibition by neurotransmitters or 
internal dialysis with GTP-γS, was elegantly revealed by Elmslie et al. (1990) using a 
novel voltage protocol (Fig 1.5A). A large depolarizing “prepulse”, also referred to as the 
“facilitating prepulse” relieved reluctant gating in a subsequent test pulse that followed 
within ms of the prepulse (Elmslie et al., 1990). Membrane-delimited inhibition was later 
reconstituted in a recombinant system and a series of depolarizations mimicking an action 
potential could relieve the inhibition (Brody et al., 1997) reinforcing the physiological 
relevance of this inhibition during trains of action potentials.    
Re-inhibition rapidly occurs after prepulse facilitation. Its dependence on the 
concentration of activated G-proteins suggested that G-proteins might directly bind to 
channels (Lopez and Brown, 1991). However, which subunit of the G protein and where 
on the channel it might bind remained unresolved for a number of years. Definitive 
evidence that Gβγ-mediated inhibition was provided by two back-to-back publications in 
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Nature. These papers showed that intracellular dialysis or over-expression of Gβγ 
subunits mimicked voltage-dependent, membrane-delimited inhibition, whereas over-
expression of Gα had no effect (Herlitze et al., 1996; Ikeda, 1996). Three sites of 
interaction of Gβγ with the channel have so far been described: the AID region on the I-II 
linker (Pragnell et al., 1994; De Waard et al., 1997; Zamponi et al., 1997), the carboxy 
cytoplasmic tail (Qin et al., 1997) and the N-terminus (Zhang et al., 1996; Page et al., 
1998; Canti et al., 1999), which physically interacts with the I-II linker to promote Gβγ 
mediated inhibition (Agler et al., 2005).  
Phosphorylation by protein kinase C blocks membrane-delimited inhibition 
(Swartz, 1993; Swartz et al., 1993) apparently by preventing G protein subunits from 
binding to the channel (Fig 1.5C).  PKC phosphorylation sites exist on the I-II linker of 
N-channels in close proximity to where Gβγ bind (Hamid et al., 1999). However in 
mutational studies, additional phosphorylation sites were identified on the II-III linker 
(Kamatchi et al., 2004). These studies underscore the difficulties in attempting to 
deconstruct membrane-delimited modulation.  
The “willing” (Gβγ-free) and “reluctant” (Gβγ-bound) states of calcium channels 
can also be observed at the single channel level where with a moderate depolarization, an 
increased first latency to open gives rise to slowed activation kinetics of whole-cell 
currents (Tedford and Zamponi, 2006). Transition between the reluctant and willing 
states was also proposed to occur via binding of phosphatidylinositol-4,5-bisphosphate 
(PIP2), to a particular low-affinity “R” (reluctant and regulatory) site (Wu et al., 2002; 
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Michailidis et al., 2007). How this translates into voltage-dependent inhibition is not clear 
at the moment but will be discussed later. 
Not surprisingly, CaVβ subunits influence membrane-delimited inhibition. Using 
antisense to deplete CaVβ subunits in DRG neurons results in significantly increased 
membrane-delimited inhibition of currents following activation of GABAB receptors 
(Campbell et al., 1995). This finding suggests possible antagonism of membrane-
delimited inhibition by CaVβ.  While co-expression of CaVβ with the channel increases 
current amplitude, accelerates activation kinetics and shifts the activation curve towards 
hyperpolarizing potentials, Gβγ causes the reverse: current inhibition, slowed activation 
kinetics and an activation curve shifted towards more depolarizing potentials. Moreover, 
during membrane-delimited inhibition, the kinetics of activation slow to different extents, 
depending on the subtype of CaVβ subunit co-expressed with the channel. For example, 
when CaVβ2a is co-expressed, modulated currents exhibit the slowest activation kinetics 
compared to the other CaVβ subunits (Bourinet et al., 1996). In the presence of 
overexpressed Gβγ, relief from membrane-delimited inhibition also varied, depending on 
the type of CaVβ present (Feng et al., 2001). The binding site of CaVβ on the AID 
overlaps with a binding site for Gβγ further suggesting a role for CaVβ in membrane-
delimited inhibition (Pragnell et al., 1994; Chen et al., 2004; Opatowsky et al., 2004; Van 
Petegem et al., 2004). Evidence based on work done by numerous labs point towards a 
role of CaVβ subunits in membrane-delimited inhibition but whether CaVβ subunits 
antagonize or support membrane-delimited inhibition remains unresolved. In Chapter V, I 
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present data that provides new information that the orientation CaVβ subunits is critical 
for prepulse facilitation of currents inhibited by the membrane delimited pathway.    
 
K. Modulation of N-channels by the slow pathway 
Another pathway that mediates inhibition of N-current is the slow pathway 
distinguished from the fast, membrane-delimited pathway by the involvement of PTX-
insensitive G-proteins and second messengers (Hille, 1994). Modulation of N-channels 
by the M1 muscarinic receptor (M1R) was originally described as PTX- and voltage-
insensitive (Wanke et al., 1987; Beech et al., 1992) and involving the Ca2+-sensitive 
enzyme phospholipase C (PLC) (Liu and Rittenhouse, 2003a). Slow pathway modulation 
of N-current is disrupted when high concentrations of bis(O-aminophenoxy)ethane-N, N, 
N’,N’-tetraacetic acid (BAPTA) (Beech et al., 1991; Mathie et al., 1992) is dialyzed into 
cells. N-channels, isolated in a cell-attached patch, remain sensitive to modulation by the 
M1R agonist indicating a diffusible second messenger pathway must mediate inhibition 
(Bernheim et al., 1991; Mathie et al., 1992; Hille, 1994). Our laboratory has identified 
arachidonic acid (AA) as a potential diffusible signaling molecule mediating N-current 
inhibition by M1Rs (Liu and Rittenhouse, 2003a). However, the identity of the final 
effector molecule mediating N-current inhibition remains a controversy in the field 
(Michailidis et al., 2007). Data in Chapters II and III support the notion that a free fatty 
acid such as AA mediates slow pathway inhibition of N-current. 
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L. Modulation of N-current by PIP2 
The inhibition of N-current by M1Rs has been proposed to occur by an analogous 
pathway that mediates modulation of a voltage-gated potassium current called  M-current 
(Hille, 1994). According to this hypothesis, N-current is modulated by PIP2, a substrate 
of the enzyme PLC (Fig. 1.7). Stimulation of GqPCRs activates PLC, which then 
catalyzes the release of inositol triphosphate (IP3) from PIP2. These observations have 
been taken to indicate that breakdown of PIP2 near the activated GqPCRs causes a local 
membrane gradient that leads to depletion of PIP2 from the membrane around the 
channels thereby inhibiting current (Hille, 1994; Delmas and Brown, 2005; Delmas et al., 
2005).  
Evidence for involvement of PIP2 in Ca2+ channel modulation was put forward by 
two groups. The first group observed CaV2.1 currents by expressing P/Q channels in the 
Xenopus oocyte expression system. Reduction in peak current or “rundown” occurred 
within minutes after excising a patch from the cell membrane (Wu et al., 2002). Current 
rundown was slowed by exogenous application of PIP2 to the cytosolic side of the 
membrane and accelerated by sequestering PIP2 with antibodies. Application of PIP2 
caused a positive shift in the activation curve of the channels thereby affecting the 
voltage-dependence of activation of the channels. This led the authors to propose that 
PIP2 binds to two sites on the channel, an S (for stabilization) site that promotes channel 
availability, stabilizing current and an R (for reluctant and regulatory) site that shifts 
channels into a reluctant gating mode with characteristics similar to channels inhibited by 
the membrane-delimited pathway, discussed earlier. The second group measured whole-
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cell and perforated-patch N-current in SCG neurons. They recapitulated the finding that 
exogenous application of PIP2 prevents current rundown (Gamper et al., 2004). The 
authors also showed that when SCG neurons were dialyzed with the water-soluble PIP2 
analog, diC8-PIP2, M1R activation no longer inhibited Ca2+ currents. However, this may 
not be so surprising since the diC8-PIP2 does not have an AA moiety that could be 
released for mediating N-current modulation. Usually, PIP2 consists of an AA moeity at 
its sn-2-position that is liberated by phospholipase A2. The released AA not only serves 
as a precursor for signaling molecules that mediate immune response but also for 
generating endocannabinoids that play a role in regulating function of ion channels 
(Sugiura et al., 2002)   This study also reported that when re-synthesis of PIP2 is blocked 
using high concentrations of wortmannin, modulation by M1Rs does not reverse. These 
data support a model for inhibition where PIP2 is required for N-current inhibition by 
M1Rs.  
Whether loss of PIP2 is sufficient for current inhibition remains unresolved since 
additional metabolites and downstream targets of PIP2 were only superficially examined 
for participation in the slow pathway. Moreover, the locations of PIP2’s modulatory sites 
remain unidentified although it is highly likely that at least one of the sites exists on the 
channel subunit.  
M. Working model for N-current inhibition by GqPCRs 
Modulation of N-current by M1R requires specific events downstream of 
phospholipid hydrolysis and is distinct from modulation of M-currents. First, M1R 
activation enhances N-current at negative potentials and inhibition of N-current at 
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positive potentials; this pattern of modulation is remarkably mimicked by exogenous 
application of AA in SCG neurons (Liu et al., 2001; Liu and Rittenhouse, 2003a). 
Second, when bovine serum albumin (BSA) is used to sequester free fatty acids liberated 
upon M1R activation in the extracellular medium, N-current inhibition by M1Rs is lost. 
Third, dialyzing BSA into SCG neurons causes loss of inhibition by AA without affecting 
N-current enhancement, indicating that inhibition and enhancement are distinct events 
that occur at two different sites of action (Barrett et al., 2001). Fourth, blocking the 
enzyme phospholipase A2 (PLA2) minimized inhibition by M1Rs (Liu et al., 2004). Fifth, 
another by-product of phospholipid metabolism by PLA2, lyosphosphatidic acid, when 
exogenously applied did not inhibit whole-cell N-current indicating the specificity of AA 
as a second messenger (Liu et al., 2004). Sixth, blocking the enzyme diacylgycerol lipase 
(DAGL) with a pharmacological antagonist minimized inhibition of N-current. In 
contrast, antagonists to PLA2, DAGL or the presence of BSA had no effect on 
modulation of M-current (Liu et al., 2003; Liu et al., 2006; Liu et al., 2008) indicating N-
current modulation is mediated by a signaling pathway that diverges from the pathway 
responsible for M-current modulation. The data support a model where inhibition of N-
current requires a specific and probably sequential breakdown of phospholipids to release 
free AA that inhibits N-channel activity by acting at an inhibitory site.  
A role of AA in modulating additional Ca2+ currents has also been observed. In 
the recombinant system AA modulates CaV3 currents (Zhang et al., 2000; Talavera et al., 
2004; Chemin et al., 2007) as well as native and recombinant CaV1 currents (Xiao et al., 
1997); Roberts-Crowley and Rittenhouse, submitted). PIP2 and AA modulate voltage-
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gated potassium channel activity where they produce opposite effects on channel 
inactivation; PIP2 promotes channel availability whereas AA causes inactivation (Oliver 
et al., 2004). Thus similar actions of PIP2 and AA occur across many channel types 
indicating a fundamental basic relevance of these two molecules for channel function. 
Here in my thesis, I present data supporting role of the slow pathway in 
modulation of N-currents by another GqPCR, the NK-1R (Chapter II). I have described 
the signaling components that are necessary for inhibition of N-current when SP activates 
NK-1Rs. The data support previous observations, reported in separate and unrelated 
studies, about phospholipid breakdown upon activation of NK-1R and phosphorylation of 
ERK1/2 in response to noxious stimuli. From a collaboration with Dr. John Heneghan, I 
present evidence that helps in understanding the mechanism of N-current modulation that 
was earlier seen by both activation of M1R and exogenous AA application (Barrett et al., 
2001; Liu et al., 2001; Liu and Rittenhouse, 2003a). Specifically, I show results that 
support a model where the palmitoyl groups of CaVβ2a block N-current inhibition 
possibly by occupying an inhibitory site (Chapter III). That the location of the 
endogenous palmitoyl groups is important for modulation is supported by data showing 
that moving the palmitoyl groups of CaVβ2a results in the appearance of current 
inhibition (Chapter IV). Earlier, I discussed that CaVβ is important for membrane-
delimited inhibition of N-channel activity. In Chapter V, I present evidence that supports 
this observation and extends it further by showing that a specific orientation of CaVβ and 
Gβγ is required for membrane-delimited inhibition and its relief by facilitating prepulses.  
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In summary, a better understanding of N-current modulation by SP advances the 
field of pain therapy where discovery of new signaling molecules brings the possibility of 
developing new drugs to provide analgesia. A better understanding of the role of 
accessory subunits may help to detect anomalies in N-channel functioning where aberrant 
modulation may arise not from defects in the channel itself but from changes in 
expression or modification of accessory subunits. Overall, this study also shows 
possibility of a new role of protein palmitoylation. 
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Adapted from: 
http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/Cell_Signaling/Key_Resour
ces/Pathway_Slides__Charts/Ascending_Pain_Pathway.html 
(DH)
(DRG)
Nociceptors
(Substance P producing neurons)
 
Figure 1.1 Diagrammatic representation of the ascending pain pathway. Painful signals 
are transmitted by the specialized nociceptive fibres that synapse onto the dorsal horn of 
the spinal cord. Efferent neurons carry nociceptive information via the spinothalamic 
tract to the higher centers for further processing. 
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http://www.sigmaaldrich.com/Area_of_Interest/Life_Science/Cell_Signaling/Key_Reso
urces/Pathway_Slides__Charts/Modulation_of_Pain_.html 
 
Figure 1.2 The dorsal horn of the spinal cord receives nociceptive inputs from the Aδ 
and C-fibres. The nociceptive dorsal horn neurons give rise to efferent fibres which 
decussate and course upwards in the ascending spinothalamic tract.  
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Figure 1.3 Classification of voltage-gated calcium channels based on nomenclature. 
Comparison of ~350 amino acids from the transmembrane segments and pore loops 
reveals three subfamilies of calcium channels (CaV1, CaV2 and CaV3) with 80% 
homology in the sequence of the channels within each family. The high voltage-gated 
channels are CaV1 or L-, CaV2.1 or P/Q, CaV2.2 or N- and CaV2.3 or R-type channels. 
CaV3 channels belong to the low voltage-gated class of channels.  
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Figure 1.4 The voltage-gated calcium channel is a heteromeric complex of proteins. (A) 
The channel is organized into four domains; each domain consists of six membrane-
spanning helices. The transmembrane α2δ subunit is linked by two disulfide bonds. The β 
subunit is cytoplasmic. The γ subunit is not shown. (B) An alternative view of the N-type 
calcium channel is shown in association with the α2δ and β subunits.  
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Adapted from Elmslie et al., 1990 and Barrett and Rittenhouse, 2000 
 
Figure 1.5 Membrane-delimited inhibition of N-channel activity. (A) Prepulse protocol 
established by Elmslie et al., 1990 to relieve tonic inhibition of N-current. (B) Current 
traces demonstrating voltage dependent inhibition and its relief by a prepulse. (C) Model 
proposed by Barrett and Rittenhouse (2000) showing that both phosphorylated and 
dephosphorylated channels are “willing” to open, but only dephosphorylated channels 
can be bound by G-protein for voltage-dependent modulation.  
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Figure 1.6 Comparison between the membrane delimited and the slow pathway. The 
membrane-delimited pathway involves inhibition of N type calcium channels by Gi/o-
coupled receptors, while the slow pathway involves inhibition by Gq-coupled receptors. 
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Figure 1.7 The PIP2 model for inhibition of N-currents. The model proposes that a loss 
of PIP2 from the channel causes current inhibition or “rundown”.  
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CHAPTER II: 
 
Modulation of voltage-gated N-type calcium  
channels by substance P involves lipids and  
proteins 
 
ABSTRACT 
 
Nociceptive stimulation from the periphery and visceral organs causes dorsal root 
ganglia neurons to release substance P (SP) onto the soma and dendrites of dorsal horn 
(DH) neurons. These DH neurons express tachykinin receptors (NK-1R) and N-type 
calcium channels (N-channels). SP, the principal neuropeptide mediating pain, binds to 
Gq-coupled NK-1Rs, resulting in N-current inhibition. Pharmacological blockers of N-
channels are used as analgesics thus implicating N-channels in pain perception. Yet the 
complete mechanism by which SP modulates N-channel activity is unknown. Gq-coupled 
M1 muscarinic receptors enhance and inhibit native N-current at negative and positive 
potentials respectively; arachidonic acid (AA) mimics this modulation. Here, by 
monitoring recombinant channel (CaV2.2, α2δ-1 and β3) activity in HEKM1 cells using 
whole-cell patch clamp techniques, we show that N-current inhibition by SP is blocked in 
the presence of a pharmacological antagonist of phospholipase A2 (PLA2). This 
observation is consistent with the need for increased levels of free fatty acid in order to 
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observe inhibition. When bovine serum albumin (BSA) was used as a fatty acid 
scavenger to reduce the levels of free fatty acids, SP no longer inhibited N-current. 
Lastly, in the presence of U0126, a pharmacological blocker for ERK1/2, N-current 
inhibition by SP was lost. Taken togther, these findings indicate that activation of 
ERK1/2 and PLA2 and breakdown of phospholipids are involved in N-current modulation 
by NK-1R. Thus our present study identifies for the first time the proteins downstream of 
Gq that mediate modulation of N-current by SP. Phospholipid metabolism involving 
PLA2 is a key component mediating pain, inflammation and immune response. Hence, a 
better understanding of the function of molecules involved in mediating pain will help in 
designing better pharmacological targets for relieving pain 
 
INTRODUCTION  
 
Pain is caused by intense external stimuli (thermal, mechanical, or chemical) that 
stimulate sensory nerve activity. This electrical activity transmits the encoded pain 
sensation through a series of synapses to the brain. Substance P (SP), an 11-amino acid 
neuropeptide (Carraway and Leeman, 1979) of the tachykinin family, is the principal 
neurotransmitter that mediates pain. In response to nociceptive stimulation, SP is released 
from terminals of dorsal root ganglion (DRG) neurons onto dorsal horn (DH) neurons. 
These latter neurons express the Gq-coupled tachykinin NK-1 receptor (NK-1R) 
(Cheunsuang et al., 2002). SP is the preferred natural ligand for NK-1Rs (Macdonald et 
al., 1996).  
 
 30
N-channels appear to be an important target of SP signaling in DH neurons 
(Westenbroek et al., 1998; Yaksh, 2006). N-channels belong to a family of voltage-
dependent Ca2+ channels that regulate Ca2+ entry into neurons. In animal pain models, 
loose ligation of the sciatic nerve causes upregulation of the expression of N-channels in 
the DH (Cizkova et al., 2002). Blockers of N-channel activity inhibit behavioral and 
neuronal responses to noxious stimuli (Malmberg and Yaksh, 1994; Diaz and Dickenson, 
1997). Knockout mice, lacking the gene encoding N-channels, are less sensitive to 
neuropathic and inflammatory pain compared to wild-type (wt) mice (Hatakeyama et al., 
2001; Saegusa et al., 2001). In addition to whole animal studies, SP inhibits N-current in 
DRG and superior cervical ganglion (SCG) neurons by an incompletely described 
pathway (Shapiro and Hille, 1993; Sculptoreanu and de Groat, 2003). While the DH is a 
key area of the spinal cord involved in mediating nociception (Yaksh, 2006), only a 
limited number of studies have focused on the role of N-channels in this region.  
In SCG neurons, N-channels also undergo modulation by another Gq-coupled 
receptor, the M1 muscarinic receptor (M1R).  N-current inhibition by M1Rs involves a 
lipid-dependent pathway, called the slow pathway (Beech et al., 1992) where inhibition 
develops over the course of many seconds. This pathway involves phosphatidylinositol-
4,5-bisphosphate (PIP2) breakdown by phospholipase C (PLC) and subsequent release of 
arachidonic acid (AA) following activation of PLA2, most likely the Ca2+-dependent 
cytosolic PLA2 (cPLA2) (Liu and Rittenhouse, 2003a; Gamper et al., 2004; Liu et al., 
2006). AA is found in the sn-2 position of membrane phospholipids. cPLA2 preferentially 
hydrolyzes the sn-2 ester bond of arachidonate-containing phospholipids generating free 
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AA and lysophospholipid (Dennis, 1997; Balsinde et al., 2002). Treatment of cerebral 
cortical slices with SP produces a significant breakdown of phospholipids (Catalan et al., 
1988), indicating possible involvement of these metabolites in downstream signaling 
following NK-1R activation. Whether phospholipid breakdown, induced by NK-1R 
activation, can modulate N-channel activity is not known. 
Painful stimuli increases phosphorylation of an extracellular-signal-related protein 
kinase (ERK) (Ji et al., 1999). Phosphorylation by an upstream mitogen-activated protein 
kinase (MAPK)/ERK kinase (MEK) causes activation of ERK. In turn, ERK 
phosphorylates cPLA2 at serine-505 (Lin et al., 1993). The MAPK/ERK pathway also 
appears to directly phosphorylate N-channels in DRG neurons, leading to current 
enhancement. This increase in current occurs on a time scale of minutes (Fitzgerald, 
2000) compared to SP inhibition of N-current that occurs in seconds (Shapiro and Hille, 
1993). Whether ERK participates in N-current inhibition by SP has not been tested.  
Here we examined whether SP inhibits recombinant N-channels (CaV2.2) by a 
pathway similar to inhibition of N-channel activity by M1Rs (Liu and Rittenhouse, 
2003a) We show that activation of NK-1Rs by SP inhibits recombinant N-current in a 
concentration-dependent manner when CaV2.2 is co-expressed with the α2δ-1 and β3 
accessory subunits. Using a high concentration of BAPTA, a Ca2+ chelator, we show that 
N-current inhibition by SP is Ca2+-sensitive. The inhibition is also significantly reduced 
in the presence of U0126 or oleyloxyethyl phosphorylcholine (OPC), pharmacological 
antagonists of ERK1/2 and PLA2 respectively. U0126 inhibits the kinase activity of MEK 
thereby preventing phosphorylation of ERK by MEK. OPC is a competitive antagonist of 
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PLA2 thereby blocking phospholipid breakdown by PLA2. Sequestering free fatty acids 
by bath applying bovine serum albumin (BSA) during NK-1R activation also diminishes 
N-current inhibition. These data indicate that NK-1Rs modulate N-channel activity by a 
“slow” pathway similar to M1Rs. For the first time, our data implicate ERK1/2 activity in 
the slow pathway, possibly upstream of PLA2. This study has important implications for 
therapeutically manipulating pain transmission since it uncovers key signaling molecules 
that mediate inhibition of N-channels by NK-1R activation.  
 
MATERIAL AND METHODS 
 
 Human embryonic kidney (HEK) cells with a stably transfected M1R (HEK-M1) 
were grown at 37°C with 5% CO2 in Dulbecco’s MEM (DMEM)/F12 supplemented with 
10% FBS, 1% G418, 0.1% Gentamicin and 1% HT supplement (Gibco Life 
Technologies, Grand Island, NY). For transfection, cells were plated in 12-well plates at 
50-80% confluency. Cells were transiently transfected using Lipofectamine and PLUS 
reagents (Invitrogen, Carlsbad, CA) as per the manufacturer’s instruction. The 
transfection mixture consisted of plasmids encoding Cav2.2e[a10, ∆18a, Δ24a, 31a, 37b, 
46] (#AF055477), α2δ−1 (#AF286488;) and CaVβ3 (#M88751) at a 1:1:1 molar ratio. 
28ng/well of plasmid encoding NK-1R (#AY462098; UMR cDNA Resource Center, 
University of Missouri, Rolla, MO) and enhanced green fluorescent protein cDNA at less 
than 10% of the total cDNA were also included in the transfection medium. After 24-48 
hours post transfection, cells were plated on poly-L-lysine coated coverslips for recording 
currents. 
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Electrophysiology 
 Whole-cell Ba2+ currents were recorded at room temperature (20-24°C) using a 
Dagan 3900a patch clamp amplifier (Dagan Instruments Inc., Minneapolis, MN). 
Currents were filtered at 1-5 kHz using the amplifier’s four-pole low-pass Bessel filter 
and digitized at 20 kHz with a CED micro1401 interface (Cambridge Electronic Design, 
(CED), Cambridge, UK). Data were collected using Signal 2.16 (CED) and stored on a 
personal computer. Prior to analysis, capacitive and leak currents were subtracted using a 
scaled-up hyperpolarizing test pulse to -100 mV. For all recordings, cells were held at -90 
mV and given a 100 ms depolarization to the test potential indicated. The protocol was 
repeated every 4 sec. Electrodes were pulled from borosilicate glass capillary tubes. Each 
electrode was fire-polished to ~1 μm to yield a pipette resistance of 2-3MΩ. The external 
solution contained (in mM): 125 NMG-aspartate, 10 HEPES and 5 barium acetate, pH 
was adjusted to 7.5 with CsOH. When the concentration of Ba2+ was lowered from 20 
mM to 5 mM for recording Cav2.2 currents, 135 NMG-aspartate was substituted for Ba2+. 
 The internal solution of the pipette consisted of (in mM): 135 Cs-aspartate, 10 HEPES, 
0.1 1,2-bis(O-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA), 5 MgCl2, 4 
ATP, 0.4 GTP, adjusted to pH 7.5 with CsOH.  
 
Pharmacology 
SP was prepared as a 0.5mM stock solution in 0.05 M acetic acid and stored at -20°C. 
The stock was serially diluted with bath solution daily to a final working concentration of 
5 or 250 nM. BSA (fraction V, heat shock, fatty acid ultra-free; Roche Applied Science, 
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Indianapolis, IN) was added directly to the bath solution yielding a final concentration of 
1 mg/ml. OPC (CalBiochem, La Jolla, California) was prepared as a stock solution made 
up in 100% ethanol and diluted 1,000 times with bath solution for a final concentration of 
10 μM. U0126 (Promega, Madison, Wisconsin) was made up in DMSO and diluted 
10,000 times with bath solution to yield a final concentration of 10 μM.  All chemicals 
were obtained from Sigma-Aldrich Inc. (St. Louis, MO) except where noted. Drugs were 
applied with a gravity-driven bath perfusion system and complete bath exchange was 
achieved within 10-14 sec. 
 
Data analysis 
 After the onset of the test pulse, maximal inward current of whole-cell traces was 
measured using Signal 2.16 (CED) using a trough seeking function. Percent change in 
current amplitude was measured as [(I-I’)/I]*100 where I is the average amplitude of 
peak current measured from 5 current traces prior to drug application. I’ is the average 
current amplitude measured from 5 current traces at least 2 mins after application of SP, 
unless otherwise noted. 
 
Statistical Analysis 
 Summary data are presented as mean ± s.e.m (standard error of the mean). 
Average current before and after application of SP was compared using a two-tailed 
paired t-test. Differences in inhibition were measured using a two-way Students t-test. 
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Statistical significance was set at *p<0.05 or **p<0.01. Data were analyzed using Excel 
(Microsoft, Seattle, WA) and Origin (OriginLab, Northampton, MA). 
 
RESULTS 
SP inhibits recombinant CaV2.2 current 
In HEK-M1 cells, co-transfection of CaV2.2, CaVβ3 and α2δ-1 is necessary to 
elicit peak currents of at least 150 pA (n=3 cells per group; 3 groups were tested where in 
each group one subunit was absent from the tranfection medium; data not shown) 
indicating that the recorded currents arise from the transfected channel subunits and not 
from endogenous channel activity. We hypothesized that NK-1R activation by 250 nM 
SP will also inhibit CaV2.2 currents in HEK-M1 cells since SP causes N-current 
inhibition in SCG neurons via a voltage-independent pathway (Shapiro and Hille, 1993; 
Kammermeier et al., 2000). M1R activation also inhibits recombinant N-current (Gamper 
et al., 2004). Since both M1Rs and NK-1Rs couple to Gq, Whole-cell currents were 
recorded by stepping from -90 mV to 0 mV. Following application of SP for three 
minutes, the maximal inward current decreased to 52 ± 8% of control levels (Fig 2.1A, B; 
n=6; p<0.05, compared to unstimulated levels). Current inhibition was significantly 
greater than that observed in cells with no NK-1R transfected (13 ± 12%; n=3; p<0.05 
compared to cells transfected with NK-1R); no significant inhibition occurred without 
receptor expression (Fig 2.1C).  
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Inhibition of N-currents by SP occurs in a concentration-dependent manner 
In the previous experiment we noted that following application of SP, N-current 
briefly increased in amplitude but then the current reversed resulting in sustained 
inhibition (Fig 2.2B). A concentration-dependent effect of SP was earlier reported in 
DRG neurons (Sculptoreanu and de Groat, 2003). We hypothesized that SP may both 
enhance and inhibit N-current, where enhancement is more sensitive to the SP 
concentration than inhibition. We predicted that at low concentrations, SP would enhance 
N-current while at higher concentrations SP would inhibit N-current. Activation of NK-
1Rs by different SP concentrations ranging from 1 - 250 nM yielded a range of N-current 
inhibition. At SP concentrations of 5 nM and above, currents were strongly inhibited (Fig 
2.2). 
 
SP inhibits N- currents via the “slow” pathway 
N-current inhibition by M1Rs involves the “slow”, BAPTA-sensitive pathway 
(Beech et al., 1991; Bernheim et al., 1991; Mathie et al., 1992). We hypothesized that the 
Gq-coupled NK-1R inhibits N-current via the same “slow” pathway. To test this 
hypothesis, we examined whether inhibition was BAPTA sensitive by comparing the 
magnitude of inhibition when 0.1 or 20 mM BAPTA was dialyzed into transfected HEK-
M1 cells for 2 mins after establishing the whole-cell configuration. Following this control 
period, application of 5 nM SP inhibited currents of cells dialyzed with 0.1 mM BAPTA 
(Fig 2.3A-C). In contrast, after dialying cells with 20 mM BAPTA N-current inhibition 
was lost (Fig 2.3C-E; p<0.001 compared to dialysis with 0.1 mM BAPTA). These 
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findings suggest that NK-1R signaling uses the same “slow” BAPTA-sensitive pathway 
that was earlier shown to mediate M1R inhibition of N-current (Beech et al., 1991) 
Next, we hypothesized that N-current inhibition by SP involves phospholipid 
metabolism as part of the signaling cascade. Inhibition of N-current by M1Rs involves 
acute activation of cPLA2 (Liu and Rittenhouse, 2003a; Liu et al., 2004). To decrease the 
availability of free fatty acids such as AA, we used two strategies. First we antagonized 
the breakdown of membrane phospholipids using OPC, a PLA2 antagonist. When cells 
were preincubated in 10 μM OPC for 60 seconds, application of 250 nM SP no longer 
inhibited N-current. This loss of inhibition is significantly different than inhibition in the 
absence of OPC (n=5; p<0.01; Fig 2.4B and D).  
Second, we tested whether the presence of BSA reduced N-current inhibition 
following stimulation of NK-1R. BSA was earlier shown to reduce N-current inhibition 
by M1Rs (Liu and Rittenhouse, 2003a). Following pre-incubation with BSA for 2 mins, 
SP no longer elicited significant current inhibition (Fig 2.4C and D). However, N-current 
in the presence of BSA significantly inactivated more rapidly (τ = 21 ± 1.4 ms) compared 
to when BSA was not included in the bath (τ = 41 ± 5 ms; data not shown). The BAPTA 
sensitivity, the requirement for PLA2 activity and free fatty acid support the initial 
hypothesis that activation of NK-1Rs by SP inhibits N-current via the same “slow” 
pathway used by M1Rs (Beech et al., 1991; Bernheim et al., 1991; Mathie et al., 1992; 
Liu and Rittenhouse, 2003a).  
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ERK1/2 is involved in mediating N-current inhibition by SP 
We next tested whether ERK1/2 activity is required for “slow” pathway 
modulation of N-current by SP. HEK-M1 cells were preincubated with 10 μM U0126 for 
15 mins before applying SP. U0126 blocks MEK’s activity, thereby preventing 
phosphorylation of ERK1/2 (Fig 2.5D). While in control conditions, SP inhibited N-
currents to 61 ± 9% of unstimulated levels, the presence of U0126 resulted in a loss of 
inhibition (p<0.05; Fig 2.5A-C) as was earlier observed by blocking the release of AA 
using OPC and reducing AA’s availability using BSA . These findings are consistent with 
a model where following Gq activation, ERK phosphorylates cPLA2 (Fig 2.5D).  
We attempted to test whether ERK phosphorylated cPLA2 in HEK-M1 cells upon 
NK-1R activation. In preliminary experiments HEK-M1 cells were exposed to the 
muscarinic agonist oxotremorine-M (Oxo-M; 10 μM) for 10 min, then fixed and stained 
with an antibody (1:5,000) specific to cPLA2, phosphorylated on serine 505 (phospho-
cPLA2). However, unstimulated cells exhibited strong staining for constitutive phospho-
cPLA2. No detectable increase in fluorescence was observed following Oxo-M since 
fluorescence appeared to be maximal under control conditions (n=5 expts; data not 
shown). Antibody concentration was lowered to 1:20,000; however the same result was 
obtained, suggesting that the HEK-M1 cell line may not be an ideal system to detect 
changes in phosphorylation of cPLA2 since a high basal level of phosphorylation exists. 
A similar observation has been reported for Madin-Darby canine kidney (MDCK) cells 
where pre-incubation with U0126 partially reversed a gel-shift due to phosphorylation of 
cPLA2 (Evans et al., 2002).  
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DISCUSSION 
 
 Inhibition of N-current by SP was first demonstrated in SCG neurons (Shapiro 
and Hille, 1993). As with M1Rs, current inhibition by SP involved PTX-insensitive G 
proteins and was not relieved by a prepulse, indicating involvement of a voltage-
independent pathway (Shapiro and Hille, 1993). As with M1Rs, inhibition was partially 
relieved following Ca2+ chelation with 20 mM BAPTA (Beech et al., 1991; Bernheim et 
al., 1991; Mathie et al., 1992). Subsequently, N-current inhibition by SP was shown to 
involve Gβγ and PLC confirming involvement of a Gq-coupled pathway in N-current 
modulation (Kammermeier et al., 2000). Here we show that activation of NK-1R by SP 
inhibits recombinant N-current via the “slow” pathway, a signal transduction cascade 
involving lipid metabolism that was earlier described for M1Rs  (Delmas et al., 1998; 
Haley et al., 2000; Liu and Rittenhouse, 2003a; Gamper et al., 2004). We tested whether 
stimulation of the Gq-coupled NK-1R will activate PLA2, which releases AA from 
membrane phospholipids. In the presence of the PLA2 antagonist OPC, N-current 
inhibition by SP is lost. When BSA is applied in the bath to reduce the availability of free 
AA, control currents inactivate faster but the currents are not inhibited by SP. We also 
predicted that ERK1/2 might also participate in the pathway downstream of receptor 
activation, since ERK1/2  phosphorylates cPLA2 leading to its acute activation (Houliston 
et al., 2001). As anticipated, in the presence of UO126, an antagonist of ERK1/2, N-
current inhibition by SP was lost. These results identify additional signaling molecules 
downstream of Gq and PLC that mediate N-current modulation by SP.  
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Together with our earlier studies we have shown that three different molecules: 
exogenously applied AA, which is a hydrophobic signaling molecule, Oxo-M, which is a 
small, hydrophilic molecule and SP, a short neuropeptide all appear to converge on the 
same pathway where free AA may be the final effector molecule that modulates N-
current (Liu and Rittenhouse, 2000; Liu et al., 2001; Liu and Rittenhouse, 2003a). In 
central and peripheral primary neurons NK-1Rs and M1Rs stimulate AA release (Catalan 
et al., 1988; Tence et al., 1994; Liu et al., 2006), further supporting the possibility that 
either endogenously released AA or bath-applied AA inhibits N-current by the same 
mechanism. 
 
Modulation of N-current by SP is concentration-dependent 
Activation of NK-1R by SP inhibits N-current in a concentration-dependent 
manner.  Inhibition of currents occurs at SP concentrations of 5 nM and above; at very 
low concentrations (< 5 nM), slight enhancement was observed (Fig 2.2). Such a 
concentration-dependent response by SP was also observed with N-current, recorded 
from DRG neurons (Sculptoreanu and de Groat, 2003). Additionally recombinant N-
current exhibits both enhancement and inhibition by either M1R or SP stimulation 
(Chapter III).  
 
SP inhibits N-currents via the voltage-independent “slow” pathway 
 M1R and NK-1R inhibition of native and recombinant N-current is BAPTA-
sensitive, indicating calcium-dependent enzymes participate in the pathway (Beech et al., 
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1991; Bernheim et al., 1991; Mathie et al., 1992). Consistent with the BAPTA studies, 
PLC, a calcium-dependent enzyme, participates in N-channel modulation by the slow 
pathway (Kammermeier et al., 2000; Liu and Rittenhouse, 2003a; Gamper et al., 2004). 
Additionally in SCG neurons, Ca2+-sensitive cPLA2 is required for N-current modulation 
by M1Rs (Liu et al., submitted).  We also show that N-current inhibition by SP requires a 
PLA2 and downstream release of lipid mediators. In the presence of the PLA2 antagonist 
OPC or BSA, which scavenges free fatty acid, inhibition by SP is lost (Fig 2.4).  These 
findings show that both receptors appear to converge on the same signaling pathway to 
inhibit N-current. 
A few studies suggest that a reduction in the level of phosphatidylinositol-4,5-
bisphosphate [PIP2] after GqPCR stimulation is sufficient for N-current inhibition (Wu et 
al., 2002; Gamper et al., 2004; Michailidis et al., 2007). However, other studies indicate 
N-current inhibition by M1R requires complete breakdown of PIP2 by PLC, PLA2 and 
diacylglycerol lipase (Liu and Rittenhouse, 2003a; Liu et al., 2004; Liu et al., 2008). 
Antagonizing any of these lipases results in loss of N-current inhibition. These effects 
appear specific since inhibition of the potassium current, M-current, is only sensitive to 
antagonism of PLC (Suh and Hille, 2002; Liu et al., 2006; Liu et al., 2008). The 
characteristics of N-current modulation by exogenously applied AA mimic modulation 
by M1Rs (Liu and Rittenhouse, 2003a)- peak current enhancement occurs at negative 
potentials and inhibition occurs at positive potentials. These findings indicate that not just 
the loss of PIP2 but its highly regulated breakdown and liberation of free AA is required 
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for mediating N-current inhibition by GqPCRs. Overall, these findings indicate that 
modulation of N-currents by SP occur via the “slow” pathway. 
 
ERK1/2 is involved in inhibition of N-currents by SP 
 Antagonism by U0236 of N-current inhibition is consistent with previous 
identification of ERK1/2 activation in NK-1R signaling. Noxious stimuli from the 
periphery is sufficient to cause phosphorylation of ERK in DRG (Dai et al., 2002) and 
DH neurons (Ji et al., 1999). U0126 serves as a highly specific inhibitor by binding to the 
active forms of MEK1 and MEK2 and preventing activation of the MAPKs (ERK1/2) 
(DeSilva et al., 1998; Favata et al., 1998). Pre-incubation of cells with 10 μM U0126 for 
10-15 mins blocks MAPK activation (Favata et al., 1998). Agonist-induced phosphoryla-
tion of cPLA2 by MAPK occurs at serine-505 (Lin et al., 1993). In a separate study, 
blocking the activation of the ERK pathway blocks agonist-induced AA release as well as 
partially blocks phosphorylation of cPLA2 (Evans et al., 2002) linking ERK activity with 
cPLA2 phosphorylation and AA release. Due to issues with current run-down when cells 
are held in the whole-cell configuration for many minutes, we could not determine the 
effect of preincubation with U0126 although previous work has shown that preincubation 
of DRG neurons with U0126 reduces peak current (Fitzgerald, 2000). While ERK1/2 
activity causes tonic enhancement of N- and L- currents (Fitzgerald, 2000) by 
phosphorylating sites on the channel and accessory CaVβ subunits (Martin et al., 2006), 
receptor-mediated inhibition of P/Q-type currents seemed to be reduced by 50% when the 
signaling pathway was uncoupled from MAPK (Wu et al., 2002) further suggesting that 
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modulation of Ca2+ channels by ERK1/2 is a mechanism observed across different 
calcium channel subtypes. Although it is possible that in the presence of U0126, loss of 
inhibition by SP occurs from a loss of a phosphorylation event either on the channel or on 
the CaVβ subunit. However the findings would still implicate ERK1/2 as a component in 
the signaling pathway. Thus we confirmed a role for ERK1/2 in N-current modulation by 
SP. Whether its role in the inhibitory pathway is only to phosphorylate cPLA2 or whether 
it serves additional functions in the pathway awaits future investigation. One way to 
address this would be to test whether mutant CaV2.2 channels lacking the putative 
ERK1/2 phosphorylation sites still undergo inhibition by SP. Thus, our present study 
along with previous studies identifies NK-1R, Gq, PLC, phosphorylation of ERK, PLA2 
and a free fatty acid, most likely AA as signaling components mediating inhibition of N-
currents by SP. 
 
Significance of the slow pathway in transmission of nociceptive stimuli 
 Overall, our present study identifies the signaling components mediating N-
current inhibition by SP. So far pharmacological antagonists of calcium channels, most 
notably N-channels have been used for treatment of chronic pain (Snutch, 2005). 
Following nerve injury, sensory neurons undergo a progressive increase in excitability 
due to entry and accumulation of Ca2+ and hence cannot be treated by antagonists of 
neurokinin receptors (Abdulla et al., 2003). N-channels play an important role in 
regulating membrane excitability by activation of calcium-activated potassium channels 
(Sah and Faber, 2002; McGivern and McDonough, 2004). Hence, targeting the signaling 
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pathway that mediates modulation of N-current by SP may be an effective way of 
reversing aberrant neuronal excitability thus providing relief from pain. 
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Figure 2.1 SP inhibits recombinant N-current. HEK-M1 cells were transfected with 
CaV2.2, β3, α2δ-1 and NK-1R expressing plasmids. (A) Representative current traces 
taken before and 3 mins after application of 0.25 μM SP. (B) Time course of currents 
taken before and after application of 0.25 μM SP. (C) Summary of inhibition by SP when 
NK-1R is co-expressed (+) compared to inhibition of currents when NK-1R is not co-
expressed (-) (n=3-7). *p<0.05 compared to control currents, **p<0.05 compared to cells 
transfected with NK-1R. The changes in N-current in –NK-1R cells was not significantly 
different compared to control cells. 
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Figure 2.2 Inhibition of N-current by SP is concentration-dependent. Different concen-
trations of SP ranging from 1 to 250 nM were tested for N-current modulation. 
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Figure 2.3 N-current inhibition by SP is BAPTA-sensitive. (A) Representative sweeps 
taken before and 90 seconds after applying 5 nM SP in the presence of 0.1 mM 
intracellular BAPTA. (B) Averaged time course showing inhibition of currents by 5 nM 
SP. (C) Summary of inhibition by SP in the presence of 0.1 mM BAPTA compared with 
inhibition in the presence of 20 mM BAPTA. *p<0.05 compared to control currents, 
**p<0.01 compared to currents when 0.1 mM BAPTA was dialysed into the cells. (D) 
Representative sweeps taken before and 90 seconds after applying 5 nM SP in the 
presence of 20 mM intracellular BAPTA. (E) Averaged time course showing inhibition 
of currents by 5 nM SP in the presence of 20 mM BAPTA. 
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Figure 2.4 PLA2 and downstream release of free AA mediate N-current inhibition by SP. 
Cells were preincubated in 10 μM OPC or 1 mg/ml BSA for at least 2 mins before 
application of SP. (A) Model of hypothesized NK-1R signal transduction cascade 
showing inhibition of N-currents by SP involves cPLA2 and release of free AA. (B) 
Representative sweeps taken before and after application of 250 nM SP in the presence of 
10 μM OPC. (C) Representative sweeps taken before and after application of SP in the 
presence of 1 mg/ml BSA. (D) Summary of inhibition by SP in the presence of OPC or 
BSA. n=4-5, *p<0.05 compared to current inhibition by SP alone. 
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Figure 2.5 ERK1/2 activity is required for N-current inhibition by SP. Cells were 
preincubated with 10 μM U0126 for atleast 15 mins before application of 5 nM SP. (A) 
Representative traces taken before and after application of SP. (B) Representative sweeps 
taken before and after application of SP in the presence of 10 μM U0126. (C) Summary 
of inhibition by SP alone and in the presence of U0126. (D) Model of hypothesized NK-
1R signal transduction cascade representing ERK1/2 phosphorylation occurring 
downstream of receptor activation. 
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CHAPTER III: 
 
Palmitoylated Cavβ2a toggles N-current  
modulation  
by Gq-coupled receptors  
from inhibition to enhancement 
 
ABSTRACT 
M1 muscarinic receptors both enhance and inhibit N-type Ca2+ channel activity. 
However, the physiological mechanisms regulating this modulation remain incompletely 
characterized and controversial. Here we report the N-channel’s β-subunit (CaVβ) acts as 
a molecular switch that determines which modulatory effect dominates N-current. In 
HEK-293 cells, M1 or neurokinin-1 receptor stimulation inhibited activity of CaV2.2 
coexpressed with CaVβ1b, CaVβ3 or CaVβ4, but enhanced activity when coexpressed with 
CaVβ2a. Arachidonic acid (AA) reproduced this profile of modulation, substantiating its 
role as the downstream effector. From studies with CaVβ mutants, chimeras and free 
palmitic acid we ascertained CaVβ2a’s mechanism of action and revealed a new role for 
protein palmitoylation. The two palmitoyl groups of CaVβ2a appear to interact with 
CaV2.2 to prevent inhibition by AA, unmasking latent enhancement. Our results predict 
that N-current modulation by Gq-protein coupled receptors will fluctuate between 
enhancement and inhibition based on the presence of palmitoylated CaVβ2a. 
 
 
 51
INTRODUCTION 
 
All neural function results from a series of electrical and chemical signals. The 
two realms of signaling are often bridged within neurons by voltage-gated Ca2+ channels, 
such as N-channels (West et al., 2001). With depolarization of postsynaptic sites, N-
channel activity (N-current) triggers biochemical changes including modulation of certain 
ion channels (Wisgirda and Dryer, 1994), enzyme activation (Rittenhouse and Zigmond, 
1999) and gene transcription (Brosenitsch and Katz, 2001; West et al., 2001).  In turn, 
GqPCRs converge on a number of signal transduction cascades to modulate the N-
channel’s response to changing membrane potential. Some of these pathways are well 
described, so that both signaling molecules and sites of modulation on N-channels are 
known.  
A notable exception is the M1 receptor (M1R), a GqPCR that modulates post-
synaptic N-current by an incompletely described signaling cascade referred to as the slow 
pathway (Beech et al., 1992). Other transmitters such as substance P (SP), the natural 
ligand for the neurokinin-1 receptor (NK-1R), also modulate N-current by a slow 
pathway (Shapiro and Hille, 1993; Kammermeier et al., 2000) coupled to Gq (Macdonald 
et al., 1996), suggesting that multiple GqPCRs converge on this pathway. Recent reports 
propose a reduction in phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2] levels 
during GqPCR stimulation suffices for inhibition (Wu et al., 2002; Gamper et al., 2004; 
Michailidis et al., 2007).  However, our previous studies with superior cervical ganglion 
(SCG) neurons indicate that modulation of native N-current by M1Rs requires events 
downstream of PtdIns(4,5)P2 hydrolysis (Liu and Rittenhouse, 2003a). We found that the 
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muscarinic agonist oxotremorine-M (Oxo-M) and arachidonic acid (AA) elicit the same 
distinct pattern of modulation (Liu et al., 2001; Liu and Rittenhouse, 2003a), not only 
inhibiting N-current at positive test potentials, but also enhancing N-current at negative 
test potentials (Fig. 3.1A).  Enhancement and inhibition by AA occur at distinct sites and 
exhibit different biophysical characteristics (Barrett et al., 2001; Liu et al., 2001).  
Moreover, M1R stimulation releases AA in central and SCG neurons (Tence et al., 1994; 
Liu et al., 2006) suggesting that AA may be a downstream effector of the slow pathway. 
Consistent with this hypothesis, inhibiting AA release from phospholipids by 
antagonizing phospholipase A2 (PLA2) activity or including bovine serum albumin 
(BSA), a scavenger of AA, in the bath minimizes N-current modulation by Oxo-M (Liu 
and Rittenhouse, 2003a). Whether both AA-sensitive sites reside in the same channel, or 
whether two distinct channel populations mediate enhancement and inhibition, remains 
untested.  Therefore, we attempted to recapitulate N-current enhancement and inhibition 
in HEK-293 cells.  
MATERIAL AND METHODS 
 
Human embryonic kidney (HEK) cells with a stably transfected M1R [HEK-M1] 
(Peralta et al., 1988), a generous gift from Emily Liman, were cultured in DMEM/F12 
[Gibco (Carlsbad, CA)], supplemented with 10% fetal bovine serum (Gibco), 1% G418 
[Geneticin selective antibiotic, non-sterile, Gibco] and 1% HT supplement (Gibco). Cells 
were transferred into 12-well plates for transfection. Recombinant cells at 60-80% 
confluence were transfected for 1 hour with CaV2.2 e[∆24a, +31a, +37b), the N-channel 
variant found in SCG neurons (Lin et al., 1997); α2δ-1, which is also expressed in SCG 
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(Lin et al., 2004); and various CaVβs at a 1:1:1 or 1:1:2 molar ratio along with enhanced 
green fluorescent protein (eGFP) at ~10% of the total DNA, using Lipofectamine and 
PLUS reagent [Invitrogen (Carlsbad, CA)] per the manufacturer’s instructions. Where 
noted, the transfection mixture contained expression plasmids encoding NK-1R (0.028 
µg/well; #AY462098; UMR cDNA Resource Center, University of Missouri, Rolla, 
MO). 500-1000 ng total DNA was transfected per well. 24-48 hours post-transfection, 
cells were replated on poly-L-lysine coated coverslips and allowed to settle for at least 1 
hour prior to recording. TSAA 201 cells stably transfected with CaV2.2, α2δ-1, and CaVβ3 
were generously provided by Diane Lipscombe. Cells were transfected with 500-1000 ng 
per well of the M1R cDNA (#J04192; a generous gift from Neil Nathanson) along with 
eGFP at 10% of the total DNA and processed as above for current recordings. 
CaVβ1b (GenBank #X61394), CaVβ2a (#M80545) and CaVβ4 (#L02315) were 
provided by Edward Perez-Reyes; CaV2.2 (#AF055477), α2δ-1 (#AF286488), and  CaVβ3 
(#M88751) provided by Diane Lipscombe; the CaVβ2a(C3,4S) mutant was provided by 
Aaron Fox, CaVβ2aβ3 and CaVβ2aβ1b chimeras, were provided by Robert Ten Eick, 
from Marlene Hosey’s lab (Chien et al., 1996; Chien et al., 1998; Chien and Hosey, 
1998). Recordings from untransfected cells yielded whole-cell currents of 9.0 ± 1.3 pA in 
20 mM Ba2+ (data provided by Mandy Roberts-Crowley).  To avoid spurious results from 
endogenous currents, any transfected cells having currents less than 150 pA were 
discarded.  
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Electrophysiology 
Ba2+ currents were recorded at room temperature (20-24°C) using the whole-cell 
configuration of a Dagan 3900a patch-clamp amplifier using methods described 
previously (Barrett et al., 2001; Liu et al., 2001). Currents were filtered at 5 kHz using 
the amplifier's four-pole low-pass Bessel filter and then digitized at 20 kHz with a CED 
micro1401 interface [Cambridge Electronic Design (CED), Cambridge, UK]. Data were 
collected using Patch 6.4 or Signal 2.15 software suites (CED) and stored on a personal 
computer. Prior to analysis, capacitive and leak currents were subtracted using a scaled-
up current elicited with a test pulse to -100 mV. Pipette resistance ranged from 2.5 to 5 
MΩ. Ba2+ currents were elicited every 4 sec by stepping from -90 to 0 mV for 100 ms 
unless otherwise noted. For cells expressing CaVβ2a, 20 mM Ba2+ was used as the charge 
carrier to improve the signal to noise ratio. The internal solution contained (in mM): 135 
Cs-aspartate, 10 HEPES, 0.1 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 
(BAPTA), 1 MgCl2, 4 ATP, 0.4 GTP, adjusted to pH 7.5 with CsOH. The external 
solution contained (in mM): 135 N-methyl glucamine-aspartate (NMG), 10 HEPES, 5 or 
20 Ba2+ (as indicated), adjusted to pH 7.5 with CsOH. NMG (135 mM) was substituted 
for Ba2+ when its concentration was lowered from 20 to 5 mM.  
 
Pharmacology 
Oxotremorine methiodide [Oxo-M; Tocris Biosciences Inc. (Bristol, UK)] was 
prepared as a stock solution in double-distilled water and then diluted 1,000 times with 
bath solution.  SP was prepared as a stock solution in 0.05 M acetic acid and then diluted 
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at least 2,000 times with bath solution. AA (Nu Chek Prep, Elysian, MN) and OPC 
(Calbiochem, La Jolla, CA), were prepared as stock solutions made up in 100% ethanol 
and diluted 1,000 times with bath solution. All chemicals were obtained from Sigma-
Aldrich Inc. (St. Louis, MO) except where noted. 
 
Data Analysis  
Patch 6.4 and Signal 2.15 (CED) were used to measure peak inward current of whole-cell 
traces. The trough seeking function of Patch was used to determine peak current where 
indicated. Data were further analyzed using EXCEL (Microsoft, Seattle, WA), and 
ORIGIN 7.0 (Microcal Software, Northampton, MA). Percent inhibition was calculated 
as: [(I-I’)/I]*100, where I is the control current amplitude, determined by an average of 
five whole-cell current measurements prior to application of a particular agent, and I’ is 
the average of five current measurements at the time specified for the determination. 
Conductance was calculated from a modified Ohm’s Law equation: G = I/(Vm− Vrev), 
where I is the peak current at each test potential, Vm is the test potential, and Vrev is the 
apparent reversal potential. Relative conductance (G/Gmax)-voltage (Vm) curves were 
plotted for whole-cell recordings before and after application of AA. Data were curve fit 
using the Boltzmann Equation function in Origin 7.0 (MicroCal) yielding a curve fitting 
the equation: G/Gmax= Gmax + (Gmin-Gmax)/(1 + exp[(Vm-Vm½ )/k)], where Gmax is the 
maximal conductance, Gmin is the minimal conductance, Vm is the test potential, Vm½ is 
the voltage at half maximal conductance and k is the slope factor. 
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Statistical analyses  
Summary data are presented as mean ± standard error of the mean. A two-tailed paired t-
test was used to determine differences between control and agonist. For comparisons of 
two different cell groups, data were analyzed by two-tailed Student’s t-test for two 
means. For multiple comparisons, statistical significance was determined by a one-way 
analysis of variance (ANOVA) using Origin followed by a Tukey multiple-comparison 
post-hoc test. Statistical significance was set at p < 0.05. 
 
Immunocytochemistry of CaVβ subunits  
Adult SCG neurons were plated on chamber slides (Nagle Nune International, 
Rochester, NY) treated with poly-L-lysine and cultured overnight. Cells were washed 
with phosphate-buffered saline (PBS; 2 × 5 min) and then fixed with 100% Acetone 
(10 min). The fixative was washed away with PBS at room temperature (3 × 5 min). 
Cells were then exposed to PBS containing 10% normal goat serum for 60 min at room 
temperature, followed by incubation with primary antibody for 60 min at room 
temperature. Anti-CaVβ2 (mouse; NeuroMap), Anti-Cavβ3 (rabbit; Sigma), Anti-Cavβ4 
(mouse; NeuroMap) were diluted 1:1,000 in DakoCytomation Antibody Diluent 
(DakoCytomation, Carpintena, CA). Thereafter, cells were washed with PBS (3 × 5 min) 
and were incubated for 60 min in the dark at room temperature with Alexa Fluor 488 
anti-mouse antibody or Alexa Fluor 488 anti-rabbit antibody (Invitrogen, Carlsbad, CA) 
diluted 1:200 in DakoCytomation Antibody Diluent. After incubation with secondary 
antibodies, cells were washed with PBS (3 × 5 min) and a second fixation was performed. 
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Slides were then washed with distilled water and covered with the aqueous mounting 
medium Prolong Gold Antifade reagent (Invitrogen). Images of immunofluorescence 
were obtained at room temperature using a custom-built, video-rate confocal microscope 
(Sanderson and Parker, 2003) with a 40× objective lens. An excitation wavelength of 488 
nm was used and emission spectra collected with long pass filters (OGSIS) at 515 nm 
(Perez and Sanderson, 2005). 
RESULTS 
 
To test whether a homogeneous population of N-channels recapitulates both 
enhancement and inhibition, N-currents were screened for sensitivity to Oxo-M. 
Recombinant currents were evoked from HEK-M1 cells transiently transfected with N-
channel subunits CaV2.2, α2δ-1 and CaVβ3, which most commonly associates with 
CaV2.2 (Witcher et al., 1993). Oxo-M rapidly inhibited peak inward current, reaching a 
stable inhibition within 90 seconds (Figs. 3.1C-D). Since N-current enhancement is 
voltage-sensitive (Liu and Rittenhouse, 2003a), we compared current-voltage (I-V) plots 
measured before and after Oxo-M expecting to observe current enhancement at negative 
test potentials. However, Oxo-M inhibited current at virtually all voltages (Fig. 3.3C). 
tsA 201 cells stably transfected with the same subunits exhibited a similar profile of 
inhibition following exposure to Oxo-M (Figs. 3.1B, E, F), ruling out a system-specific 
effect. 
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CaVβ subunit controls N-current modulation by GqPCRs. 
Lack of enhancement at any potential indicated the recombinant system was 
fundamentally different from N-current modulation observed in SCG neurons. In addition 
to incomplete recapitulation of GqPCR modulation, recombinant N-current exhibited 
robust, fast inactivation (Figs. 3.1D,F; 3.3C) as previously observed with channels 
containing CaVβ3 (Olcese et al., 1994). In contrast, native N-current in SCG neurons 
exhibits kinetics with little inactivation (Plummer et al., 1989), similar to recombinant N-
current from channels containing CaVβ2a (Hurley et al., 2000; Yasuda et al., 2004). 
Moreover, AA robustly inhibits noninactivating current in SCG neurons evoked with test 
pulses ranging in duration from 20 (Fig. 3.2) to 700 ms (Liu et al., 2001). Since SCG 
neurons express CaVβ2a mRNA (Lin et al., 1997), we hypothesized that the majority of 
N-current arises from CaVβ2a-containing channels. If true, these channels might exhibit 
both inhibition and enhancement. We found that Oxo-M rapidly inhibited N-current from 
cells expressing CaVβ2a. However, unlike CaVβ3, initial inhibition gave way to stable 
enhancement (Figs. 3.1G-H). Moreover, comparison of I-V plots revealed that Oxo-M no 
longer inhibited current at any potential, but enhanced current at negative test potentials 
(Fig. 3.3B). Although we hypothesized expression of CaVβ2a would elicit enhancement 
at negative potentials, separation of enhancement from inhibition based on CaVβ 
expression was unanticipated. Therefore, we tested whether other CaVβs would dually 
modulate N-current by repeating the above experiments with two other neuronal CaVβs: 
CaVβ1b and CaVβ4. As with CaVβ3, when either CaVβ1b (Fig. 3.3A) or CaVβ4 (Fig. 
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3.3D) was expressed, Oxo-M inhibited current at all test potentials, indicating that 
channels containing CaVβ2a exhibit unique N-current modulation by M1Rs. 
To determine whether M1Rs uniquely influence the profile of modulation, we 
examined whether N-current modulation by another GqPCR depends on CaVβ.  We tested 
NK-1Rs since in SCG neurons, stimulation of M1Rs and NK-1Rs inhibit N-current 
through converging signaling pathways that require Gαq and downstream activation of 
phospholipase C (PLC) (Shapiro et al., 1994a; Kammermeier et al., 2000). We examined 
current modulation that occurred following exposure to SP. As with Oxo-M, an initial 
transient inhibition progressed to a stable current enhancement when CaVβ2a was 
expressed along with CaV2.2 and α2δ-1 (Figs. 3.4A, C). In contrast, SP elicited sustained 
inhibition with CaVβ3 expression (Figs. 3.3E & 3.4B-C). These data indicate that control 
of modulation by CaVβ is a mechanism used by numerous GqPCRs, rather than unique to 
M1Rs (Fig. 3.1A).  
 
AA elicits a profile of N-current modulation similar to GqPCR stimulation. 
AA mimics N-current modulation by M1Rs in SCG neurons and may serve as the 
downstream effector of this pathway (Liu and Rittenhouse, 2003a). If so, AA also should 
inhibit or enhance recombinant N-current similarly to M1R or NK-1R stimulation. When 
this hypothesis was tested, AA’s actions recapitulated the pattern of modulation observed 
with M1R or NK-1R stimulation; enhancement and inhibition separated based on CaVβ 
expression (Figs. 3.3F-J). If elevated AA levels mediate enhancement and inhibition, 
both should reverse following washout of exogenous AA. As with SCG neurons, washing 
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with copious amounts of bath solution or with 1 mg/ml BSA reversed modulation (Figs. 
3.5A-F). Moreover, enhancement recurred with a second application of AA following 
wash with BSA (Fig. 3.5A). These findings corroborate our assertion that AA mediates 
N-current modulation by the slow pathway (Liu and Rittenhouse, 2003a; Liu et al., 
2004).   
As a final test of AA’s role in the slow pathway, we antagonized endogenous 
AA’s release from membrane phospholipids using the PLA2 antagonist oleyloxyethyl 
phosphorylcholine (OPC) to determine whether OPC minimizes N-current inhibition by 
Oxo-M.  Exposure to Oxo-M for 60 seconds significantly inhibited N-current from 
CaVβ3-containing channels (P<0.05 n=16). In contrast, OPC eliminated significant 
current inhibition by Oxo-M (P>0.05 n=7) (Figs. 3.1I-J). A similar profile was observed 
with SP (Chapter II). The striking recapitulation by AA of GqPCR-induced N-current 
enhancement and inhibition, coupled with the loss of modulation when antagonizing AA 
release or sequestering free AA with BSA advance our previous hypothesis that PLA2 
and AA participate in the slow pathway (Liu and Rittenhouse, 2003a).  
 
Expression of multiple CaVβ isoforms produces heterogeneous N-currents. 
Our findings yield a possible explanation for why SCG neurons exhibit both 
enhancement and inhibition of whole-cell N-current (Barrett et al., 2001; Liu and 
Rittenhouse, 2003a; Liu et al., 2004).  N-current’s diverse biophysical properties in 
different neurons have been attributed to CaV2.2 coexpression with different CaVβ 
isoforms within individual neurons (Scott et al., 1996). Similarly, SCG neurons may 
 
 61
exhibit both forms of modulation because CaV2.2 co-assembles with different CaVβs. If 
this hypothesis is correct, the pattern of modulation observed in SCG neurons should 
recapitulate in HEK-M1 cells transfected with multiple CaVβs. When cells were 
transfected with CaVβ2a and CaVβ3, the I-V plots strikingly recapitulated I-V plots from 
SCG neurons (Liu and Rittenhouse, 2003a), with enhancement occurring at negative 
potentials and inhibition at positive potentials (Fig. 3.6A). However, unlike activity from 
SCG neurons (Liu et al., 2001; Liu and Rittenhouse, 2003a), the currents rapidly 
inactivated. SCG express CaVβ2a, CaVβ3 and CaVβ4 mRNA with trace amounts of 
CaVβ1b mRNA (Lin et al., 1996). When immunocytochemistry was performed on 
dissociated SCG neurons to determine which CaVβ proteins are expressed, neurons 
exhibited immunofluorescence with a rank order density of CaVβ2a>CaVβ3>CaVβ4 (Fig. 
3.6B). Therefore, we retested the modulatory response in cells transfected with CaVβ2a, 
CaVβ3 and CaVβ4. In these cells, N-current closely recapitulated both the I-V relationship 
and current kinetics of native N-current under control conditions and following Oxo-M 
(Fig. 3.6C). These findings indicate that the characteristic pattern of modulation observed 
in SCG neurons (Liu and Rittenhouse, 2003a) most likely results from heterogeneous 
expression of different CaVβ isoforms with CaV2.2.  
 
A model for dual modulation of N-current  
 We established a working model for how CaVβ2a controls modulation based on 
previous studies that examined AA’s mechanism of inhibition of different Ca2+ channels. 
Our studies with SCG neurons demonstrated that current inhibition by AA occurs 
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intracellularly or within the inner leaflet of the membrane. In contrast, enhancement 
appears located extracellularly or within the outer leaflet of the bilayer (Barrett et al., 
2001; Liu et al., 2001). CaVβ subunits bind to cytoplasmic loops of CaV2.2 (Pragnell et 
al., 1994). Thus, we hypothesized that the unique interactions of CaVβ2a with CaV2.2 
somehow attenuates inhibition. The observation that in SCG neurons (Barrett et al., 2001; 
Liu et al., 2001) and with recombinant channels containing either CaVβ2a or CaVβ3 (Figs. 
3.7A-B), AA induces initial N-current enhancement, which is sustained with CaVβ2a, but 
for CaVβ3 is followed by a more slowly progressing inhibition supports this model. Thus, 
we postulated that N-current modulation first exhibits enhancement that becomes masked 
by subsequent, more dominant inhibition. Since our previous work indicated 
enhancement by AA arises from increased voltage sensitivity (Barrett et al., 2001), we 
compared normalized conductance-voltage (G-V) curves to determine whether increased 
voltage sensitivity occurs independently of CaVβ2a expression. Both CaVβ2a- and CaVβ3-
containing cells exhibited a negative shift in conductance in response to AA (Figs. 3.7C-
D), demonstrating that AA increases N-channel voltage sensitivity independently of CaVβ 
subunit expression. These data indicate that CaVβ2a’s unique ability to attenuate 
inhibition reveals sustained enhancement. In contrast, inhibition results from increased 
stability of a closed state (Liu and Rittenhouse, 2000) essentially reducing the number of 
channels available to open. This type of inhibition should dominate an increase in voltage 
sensitivity; if channels will not open at any voltage, increasing their voltage sensitivity 
will have little effect on currents. Thus by blocking a dominating inhibition (Fig. 3.7E), 
CaVβ2a unmasks latent enhancement. 
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Loss of CaVβ2a palmitoylation restores partial inhibition of N-current by Oxo-M or 
AA 
Having established that CaVβ2a uniquely blocks N-current inhibition by GqPCR 
stimulation or exogenous AA, we investigated the structural aspects of CaVβ2a to 
determine its mechanism of action. A conspicuous feature of CaVβ2a is its unique 
palmitoylation of two cysteine residues near the N-terminus (Chien et al., 1996). Our 
observation that palmitoylated CaVβ2a interferes with a fatty acid-mediated inhibition of 
CaV2.2 raises the possibility of direct antagonism between palmitic acid and AA. 
Therefore, we tested a depalmitoylated mutant to determine whether CaVβ2a must be 
palmitoylated to minimize inhibition and reveal enhancement. Currents from channels 
containing depalmitoylated CaVβ2a [CaVβ2a(C3,4S)] (Chien et al., 1996) exhibited an 
initial transient inhibition following Oxo-M that relaxed, yielding a small but 
insignificant inhibition (Figs. 3.8A, G). AA initially enhanced current amplitude, 
followed by significant inhibition (Figs. 3.8B, G). The loss of enhancement and 
appearance of inhibition, though differing in magnitude with Oxo-M or AA, support the 
idea that palmitoylation blocks inhibition.  
If the palmitic acid groups on Cavβ2a are both necessary and sufficient for 
antagonizing inhibition, then palmitoylating another CaVβ should convert current 
inhibition to enhancement. Therefore we tested a chimera in which the variable N-
terminus of CaVβ1b was replaced with the palmitoylated, 16 amino acid N-terminus of 
CaVβ2a (CaVβ2aβ1b) (Chien et al., 1998). In cells expressing CaVβ2aβ1b, application of 
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Oxo-M enhanced current with no inhibition (Fig. 3.8G). AA no longer inhibited these 
currents significantly compared to Cavβ1b (n=4) (Fig. 3.3J). The difference in modulation 
by AA and Oxo-M may be attributed to an exaggerated response to exogenous 
application of AA compared to the response to physiological concentrations of AA 
released upon M1R stimulation. I-V plots after either Oxo-M or AA exhibited 
enhancement of current at negative test potentials and no inhibition at positive test 
potentials (Figs. 3.8C-D), indicating that the palmitoylated N-terminus is both necessary 
and sufficient to block inhibition.   
However, a second chimera, in which the N-terminus of CaVβ3 was replaced with 
the N-terminus of CaVβ2a (CaVβ2aβ3) (Chien et al., 1998), did not block inhibition as 
effectively. In cells expressing CaVβ2aβ3, inhibition by Oxo-M was diminished 
compared to wild-type CaVβ3, while AA reversibly inhibited currents similarly to wild-
type levels (Figs. 3.8E-G). I-V plots taken before and 90 seconds after application of 
Oxo-M or AA exhibited inhibition at positive test potentials (Figs. 3.8E-F). These results 
indicate that addition of CaVβ2a’s palmitoylated N-terminus to CaVβ3 only partially 
reproduced the stable enhancement by Oxo-M or AA normally observed with wild-type 
CaVβ2a. However, CaVβ2a protein shares highest sequence homology to CaVβ1b 
(Birnbaumer et al., 1998).  
Thus, the simplest interpretation for the varied results with the different chimeras 
is that CaVβ2aβ1b binds to CaV2.2 similarly to wild-type CaVβ2a to minimize N-current 
inhibition. In contrast, the more divergent CaVβ2aβ3 interacts differently with CaV2.2 
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(Fig. 3.8H). In support of this notion, CaVβ2aβ3-containing cells exhibited varied 
kinetics, from noninactivating currents resembling CaVβ2a-containing channel activity 
(Fig. 3.3B) to rapidly inactivating currents resembling depalmitoylated CaVβ2a-
containing channel activity (Figs. 3.8A-B). Moreover, the kinetics varied within 
individual recordings and from cell to cell from a rapidly inactivating to a noninactivating 
kinetic profile (data not shown). The unstable inactivation kinetics suggests that 
CaVβ2aβ3 cannot dock properly to CaV2.2, thus destabilizing and changing the location 
of CaVβ2a’s palmitoyl groups.  
 
Free palmitic acid minimizes N-current inhibition. 
If our interpretation that the palmitoyl groups antagonize inhibition is correct, 
freeing the palmitoyl groups from protein constraints might allow the fatty acids to find 
and assume their optimal position for interacting with CaV2.2 and blocking inhibition 
(Fig. 3.9A). Alternatively, if the palmitic acids do not interact directly with CaV2.2 then 
introducing free palmitic acid should not alter N-channel modulation by agonist. We 
tested this prediction by preincubating cells expressing NK-1Rs and CaVβ3-containing 
channels with free palmitic acid. Under these conditions, the sustained inhibition 
normally observed with SP (Figs. 3.9B-C) was replaced by an initial enhancement that 
relaxed resulting in no significant change (p>0.24) in current amplitude over time (Figs. 
3.9B, D). Moreover compared to control conditions, little inhibition by SP was detected 
in I-V plots from cells preincubated with palmitic acid (Figs. 3.9C-D). On its own, 
palmitic acid did not affect N-current when compared to exposure of the cells to bath 
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solution for 8 mins (Fig 3.9E). Preliminary recordings with a shorter duration of 
preincubation with palmitic acid did not result in significant reduction in modulation of 
N-currents by SP. These findings demonstrate that exogenous application of free palmitic 
acid suffices to block current inhibition of CaVβ3-containing N-channels. More 
importantly, these results support a model where CaVβ2a’s palmitic acids interact directly 
with CaV2.2 to antagonize N-current inhibition by endogenously released AA (Fig. 3.10). 
 
DISCUSSION 
 
A New Role for Palmitoyl Groups of Palmitoylated Proteins  
 
Our data identify a previously unrecognized role for protein palmitoylation where 
it serves as the key feature of CaVβ2a’s capacity to toggle CaV2.2 modulation from 
inhibition to enhancement following stimulation of GqPCRs. Here and in other systems, 
palmitoylation serves to target or anchor proteins to specific membrane domains (Chien 
et al., 1996; Resh, 2006). Once positioned in the membrane, palmitoylation increases 
stability and efficiency of action, but normally does not alter the functional properties of 
proteins. One exception to this generalization is retinal epithelial protein 65 (RPE65), a 
chaperone protein for all-trans-retinal esters. In this case, palmitoylation not only targets 
RPE65 to the membrane, it also reverses RPE65’s binding specificity for vitamin A to 
all-trans retinyl ester, consequently affecting how rapidly photoreceptors respond to light 
(Xue et al., 2004). Thus, palmitoylation qualitatively alters the substrate specificity of the 
same protein that is reversibly palmitoylated. Here, our data extend the functions of 
palmitoylation in a new direction by revealing that following stimulation of GqPCRs, the 
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palmitoyl groups of one protein, CaVβ2a, block inhibition of a second protein, CaV2.2. 
Moreover, we have shown that coexpression of CaVβ2a with other CaVβs in a 
recombinant system recapitulates the dual enhancement and inhibition of N-current 
observed in SCG neurons. This finding provides an explanation of how stimulation of 
M1Rs or exogenous AA elicit both enhancement and inhibition of N-current in individual 
sympathetic neurons (Liu and Rittenhouse, 2003a). 
Our finding that palmitoylation antagonizes an inhibition mediated by 
PtdIns(4,5)P2 breakdown and increased free AA (Liu and Rittenhouse, 2003a; Gamper et 
al., 2004) raises the possibility that dual palmitoyl groups interact directly with CaV2.2 to 
antagonize AA’s interaction with CaV2.2 and subsequent inhibition of N-channel activity. 
The idea that AA directly interacts with Ca2+ channels is supported by the finding that 
M1R stimulation or application of exogenous AA also inhibits recombinant CaV3 currents 
in whole-cell (Zhang et al., 2000; Talavera et al., 2004; Hildebrand et al., 2007) and 
ripped-off patch configurations (Chemin et al., 2007). Since CaV3 (T-type) channels do 
not require coexpression of a CaVβ or α2δ to open, T-channel modulation must occur at a 
site on the pore-forming subunit. Moreover, AA inhibits T-current with a Hill coefficient 
of 1.6, indicating cooperative binding of at least two AA molecules to the T-channels 
(Talavera et al., 2004). Taken together these findings are consistent with a direct 
interaction between AA and T-channels. Similarly, AA most likely confers N-current 
inhibition by acting at a homologous site on CaV2.2 because both N- and T-channels 
exhibit similar changes in gating following application of AA (Liu and Rittenhouse, 
2000; Talavera et al., 2004). 
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Palmitoylated CaVβ2a may serve as a phospholipid mimic by competing with 
PtdIns(4,5)P2 and free AA for interaction with CaV2.2. 
Under basal conditions AA normally resides in the sn-2 position of PtdIns(4,5)P2. 
Since palmitoylated CaVβ2a appears to antagonize the actions of free AA on CaV2.2, it 
may also compete with PtdIns(4,5)P2 for interaction with CaV2.2; the two palmitic acids 
of CaVβ2a residing in sites normally occupied by the two fatty acid tails of PtdIns(4,5)P2. 
Consistent with its ability to block N-current inhibition by free AA, palmitoylated 
CaVβ2a acts as a “phospholipid mimic” to maintain normal channel activity. This model 
is attractive in that it incorporates previous findings that PtdIns(4,5)P2 associates with 
channels increasing their availability to open (Wu et al., 2002; Gamper et al., 2004). The 
model also supports our previous findings (Liu and Rittenhouse, 2003a) that increased 
free AA confers current inhibition either by displacing PtdIns(4,5)P2 or by remaining 
associated with channels following phospholipid breakdown. Lastly, our finding that free 
palmitic acid blocks inhibition by SP of CaVβ3-containing channels supports the idea that 
the palmitic acids occupy the same or overlapping sites recognized by AA.   
Whether PtdIns(4,5)P2 as well as AA compete for the same site of interaction with 
CaV2.2 as the palmitoyl groups of CaVβ2a and where the location of that site is awaits 
future investigation. However, we have observed that whole-cell recombinant current 
from CaVβ2a-containing channels, in contrast to CaVβ3-containing channels (Gamper et 
al., 2004), rundown only minimally over time (data not shown), consistent with 
palmitoylated CaVβ2a functionally substituting for PtdIns(4,5)P2. Thus, when taken 
together, our findings and the results of other laboratories best fit a model where 
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palmitoylated CaVβ2a, PtdIns(4,5)P2 and free AA compete for an overlapping interaction 
site on CaV2.2. Given the extent that lipids such as PtdIns(4,5)P2 and AA associate with 
membrane protein complexes, the interference of such interactions by palmitoylated 
proteins is predicted to occur in other protein complexes, yielding broad importance 
beyond ion channel functioning.    
 
Expression of palmitoylated CaVβ2a may underlie novel forms of synaptic plasticity 
The presence or absence of palmitoylated CaVβ2a may have far-reaching con-
sequences for synaptic plasticity. CaVβ2a expression displays an overlapping distribution 
with GqPCRs (Tence et al., 1994; Liu and Rittenhouse, 2003a) throughout the brain and 
is primarily localized postsynaptically in dendrites and cell bodies (Lie et al., 1999), 
indicating that enhancement of Ca2+ channel activity will affect postsynaptic membrane 
excitability. In support of this notion, increased current amplitude and/or kinetic changes 
associated with Ca2+ current enhancement (Zhang et al., 2000; Bannister et al., 2004; Guo 
and Ikeda, 2004; Talavera et al., 2004; Tai et al., 2006; Chemin et al., 2007) occur in 
different neurons and recombinant channels from the CaV2 and CaV3 families (Keyser 
and Alger, 1990; Melliti et al., 2001; Chemin et al., 2007; Meza et al., 2007). In contrast, 
native or recombinant channels associated with CaVβ1b, CaVβ3 or CaVβ4, exhibit 
inhibition following similar stimulation (Keyser and Alger, 1990; Liu and Rittenhouse, 
2003a; Gamper et al., 2004; Guo and Ikeda, 2004; Meza et al., 2007). Since CaVβ2 
expression changes developmentally (Tanaka et al., 1995) and with activity (Lie et al., 
1999), synaptic output also may change over time. Patients with temporal lobe epilepsy 
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exhibit increased postsynaptic CaVβ2 expression in damaged hippocampal regions. In 
contrast, hippocampal specimens obtained from patients who underwent surgical 
lesioning exhibit immunoreactivity for CaVβ that is indistinguishable from control 
patients (Lie et al., 1999).  
Whether upregulation of CaVβ2 is a response to counteract hyperexcitability or 
whether increased CaVβ2 levels contribute to excitotoxic neurodegeneration has not been 
determined. Nevertheless, these findings document in vivo plasticity of CaVβ2 
expression. In the short term, palmitoyl acyl transferases dynamically regulate protein 
palmitoylation in hippocampal dendrites and cell bodies to control synaptic function (El-
Husseini Ael et al., 2002; Fukata et al., 2004). Thus, expression of CaVβ2 in postsynaptic 
regions should create a previously unrealized level of plasticity where the response to a 
transmitter, acting on its GqPCR from moment to moment, may switch from inhibitory to 
excitatory depending on whether CaVβ2a’s palmitoyl groups interact with CaV2.2.  
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Figure 3.1 M1R induced inhibition of recombinant N-current is blocked by a PLA2 
antagonist. HEK-M1 cells were transiently transfected with N-channel subunits CaV2.2, 
α2δ-1 and CaVβ3. (A) Working model of the slow pathway where AA release, catalyzed 
by PLA2, is a necessary component to elicit N-current modulation. AA enhances current 
(green arrow) by acting at a distinct site that may be in the outer leaflet of the membrane 
(Barrett et al., 2001). AA inhibits current by acting at an intracellular site or a site within 
the inner leaflet  (Barrett et al., 2001; Liu et al., 2001). (B) Summary of current inhibition 
after 1 minute exposure to Oxo-M. (C) Time course of peak inward current using 5 mM 
Ba2+ as charge carrier; before, and 3 minutes after bath application of Oxo-M (10 µM). 
(D) Representative whole-cell current traces taken from the respective time course prior 
to (▬) and 1 min after (▬) Oxo-M application. Currents were elicited every 4 seconds 
by stepping to a test potential of 0 mV for 100 ms. Scale bars in D, F, H, J correspond to 
0.4 nA. (E, F) Modulation of N-current from tsA 201 cells stably transfected with 
CaV2.2, α2δ-1 and CaVβ3 and transiently transfected with M1Rs (500-1000 ng/well) and 
eGFP is shown in the time course and representative sweeps as described above. The 
charge carrier was increased to 20 mM Ba2+ to improve signal to noise ratio, and 
accordingly the test potential was adjusted to +10 mV. (G, H) HEK-M1 cells were 
transiently transfected with N-channel subunits CaV2.2, α2δ-1 and CaVβ2a. Modulation of 
N-current by M1R stimulation illustrated in a time course (G) and current traces (H). (I, 
J) N-current modulation from cells expressing HEK-M1 cells transfected as for C. Cells 
were exposed to the PLA2 antagonist OPC (10 μM) for at least 3 minutes prior to 
application of Oxo-M. 
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Figure 3.2 AA inhibits whole-cell current in SCG neurons. SCG neurons were acutely 
dissociated following the methods of Liu et al. (Liu et al., 2006). The whole-cell current 
is composed primarily of N-current (80-90%) and the remaining component is primarily 
L-current. Whole-cell currents were recorded using the voltage protocol shown above the 
current traces. FPL 64175 (FPL; 1 μM) was included in the bath to elicit a long-lasting 
tail current made up exclusively of L-type Ca2+ channel activity. ETYA (30 μM) was 
included in the bath to serve two functions. First ETYA will block breakdown of AA, by 
acting as a competitive substrate for enzymes such as cyclooxygenase and lipooxy-
genases that metabolize AA. Second, ETYA mimics current enhancement by AA, but not 
inhibition (Barrett et al., 2001). Thus under these conditions, inhibition by AA can be 
examined in isolation from enhancement. (A) In the presence of FPL and ETYA, SCG 
currents exhibit noninactivating kinetics. AA inhibits the noninactivating peak current 
primarily composed of N-current as well as the long-lasting tail current, a measure of L-
current. (B) Summary data of the effect of AA on whole-cell currents from SCG neurons 
demonstrating significant inhibition by AA (***p< 0.002 using a two-tailed paired t-test; 
n=6). 
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Figure 3.3 CaVβ determines N-current modulation by GqPCRs and AA. (A-D) HEK-M1 
cells were transiently transfected with CaV2.2, α2δ-1 and various CaVβ subunits. Currents, 
measured in 5 mM Ba2+, were elicited every 4 sec by stepping from -90 to 0 mV for 100 
ms unless noted.  Representative whole-cell current traces were always taken prior to (▬) 
and 3 min after (▬) drug application. Scale bars, 0.4 nA. Averaged normalized I-V plots 
were taken before (●) and 90 seconds after (o) agonist application. (n=3-6 cells per 
group).  For cells expressing CaVβ2a, 20 mM Ba2+ was used as charge carrier to improve 
the signal to noise ratio. The test potential was adjusted to +10 mV to correct for the shift 
in peak inward current. (E) Histogram summarizing N-current modulation following 3 
minutes of Oxo-M (10 µM; gray bars) and SP (5 nM; black bars). Percent change in 
current amplitude was highly significant between CaVβ2a and CaVβ1b, CaVβ3 or CaVβ4 
irrespective of whether Oxo-M or SP was applied (**p<0.005, one way ANOVA). (F-I) 
Modulation of N-current by 10 µM AA shown as current traces and averaged I-V plots 
(n=4-5 cells per group). (J) Histogram summarizing N-current modulation following 3 
minutes of AA (**p<0.005, one way ANOVA). 
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Figure 3.4 NK-1R stimulation elicits a similar profile of N-current modulation as M1Rs. 
HEK-M1 cells were transiently transfected with the NK-1R along with CaV2.2, α2δ-1 and 
either (A) CaVβ2a or (B) CaVβ3. Using SP (5 nM) as the agonist, current modulation is 
shown in left, a time course of peak current; middle, representative whole-cell current 
traces; and right, averaged I-V plots (n=4). (C) Summary of the modulatory effects of SP 
on currents from cells expressing either CaVβ2a or CaVβ3 (***p<0.005, one-way 
ANOVA). No significant difference in current inhibition was observed from cells 
expressing CaVβ3 with 5 nM and 250 nM SP (p>0.26). 
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Figure 3.5 Absorption of AA with BSA minimizes N-current enhancement. Modulation 
of N-current by AA in HEK-M1 cells transiently transfected with CaV2.2, α2δ-1, CaVβ2a, 
CaVβ1b or CaVβ4 is demonstrated by (A) time courses using 20 mM Ba2+ as the charge 
carrier before, during, and after two separate applications of AA (10 μM). Washout of 
AA was achieved by bath application of 1 mg/ml BSA. (B) Representative whole-cell 
current traces taken at arrows in A. (C) Comparison of I-V plots taken from A before (●) 
and after (o) the first application of AA. (D) Comparison of I-V plots taken after washout 
of AA by BSA (●) and after (o) the second application of AA. (E, F) Example time 
course of reversible inhibition of N-current from (E) CaVβ1b-containing and (F) CaVβ4- 
containing channels. 
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Figure 3.6 Expression of multiple CaVβ subunits recapitulates modulation pattern 
observed in SCG neurons following M1R stimulation. Currents were recorded using 20 
mM Ba2+. Current traces and average I-V plots from HEK-M1 cells transiently 
transfected with (A) CaV2.2:α2-δ-1:CaVβ2a:CaVβ3 in a 12:12:10:1 ratio; (B) Lower panel, 
individual SCG neurons shown in bright field. Upper panel, corresponding view when 
cells were excited with a wavelength of 580 nm. (C) CaV2.2:α2-δ-1:CaVβ2a:CaVβ3:CaVβ4 
in a 12:12:10:1:1 ratio (n=3-4 cells per group).  
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Figure 3.7 CaVβ2a blocks N-current inhibition revealing latent enhancement. (A, B) 
Time courses with AA. AA caused a negative shift in G/Gmax for cells expressing (C) 
CaVβ2a or (D) CaVβ3. (E) Schematic representation of working model. Upon GqPCR 
stimulation, the released AA can bind to both inhibitory and enhancement sites on the 
channel. When CaVβ3 is present, both inhibitory and enhancement sites are available for 
AA to bind. However, since inhibition dominates, the resultant modulation is inhibition 
of current. When CaVβ2a is present, inhibition no longer occurs probably because the 
palmitoylated CaVβ2a blocks or occupies the inhibitory site and the resultant modulation 
is enhancement of current.
 
 80
 
 
 
Figure 3.8 Palmitoylation determines which form of modulation is observed. Using 20 
mM Ba2+, modulation by Oxo-M or AA of cells expressing (A, B) mutant 
CaVβ2a(C3,4S); (C,D) CaVβ2aβ1b; or (E, F) CaVβ2aβ3 is shown in current traces and I-
V plots. (G) Summary of the modulatory effects on currents after application of Oxo-M 
or AA for 3 minutes (n=4-7). (H) Working model for N-current modulation in the 
presence of CaVβ2aβ1b and CaVβ2aβ3. 
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Figure 3.9 Palmitic acid antagonizes inhibition of N-current by NK-1R stimulation. 
HEK-M1 cells were transiently transfected with NK-1R, CaV2.2, α2δ-1 and CaVβ3. (A) 
Diagram showing preincubation of HEK-M1 cells with exogenously applied palmitic 
acid blocks inhibition of N-channels by fatty acids, such as AA, released after NK-1R 
activation. (B) Summary showing preincubation of cells with 10 μM palmitic acid 
significantly attenuates inhibition by SP (*p<0.05). (C) Modulation of N-current by SP 
from cells expressing CaVβ3 is shown in time course, current traces and I-V plots (n=5). 
(D) Preincubation of cells with palmitic acid causes loss of inhibition by SP as shown in 
time course, current traces and I-V plot (n=6). (E)  Exposure of cells to either Ba (left) or 
palmitic acid (middle) for 8 mins has similar effect on amplitude of peak current (right) 
(n=4-7). 
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Figure 3.10 Model of interference of inhibition by palmitoylated CaVβ2a. (A) As 
presented, our data support a model where upon GqPCR stimulation, release of AA 
initially enhances N-current by acting at a site distinct from inhibition. However, N-
current inhibition by AA of channels containing CaVβ1b, CaVβ3, or CaVβ4, dominates 
modulation of CaV2.2 and obscures enhancement. (B) In the presence of CaVβ2a, the 
palmitoylated N-terminus of the CaVβ subunit blocks N-current inhibition by 
endogenously released AA due to the two palmitic acids competitively interacting with 
CaV2.2 thus revealing latent enhancement. 
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CHAPTER IV: 
 
Orientation of palmitoylated Cavβ2a relative to  
Cav2.2 is critical for slow pathway modulation of  
N-current by the tachykinin receptor NK-1R 
 
ABSTRACT   
 
The Gq-coupled tachykinin receptor (NK-1R) modulates N-type Ca2+ channel 
(CaV2.2 or N-channel) activity at two distinct sites by a pathway involving a lipid 
metabolite, most likely arachidonic acid (AA). In the previous study, we found that the 
form of modulation observed depends on which accessory CaVβ subunit  is co-expressed 
with CaV2.2. When palmitoylated CaVβ2a is co-expressed, activation of NK-1R by 
substance P (SP) enhances N-current. In contrast, when CaVβ3 is co-expressed, SP 
inhibits N-current. However, exogenously applied palmitic acid minimizes this inhibition. 
These findings raise the possibility that the palmitoyl groups of CaVβ2a may occupy an 
inhibitory site on CaV2.2, or prevent AA from interacting with that site, thereby 
minimizing inhibition. If so, changing the orientation of CaVβ2a relative to CaV2.2 may 
displace the palmitoyl groups and prevent them from antagonizing AA at the inhibitory 
site thereby allowing inhibition even in the presence of CaVβ2a. Here we tested this 
hypothesis by deleting one (Bdel1) or two (Bdel2) amino acids proximal to the alpha 
interacting domain (AID) of CaV2.2’s I-II linker. CaVβs bind tightly to the AID while the 
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rigid and helical region proximal to the AID is thought to regulate CaVβ’s orientation and 
consequently its secondary interactions with CaV2.2. While Bdel1 currents exhibited 
more variable enhancement by SP, Bdel2 current enhancement was lost at all voltages; 
instead, inhibition was observed. This inhibition remarkably mimicked the profile of 
current inhibition elicited from wt CaV2.2 co-expressed with CaVβ3. Moreover, adding 
back exogenous palmitic acid minimized inhibition of Bdel2 currents. These findings 
support the hypothesis that CaVβ2a’s palmitoyl groups, when appropriately positioned, 
can minimize N-current inhibition following NK-1R activation by preventing 
endogenously released AA from binding to the N-channel’s inhibitory site.  
INTRODUCTION 
 
NK-1R couples to a Gq signal transduction cascade (Macdonald et al., 1996) to 
release inflammatory products from phospholipid breakdown and mediates nociception 
(Duffy, 2004). N-type voltage-gated Ca2+ (N-channels) appear to be involved in 
transmission of nociceptive signals to the spinal cord since selectively antagonizing N-
current disrupts substance P release from spinal cord slices (Smith et al., 2002). At the 
level of the whole organism, CaV2.2 knockout mice display reduced responses to 
neuropathic and inflammatory pain (Hatakeyama et al., 2001; Saegusa et al., 2001). 
Pharmacological antagonists of N-channels also effectively relieve pain (Schroeder et al., 
2006), suggesting that N-channels may serve as a target of NK-1Rs to transduce pain 
signals into neuronal activity. Indeed NK-1Rs inhibit N-current using a similar pathway 
to that which mediates pain. N-current inhibition by SP requires activation of Gq and 
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Ca2+-dependent phospholipase C (PLC) downstream of NK-1R activation (Shapiro and 
Hille, 1993; Kammermeier et al., 2000). In sympathetic neurons, M1 muscarinic receptors 
(M1Rs) converge on the same pathway, therefore called the slow pathway. Its stimulation 
results in voltage-independent, BAPTA-sensitive and phospholipase A2 (PLA2)-
dependent inhibition of N-current (Beech et al., 1992; Shapiro and Hille, 1993; 
Kammermeier et al., 2000; Liu and Rittenhouse, 2003a). 
Exogenously applied AA or stimulation of M1Rs or NK-1Rs enhance as well as 
inhibit N-current (Barrett et al., 2001; Liu et al., 2001; Liu and Rittenhouse, 2003a); 
Chapter III). As shown in Chapter III, the form of modulation observed depends on 
which accessory CaVβ subunit is coexpressed with CaV2.2. When CaVβ1b, CaVβ3, or 
CaVβ4, is present, AA (or receptor agonist) rapidly enhances N-current; however 
enhancement quickly progresses to robust inhibition. In contrast, currents from CaVβ2a-
containing channels exhibit sustained enhancement. Of the known CaVβ subunits, only 
CaVβ2a is palmitoylated on its two N-terminal cysteine residues (Chien et al., 1996; 
Takahashi et al., 2003). We hypothesized that persistent enhancement may result from 
the palmitoyl groups of CaVβ2a assuming a position within the membrane that prevents 
AA from interacting with the N-channel’s inhibitory site(s) (Chapter III). In support of 
this possibility, we found that AA no longer enhanced but instead inhibited N-current 
from channels containing a depalmitoylated CaVβ2a [CaVβ2a(C3,4S)] (Chien et al., 1996) 
(Chapter III). Additionally, when CaVβ2a’s N-terminus was substituted into CaVβ1b to 
form a chimeric CaVβ2a/β1b (Chien et al., 1998), N-current was no longer inhibited 
(Chapter III), consistent with the palmitoyl groups preventing inhibition. Lastly, 
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exogenously applied palmitic acid successfully minimized the inhibition normally 
observed with CaVβ3. Taken together, these findings suggested that the palmitoyl groups 
are sufficient for preventing N-current inhibition via the slow pathway.   
From these findings, we proposed a model in Chapter III whereby the palmitoyl 
groups of CaVβ2a (Fig. 4.1B) interact with CaV2.2 at the inhibitory site normally 
occupied by AA released during phospholipid breakdown that follows stimulation of 
PLC. For such an interaction to occur, CaVβ2a must reside in a specific orientation so that 
the palmitoyl groups situate close to or overlap with the channel’s inhibitory site (Fig 
4.1D). However, while our previous findings suggest that the palmitoyl groups may 
compete for an inhibitory site on CaV2.2, they do not rule out the possibility that 
nonspecific actions of free or tethered palmitic acid disrupt inhibition. Therefore, we 
tested whether changing CaVβ2a’s orientation relative to CaV2.2 rescues inhibition (Fig. 
4.1B).  
All CaVβs bind with high affinity to the cytoplasmic linker between domains I and 
II (Fig. 4.1B) at the alpha-interacting domain (AID) (Pragnell et al., 1994; Chen et al., 
2004; Opatowsky et al., 2004; Van Petegem et al., 2004). Their presence tunes the gating 
properties of channels possibly by modulating the movements of IS6. The region 
proximal to the AID appears to couple CaVβ’s movements to regulate the gating 
properties of the channel (Vitko et al, submitted). This IS6-AID segment appears to form, 
in part, a rigid helical structure that regulates the orientation of CaVβ2a and consequently 
its secondary interactions with CaV2.2. By deleting one (Bdel1) or two (Bdel2) amino 
acids in the IS6-AID segment (Fig 4.1C), the orientation of CaVβ2a to CaV2.2 should 
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change with each shift in the helix. When the mutated channels were tested for sensitivity 
to SP, Bdel1 exhibited minimal current enhancement, while Bdel2 rescued current 
inhibition by the slow pathway. In turn, exogenous palmitic acid reduced Bdel2/β2a 
current inhibition. This is the first demonstration that the orientation of a palmitoylated 
cytoplasmic protein alters the regulation of a transmembrane protein: CaV2.2.  
MATERIAL AND METHODS 
 
Site directed mutagenesis 
The cDNA encoding the rat brain CaV2.2 (GenBank entry #AF055477) was 
cloned into the plasmid vector pcDNA6 (Lin et al., 1997). A 1.5 kb fragment was 
subcloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA), then mutated using the 
Quikchange® protocol and Pfu Ultra DNA polymerase (Stratagene, La Jolla, CA). 
Oligonucleotide primers were obtained from Invitrogen and used without purification. 
All restriction enzymes were purchased from New England Biolabs (Ipswich, MA). The 
full-length cDNA was reassembled in the original plasmid vector that was cut with AscI 
and BsiWI by ligating the following fragments: AscI(32)/BlpI(355), BlpI/SacI (1407), and 
SacI/BsiWI (2991). The Bdel1 and Bdel2 amino acid mutations were contained in the 
BlpI/SacI fragment, and the sequence of this fragment was verified for each mutant by 
automated sequencing at the University of Virginia Biomolecular Research Facility. 
 
Transfection 
 Human embryonic kidney (HEK) cells with a stably transfected M1R (HEK-M1) 
were grown at 37°C with 5% CO2 in Dulbecco’s MEM (DMEM)/F12 supplemented with 
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10% FBS, 1% G418, 0.1% Gentamicin and 1% HT supplement (Gibco Life 
Technologies, Grand Island, NY). For transfection, cells were plated in 12-well plates at 
50-80% confluency. Cells were transiently transfected using Lipofectamine and PLUS 
reagents (Invitrogen, Carlsbad, CA) as per the manufacturer’s instruction. The 
transfection mixture consisted of plasmids encoding wt or mutant Cav2.2 e[a10, ∆18a, 
Δ24a, 31a, 37b, 46] (#AF055477; Vitko et al., submitted; Fig 1C), α2δ−1 (#AF286488;) 
and either CaVβ2a (#M80545) or CaVβ3 (#M88751) at a 1:1:1 molar ratio. 28 ng/well of 
plasmid encoding NK-1R (#AY462098; UMR cDNA Resource Center, University of 
Missouri, Rolla, MO) and enhanced green fluorescent protein cDNA (used at less than 
10% of total cDNA), were also included in the transfection medium. Cells were plated on 
poly-L-lysine coated coverslips 24-72 hours post transfection. However, currents elicited 
from Bdel1 and Bdel2 mutants were not detectable using the above-mentioned 
transfection protocol. To boost mutant expression by increasing transcription, 80 ng of 
plasmid containing the SV40 T antigen was included during transfection. Currents were 
recorded between 24 and 76 hours post transfection. 
 
Electrophysiology 
 Whole-cell Ba2+ currents were recorded at room temperature (20-24°C) using a 
Dagan 3900a patch clamp amplifier (Dagan Instruments Inc., Minneapolis, MN). 
Currents were filtered at 1-5 kHz using the amplifier’s four-pole low-pass Bessel filter 
and digitized at 20 kHz with a CED micro1401 interface [Cambridge Electronic Design, 
(CED), Cambridge, UK]. Data were collected using Signal 2.16 software (CED) and 
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stored on a personal computer. Prior to analysis, capacitive and leak currents were 
subtracted using a scaled-up hyperpolarizing test pulse to -100 mV. For all recordings, 
cells were held at -90 mV and given either a 24 or 100 ms depolarization to the test pulse 
indicated. Unless mentioned, the protocol was repeated every 4 sec. For prepulse 
experiments, a 24 ms depolarization was followed 250 ms later by a step depolarization 
to +120 mV for 25 ms, then followed 30 ms later by another 24 ms depolarization (see 
Fig 4.2D) and repeated every 10 sec. Electrodes were pulled from borosilicate glass 
capillary tubes. Each electrode was fire-polished to ~1 μm to yield a pipette resistance of 
2-3 MΩ. The external solution contained (in mM): 125 N-methyl glucamine (NMG)- 
aspartate, 10 HEPES and 5 or 20 barium (Ba2+) acetate, pH was adjusted to 7.5 with 
CsOH. When the Ba2+ concentration was lowered from 20 mM to 5 mM (for recording 
wt Cav2.2 currents), 135 NMG-aspartate was substituted for Ba2+.  The internal solution 
of the pipette consisted of (in mM): 135 Cs-aspartate, 10 HEPES, 0.1 1,2-bis(O-amino-
phenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA), 5 MgCl2, 4 ATP, and 0.4 GTP; the 
pH was adjusted to 7.5 with CsOH. When 20 mM BAPTA was included in the pipette 
solution, the Cs-aspartate concentration was lowered accordingly in the internal solution. 
 
Bimolecular fluorescence Complementation (BiFC) 
BiFC imaging was carried out as per methods earlier described (Vitko et al., 
submitted). Briefly, a small C-terminal (a.a. 159-238) sequence of cyan fluorescent 
protein (CFP) was fused to the C-terminus of full length β2a. The big N-terminal 
fragment of CFP (a.a. 1-158) was fused to the N-terminus of CaV2.2, Bdel1 or Bdel2. 
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Plasmids encoding CaV2.2, Bdel1 or Bdel2 (250 ng), α2δ-1 (1 μg) and full length β2a (1 
μg) were transiently transfected into HEK-293 cells. After 18 hrs the cells were plated 
onto polylysine-treated glass bottom dishes (Fluorodish, World Precision Instruments, 
Saratoga, FL).BiFC was visualized by cyan fluorescence signals which were collected 
with IPLab software and a Cooke Sensicam QE (Romulus, MI) mounted on an Olympus 
BX61WI (100x objective, 2x2 binning) equipped with an Olympus confocal spinning 
disk unit (Melville, NY). Digital images were background subtracted using a region 
devoid of cells.  
 
Pharmacology 
SP was prepared as a 0.5 mM stock solution in 0.05 M acetic acid and stored at -20°C. To 
make a working concentration of 5 nM, the stock was serially diluted with bath solution 
daily. Palmitic acid was dissolved in 100% ethanol to make a stock solution. Working 
solutions were made by diluting the stock 1:1,000 times with bath solution. Bovine serum 
album (BSA; fraction V, heat shock, fatty acid ultra-free; Roche Applied Science, 
Indianapolis, IN) was dissolved in the bath solution and diluted further to make a final 
concentration of 1mg/ml. All chemicals were obtained from Sigma-Aldrich Inc. (St. 
Louis, MO) except where noted. Drugs were applied with a gravity-driven bath perfusion 
system and complete bath exchange was achieved within 10-14 sec. 
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Data analysis 
 After the onset of the pulse, maximal inward current of whole-cell traces 
was measured using Signal 2.16 (CED). Percent change in current amplitude was 
measured as [(I-I’)/I]*100, where I is the average amplitude of peak current measured 
from 5 current traces prior to drug application and I’ is the average current amplitude 
measured from 5 current traces atleast 2 mins after application of SP, unless otherwise 
noted. Data were acquired and analyzed using IPLab 4.0 (Scanalytics, Fairfax, VA) as 
described previously (Vitko et al., 2007).  
 
Statistical Analysis 
 Summary data are presented as mean ± s.e.m (standard error of the mean). 
Average current amplitude before and after application of SP was compared using a two-
tailed paired t-test. Two means were compared using a two-way Student’s t-test. 
Statistical significance was set at p<0.05 or p<0.001. Data was analyzed using Excel 
(Microsoft, Seattle, WA) and Origin (OriginLab, Northampton, MA). 
 
RESULTS 
 
SP enhances wt Cav2.2 current via a BAPTA-sensitive pathway. 
To test whether palmitoylated CaVβ2a blocks inhibition to reveal enhancement, 
we first characterized several biophysical properties of N-current enhancement by NK-1R 
in a recombinant system. First, we tested whether the enhancement of N-current as with 
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inhibition occurs via a BAPTA- sensitive pathway. Application of 5 nM SP enhanced 
currents (Fig 4.2A left, 4.2B). To chelate intracellular Ca2+, 20 mM BAPTA was dialyzed 
into cells for at least 2 min. Under these conditions, SP no longer enhanced currents (Fig 
2A right, 4.2B). Thus enhancement involves a BAPTA-sensitive pathway similar to that 
shown earlier for M1R-mediated N-current inhibition (Beech et al., 1991; Bernheim et al., 
1991; Mathie et al., 1992; Liu et al., 2001; Liu and Rittenhouse, 2003a). 
Second, we tested whether enhancement as with inhibition, is insensitive to 
prepulses. Similar to our previous studies using exogenously applied AA (Barrett et al., 
2001; Liu et al., 2001) or activation of either M1Rs (Liu and Rittenhouse, 2003a) or NK-
1Rs (Chapter III), current enhancement occurs at -10 and 0 mV (Fig 4.2C). The current-
voltage (I-V) plot reveals that maximal current enhancement occurs 10 mV negative to 
the voltage that elicits peak inward current (in this case +10 mV; Fig 4.2C). Hence, we 
measured whole-cell currents over time by stepping to a test potential 10 mV to the left of 
where maximal peak current occurs. While a slight relief from tonic prepulse inhibition is 
observed using this protocol under control conditions, following SP application both P1 
and P2 currents exhibit similar significant enhancement (62 ± 18% and 50 ± 11%; p<0.01 
compared to control currents) (Fig. 4.2D, E).  
Third, AA-induced enhancement of N-current coincides with an increased rate of 
activation, in SCG neurons (Barrett et al., 2001). Therefore, we tested whether enhance-
ment of recombinant N-current by SP involves an increase in activation kinetics, detected 
as a change in time to peak inward current (TTP). We measured the TTP of CaV2.2 
currents before and after application of SP. As shown in Fig 4.2F, SP significantly 
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decreased TTP (p<0.05; n=6), when CaVβ2a was co-expressed with CaV2.2. Taken 
together, these three tests indicate that enhancement involves a similar slow pathway as 
N-current inhibition by SP. 
Modulation of mutant Bdel1 current by SP is disrupted. 
Since Bdel1 has a single amino acid deletion in the middle of the helical IS6-AID 
segment (Vitko et al., submitted; Fig 4.1C), the bound palmitoylated CaVβ2a may 
reorient to a different position relative to Bdel1. We hypothesized that if CaVβ2a is 
sufficiently displaced, the palmitoyl groups will move from the inhibitory site and 
inhibition will occur (Fig 4.3A). Although SP enhanced Bdel1/β2a currents in 7 of 7 cells 
(Figs 4.3B, C), enhancement varied from as little as 12% to as high as 135% and hence 
was not significant (Fig 4.3D). To rule out the possibility that inhibition could not be 
recovered due to a change in CaV2.2’s inhibitory site, we tested Bdel1 mutants co-
expressed with CaVβ3 for modulation by SP. Indeed, SP inhibited currents of Bdel1 co-
expressed with CaVβ3 by 32 ± 10% (p<0.05; Figs 4.3E, F). The magnitude of inhibition 
did not differ significantly from wt CaV2.2/β3 currents indicating that the site of 
inhibition remained unaffected by the amino acid deletion in the IS6-AID segment. 
 
SP inhibits Bdel2 currents in the presence of palmitoylated β2a.   
To determine whether an additional amino acid deletion affects current 
modulation, we tested the Bdel2 mutant (Fig 4.1C) for modulation. We hypothesized that 
the additional deletion would further displace CaVβ2a from its normal position resulting 
in disruption of N-current modulation (Fig 4.4A). After application of SP, robust 
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inhibition of Bdel2 current was observed rather than enhancement (Figs 4.4B-D). 
Inhibition was observed at all voltages (Fig 4.4B) and was not relieved following a 
prepulse (P1: 46 ± 7%; P2: 45 ± 8%; p<0.05 compared to control currents before 
application of SP; Fig 4.4C, D).   
To determine whether the amino acid deletions may affect tonic facilitation of 
control currents, we measured the control prepulse facilitation ratio, measured by the 
ratio of peak P2 current to peak P1 current. While Bdel1 currents showed a loss of 
prepulse facilitation, the ratio for Bdel2 was significantly higher than Bdel1; Bdel2 
currents were further decreased rather than being enhanced after a prepulse (Figs 4.4E). 
Overall, current modulation by SP exhibited unique properties with each change in the 
orientation of CaVβ2a: enhancement of N-current normally observed with wt CaV2.2/β2a 
channels becomes more variable with Bdel1/β2a channels, while Bdel2/β2a currents 
exhibit robust inhibition similar to CaV2.2/β3 currents (Fig 4.4F).  
To confirm that differences in modulation of the Bdel mutants compared to wt 
Cav2.2 does not arise from a difference in their expression levels, we performedBiFC 
analysis (Kerppola, 2006; Vitko et al., submitted) using wt CaV2.2, Bdel1 and Bdel2 with 
Cavβ2a. In this method, CFP is split into two fragments: one fragment is fused to 
CaV2.2’s N-terminus and the other fragment is fused to CaVβ2a’s C-terminus. 
Fluorescence occurs when the two non-fluorescent components of CFP associate or 
reside close enough to each other to bind, forming an intact fluorescing CFP. We found 
that wt CaV2.2, Bdel1 and Bdel2 coexpressed with CaVβ2a produced a fluorescent signal 
at the plasma membrane (Fig 4.5).  
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Inhibition of Bdel2/β2a currents by SP mimics inhibition of wt Cav2.2/β3 currents. 
By deleting amino acids in the IS6-AID segment, N-current modulation changes 
from robust enhancement to robust inhibition. We wanted to determine whether 
inhibition of Bdel2/β2a currents occurs via the slow pathway similar to inhibition of 
CaV2.2/β3 or Βdel1/β3 currents. Since Bdel2/β3 currents inactivate so rapidly that their 
peak current  could not be compared to modulation of other N-channel complexes (Vitko 
et al., submitted), we did not examine Bdel2/β3  for inhibition by SP. Instead, we took a 
pharmacological approach to determine whether the same slow pathway used to inhibit 
wt CaV2.2/β3 currents confers Bdel2/β2a current inhibition. First, we tested whether 
bovine serum album (BSA) minimizes N-current inhibition by SP. When BSA is 
included in the bath solution, inhibition of native and recombinant N-current by M1R 
stimulation is lost (Liu and Rittenhouse, 2003a; Liu et al., 2006; Chapter III). Since BSA 
sequesters free AA released from phospholipids following receptor activation (Liu et al., 
2006), decreased N-current inhibition is attributed to decreased availability of free AA. 
When we recorded currents in the presence of BSA, current inhibition by SP normally 
observed with both CaV2.2/β3 and Bdel2/β2a (Fig. 4.6A, D) was lost (Fig 4.6B, D).  
We also tested whether N-current inhibition of CaV2.2/β3 and Bdel2/β2a channels 
by SP occurs via a BAPTA-sensitive pathway  (Beech et al., 1991; Bernheim et al., 1991; 
Mathie et al., 1992). In the presence of 20 mM BAPTA, N-current inhibition by SP is no 
longer significant (Figs 4.6C, D) similar to wt CaV2.2/β3. Additionally CaV2.2/β3 current 
inhibition by SP is not relieved by a prepulse consistent with inhibition occurring via a 
voltage-independent pathway (Kammermeir et al., 2000, n=6 data not shown). 
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Comparison of Bdel2/β2a and CaV2.2/β3 current inhibition (Fig 4.6D) shows that for 
both currents, inhibition involves a voltage-independent, BAPTA-sensitive pathway that 
utilizes a free fatty acid, most likely AA as an effector. These findings are consistent with 
Bdel2/β2a current inhibition by SP occurring by a similar mechanism as 
CaV2.2/β3 current inhibition by the slow pathway (Fig 4.1A; Chapter II).  
 
Free palmitic acid blocks inhibition of Bdel2 currents 
In Chapter III, we found that exogenous application of palmitic acid blocks 
inhibition of CaV2.2/β3 currents by SP. If inhibition of Bdel2/β2a currents involves a 
similar pathway as inhibition of CaV2.2/β3 currents, exogenously applied palmitic acid 
also should minimize inhibition of Bdel2/β2a currents following SP application. To test 
this hypothesis, cells expressing Bdel2 and CaVβ2a were preincubated with 10 μM 
palmitic acid for at least 8 min prior to application of SP (Fig 4.7A). Under these 
conditions, current inhibition by SP (Fig 4.7C, E) was reduced by more than 50% 
compared to recordings in the absence of palmitic acid (46 ± 7%; p<0.05 compared to 
inhibition by SP in the absence of palmitic acid; Fig 4.7C, D). This finding supports our 
model where the palmitoyl groups of CaVβ2a (Fig 4.7B) antagonize N-current inhibition 
by free AA that is released upon SP application. 
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DISCUSSION 
 
We hypothesized that when CaVβ2a is displaced sufficiently such that its 
palmitoyl groups can no longer interact with an inhibitory site, the N-current 
enhancement, normally observed with SP should be replaced by inhibition. Using Bdel1 
mutant channels co-expressed with CaVβ2a, we found that the single amino acid deletion 
in the helical IS6-AID segment, predicted to rotate CaVβ2a’s position relative to the 
Bdel1 channel resulted in highly variable N-current enhancement. Furthermore, deleting 
two amino acids in the IS6-AID segment to form Bdel2 channels resulted in robust N-
current inhibition by SP. We found that the same signal transduction pathway involving 
phospholipid metabolism that mediates inhibition of wt N-current, also mediates both 
enhancement of wt N-current and inhibition of Bdel2/β2a current. (Figs. 4.2 and 4.6). 
Inhibition of both CaV2.2/β3 and Bdel2/β2a currents are minimized by exogenous 
application of 10 μM palmitic acid (Chapter III and Fig. 4.7). These findings support the 
hypothesis that the palmitoyl groups interact with a site on CaV2.2 that overlaps with a 
site that confers inhibition by the slow pathway.  
 
N-current enhancement and inhibition involve a similar voltage-independent slow 
pathway 
Inhibition of native and recombinant N-current by Gq-coupled NK-1R via a 
voltage-independent pathway was first characterized in SCG neurons (Shapiro and Hille, 
1993; Kammermeier et al., 2000). More recently enhancement of native N-current (Liu 
and Rittenhouse, 2003a) and recombinant CaV2.2 and CaV2.3 current by M1Rs and NK-
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1Rs has been described (Meza et al., 2007; Chapter III). In the presence of CaVβ2a, M1R 
activation enhances N- but not L-currents (Chapter III; Roberts-Crowley, submitted). 
These two channels show similar transmembrane organization (Catterall, 2000). Hence, 
the difference in modulation that is observed cannot arise from any non-specific effect 
such as changes in the lipid bilayer that might alter gating.  
To understand the mechanism for current enhancement, we first show that 
enhanc
rientation of CaVβ2a is important for proper channel modulation 
equired, we used 
two mu
ement occurs via a signaling pathway (Fig 4.1 and 4.2) that is minimized using 
high concentrations of BAPTA similar to the slow pathway described for inhibition of 
native N-current in SCG neurons and hippocampal pyramidal neurons by M1Rs (Beech et 
al., 1991; Bernheim et al., 1991; Mathie et al., 1992; Shapiro and Hille, 1993; Liu and 
Rittenhouse, 2003b; Tai et al., 2006) and recombinant R-type (CaV2.3) current by NK-1R 
in HEK cells (Meza et al., 2007). Additionally we found that following a strong 
depolarizing prepulse, current enhancement by SP remained unchanged. N-current 
inhibition by SP exhibits these same two properties (Chapters II and V). Taken together, 
these findings suggest that while enhancement and inhibition may occur at different sites 
on N-channels they are different manifestations of overlapping or the same signaling 
pathway. 
 
O
To test our hypothesis that a specific orientation of CaVβ2a is r
tants of CaV2.2 that align the CaVβ 2a subunits differently relative to CaV2.2.  
CaVβ does not regulate the the opening probability of Bdel1 channels and also fails to 
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regulate the kinetics of activation and inactivation of Bdel1 and Bdel2 currents (Vitko et 
al., submitted). This could be due to a loss of interaction between the α1 subunit and the 
low affinity interaction sites on CaVβ  subunits (He et al., 2007), indicating that altering 
CaVβ's relative orientation disrupts its ability to regulate channel gating. Whether this 
change translates into a disruption in channel modulation by the slow pathway was tested 
here. We found that Bdel1 currents show a variable degree of enhancement by SP. The 
data supports our model where a slight disruption in the relative orientation of 
CaVβ moves the palmitoyl groups away from their original site but not enough to prevent 
the palmitoyl groups from completely blocking the inhibitory sites on all CaV2.2 
channels. Co-expression of CaVβ3 with Bdel1 resulted in current inhibition by SP. This 
finding indicated that the variable enhancement occurring in the presence of CaVβ2a is 
not due to random disruption of the channel’s inhibitory site. Rather, this finding 
indicates that the low affinity interactions between CaVβ3 with Bdel1 play at most a 
minor role in slow pathway inhibition of N-current. 
While deletion of a single amino acid in the Bdel1 mutant channels did not 
abolish enhancement by SP, deletion of two amino acids in the Bdel2 mutants resulted in 
modulation changing from enhancement to inhibition. The appearance of current 
inhibition following receptor activation may occur because the palmitoyl groups are 
sufficiently displaced from the inhibitory site. This site that is masked by the palmitoyl 
groups when CaV2.2 is co-expressed with CaVβ2a now becomes available for binding by 
released free AA. The inhibited Bdel2/β2a currents did not show voltage-dependent relief 
from inhibition following a prepulse (Fig 4.3, 4.4). The I-II linker of the N-channel 
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mediates CaVβ-dependent regulation of the channel’s voltage-dependent activation and 
inactivation (Arias et al., 2005). Yet, loss of CaVβ-dependent regulation of the channel’s 
current-voltage properties was lost with the Bdel1 mutant, but restored with the Bdel2 
mutant (Vitko et al., submitted), indicating a role for the orientation of CaVβ2a not just in 
channel modulation, but also in regulating the channel’s  kinetic properties.  
One possibility remains untested: the disruption in the block of inhibition could be 
due to c
Ca2+ currents exhibit little 
inactiva
hanges in the low affinity interactions between CaVβ2a and CaV2.2. However, the 
robust inhibition observed with Bdel2 was significantly reduced simply by adding back 
exogenous palmitic acid. The simplest interpretation of the findings is that though two 
amino acids are deleted in the IS6-AID segment, N-current inhibition by SP can be 
minimized by providing palmitic acid to compete with endogenously released AA for a 
binding site, possibly located on the channel. However, another possibility is that the 
actions of AA and palmitic acid are indirectly converging on an enzyme, such as a 
phosphatase that in turn covalently modifies channel proteins. 
Previous studies show that in the presence of CaVβ2a, 
tion in expression system or in primary cells (Qin et al., 1998; Hurley et al., 2000; 
Yasuda et al., 2004). Palmitoylation of Cys3 and Cys4 residues of CaVβ2a slows the rate 
of inactivation of Ca2+ currents in heterologous expression systems (Chien and Hosey, 
1998; Hurley et al., 2000). The I-II linker region is thought to participate in channel 
inactivation possibly by occluding the mouth of the open channel (Herlitze et al., 1997; 
Restituito et al., 2000; Stotz and Zamponi, 2001; Hering, 2002). Since the palmitoyl 
groups serve as an anchor to tether CaVβ2a to the membrane, slowed  inactivation may 
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result from restricted movement of the I-II linker being restricted by the anchored CaVβ2a 
(Restituito et al., 2000). Removing the palmitoyl groups of CaVβ2a, either by mutation or 
by using a depalmitoylating agent, restores inactivation of currents indicating that 
palmitoylation of CaVβ2a slows voltage-induced inactivation (Chien and Hosey, 1998; 
Qin et al., 1998; Hurley et al., 2000).   
When CaVβ2a is co-expressed with either Bdel1 or Bdel2, channel activity now 
exhibit
e 
earlier 
s more rapid inactivation kinetics similar to channels containing a depalmitoylated 
CaVβ2a (Vitko et al., submitted), suggesting that the palmitoyl groups no longer reside in 
their original position relative to CaV2.2. Consequently, the palmitoyl groups can no 
longer slow the channel’s inactivation kinetics. Thus, the kinetic changes observed with 
the mutant channels corroborate the findings presented here, that the orientation of the 
palmityolated CaVβ2a relative to CaV2.2 is not only critical for regulating N-channel’s  
biophysical properties (Vitko et al., submitted), but also for its modulation by GqPCRs.  
In addition to participating in the slow pathway modulation, CaVβ subunits hav
been implicated in modifying current kinetics and amplitude as well as in 
trafficking channel complexes to the plasma membrane (Singer et al., 1991; Olcese et al., 
1994; Chien et al., 1996; Brice et al., 1997). Binding of CaVβ to the AID region masks an 
ER retention site that facilitates channel expression at the plasma membrane (Bichet et 
al., 2000). Co-expression of a CaVβ subunit is necessary for inhibition of CaV2.2 currents 
by a dopamine D2 receptor agonist via Gβγ-mediated voltage-dependent pathway (Meir 
et al., 2000). Gβγ also binds to the channel’s I-II linker and elicits a change in the 
association between the channel and CaVβ, probably by changing the orientation of the 
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CaVβ subunit (Hummer et al., 2003). Compared to other CaVβs, when CaVβ2a is co-
expressed, channels undergo increased voltage-dependent, membrane-delimited 
inhibition by Gβγ and slowed prepulse-induced relief from inhibition (Canti et al., 2000; 
Feng et al., 2001). Our findings suggest that the specific orientation of CaVβ2a also is 
required for channel modulation by the voltage-independent pathway.  
 Together with the findings in Chapter III, our data provide evidence for a new 
role of palmitoylation in channel modulation where the palmitoyl groups not only block 
modulation, but the palmitoylated CaVβ2a must be in a specific orientation for this to 
occur. This idea of a lipid modification of a cytosolic protein interacting with a 
transmembrane protein is quite novel and extends the role of palmitoylation beyond its 
known functions of targeting or tethering proteins to the membrane (Resh, 2006). An 
exception exists in the visual system where besides ensuring membrane targeting, 
palmitoylation of a membrane-associated form of retinal epithelial protein 65 (RPE65) 
not only enhances its targeting to membranes but most importantly enhances its 
selectivity for binding to all-trans-retinyl-esters. or even in one case, changing the 
binding affinity of one protein for another (Xue et al., 2004). However, a change in the 
function of a palmitoylated protein arising from a change in its position has never been 
shown. 
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Inhibition of Bdel2/β2a current occurs via the slow pathway  
We found that the inhibition of Bdel2 currents by SP in the presence of CaVβ2a 
occurs via the same slow pathway that mediates inhibition of wt CaV2.2/ CaVβ3 currents 
by SP. This finding raises the question that if the palmitoyl groups of CaVβ2a are unable 
to block inhibition of Bdel2 currents, would adding back palmitic acid be sufficient to 
block Bdel2/β2a inhibition? Previously we showed that exogenous application of 
palmitic acid blocked SP-mediated inhibition of CaV2.2/β3 currents (Chapter III). Here 
we show that palmitic acid also minimizes inhibition of Bdel2/β2a currents (Fig 4.6). It is 
possible that due to a loss of low-affinity interactions of CaVβ2a arising from the 
deletions in the I-II linker, Bdel2 currents are no longer enhanced but become inhibited 
instead. However, we can rule out this possibility because exogenous palmitic acid is 
sufficient to reduce Bdel2/β2a current inhibition. This piece of evidence taken together 
with the rest of the data presented here indicates that inhibition of Bdel2/β2a currents 
occurs due to a loss of interaction of the palmitoyl groups with the inhibitory site. 
Overall, our finding provides an insight into the coupling of GqPCR activation 
with modulation of CaV2.2 involving the CaVβ subunit. CaVβ not only determines the 
modulation of CaV2.2 by the subtype that is co-expressed with the channel but also by its 
relative orientation with the channel. Mutations in the IS6-AID segment have the 
potential to disrupt critical protein-lipid interactions between the palmitoyl moities of 
CaVβ2a and CaV2.2 that in turn uncouples the otherwise tight regulation of CaV2.2 by 
GqPCRs. Entry of Ca2+ ions through voltage-gated Ca2+ channels regulates opening of 
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small-conductance potassium channels during afterhyperpolarization (Stocker, 2004). N-
channels expressed post-synaptically on the dorsal horn affect neuronal excitability 
during and following transmission of nociceptive stimuli (Yaksh, 2006).  It is not known 
if up- or down-regulation of the different Cavβ subunits can occur as an adaptation to a 
nociceptive stimulus; however both increases and decreases in calcium currents have 
been observed in different neuronal subtypes following nerve injury (McGivern and 
McDonough, 2004). Thus any disruption in modulation of N-current by SP, for example, 
during transmission of nociceptive stimulation in the spinal cord may alter the frequency 
of action potential firing that conveys nociceptive information to the brain for further 
processing. 
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Figure 4.1 Schematic representation of CaV2.2 by NK-1R activation. (A) Flowchart 
representing the signaling cascade used by substance P to modulate N-current. (B) N-
channels consist of a pore-forming CaV2.2 α1 subunit complexed with one cytoplasmic 
CaVβ and one transmembrane α2-δ (not shown) subunit. CaV2.2 consists of four 
homologous domains (I-IV) that serve as four pseudo-subunits tethered to the subsequent 
domain by intracellular linkers. Shown here, the I-II linker connects domains I and II. 
CaVβ binds to the AID region (delineated by the dotted line) on the I-II linker at a site 
that overlaps with the binding site for Gβγ. (C) The amino acid deletions in the region 
proximal to the AID result in Bdel1 and Bdel2 mutant channels.  
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Figure 4.2 NK-1R activation enhances wt Cav2.2 current in the presence of a β2a 
subunit. HEK cells were transiently transfected with wt CaV2.2, α2δ−1, β2a and NK-1R. 
(A) Individual sweeps taken before (con) and 2 mins after application of 5 nM SP left, in 
the presence of 0.1 mM BAPTA and right, in the presence of 20 mM BAPTA. (B) 
Comparison of the average inhibition in the presence of 0.1 mM and 20 mM BAPTA 
(n=4-9); *p<0.05 compared to inhibition in the presence of 0.1 mM BAPTA. (C) 
Averaged current-voltage plots measured before (■) and after (□) application of SP. (D) 
Individual sweeps taken before and 2 min after application of SP. P1 and P2 represent 
current measured before (P1) after (P2) a prepulse. (E) Summary of enhancement at 0 
mV before and after a prepulse (n=9); **p<0.01 compared to P1 and P2 control currents 
prior to SP application. (F) Summary of time to peak (TTP) before and after application 
of SP (n=6), *p<0.05 compared to control.  
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Figure 4.3 Modulation of Bdel1 current by 5 nM SP is modestly disrupted. HEK cells 
were transiently transfected with NK-1R, Bdel1, α2δ−1, β2a (B-D) or β3 (E, F). (A) 
Working model of the Bdel1 channel with an associated β2a subunit. (B) Individual 
sweeps taken before (con) and 2 min after application of SP. (C) Summary of 
enhancement at +20 mV due to SP before and after a prepulse (n=7). (D) Averaged 
current-voltage plot measured before (■) and after (□) application of SP. (E) 
Representative sweeps taken before (con) and 2 min after application of SP. (F) 
Summary of the inhibition at +20 mV due to SP before and after a prepulse (n=4); 
*p<0.05 compared to currents before SP was applied. 
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Figure 4.4 NK-1R activation inhibits Bdel2 currents. HEK cells were transiently 
transfected with Bdel2, α2δ−1, β2a and NK-1R. (A) Working model of the mutant Bdel2 
channel associated with β2a. (B) Averaged current-voltage plot measured before and 
after application of 5 nM SP. (C) Individual sweeps taken before (con) and 2 min after 
application of SP. (D) Summary of modulation of wt Cav2.2 (■), Bdel1 (●) and Bdel2 
(▲) by SP before (filled) and after (open) a prepulse; *p<0.05 compared to control 
currents (n=4-9). (E) Prepulse facilitation (ratio of P2/P1) for wt Cav2.2 (■), Bdel1 (●) 
and Bdel2 (▲); *p<0.05 compared to Bdel1. (F) Individual sweeps taken before (con) 
and 2 min after application of SP. 
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Figure 4.5 Bdel1 and Bdel2 channels both localize to the plasma membrane with 
CaVβ2a. (A) Images of representative HEK cells transfected with wt CaV2.2 (left), Bdel1 
(middle) and Bdel2 (right) obtained after bimolecular fluorescence complementation 
(BIFC). Scale bar in A, 5 μm. Schematic representation ofBiFC imaging using (B) wt 
CaV2.2 and (C) Bdel1. 
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Figure 4.6 Inhibition of Bdel2 currents by SP is voltage-independent and occurs via a 
similar slow pathway as wt CaV2.2. HEK cells were transiently transfected with NK-1R, 
either Bdel2 or wt CaV2.2; α2δ-1, and either β2a or β3. Individual traces from left wt 
CaV2.2/β3 and right Bdel2/β2a currents taken before and 90 secs following application of 
5 nM SP (A) alone, (B) in the presence of 1mg/ml BSA and (C) in the presence of 20 
mM BAPTA. (D) Summary of loss of inhibition of CaV2.2/β3 and Bdel2/β2a currents by 
SP; *p<0.05 compared to control currents (n=5-6). 
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Figure 4.7 Palmitic acid blocks inhibition of Bdel2 currents by 5 nM SP. HEK cells were 
transiently transfected with Bdel2, α2δ-1, CaVβ2a, and NK-1R. (A) Schematic 
representing preincubation of cells with palmitic acid blocks free AA, released after 
stimulation of NK-1R, from occupying the inhibitory site (B) Cross sectional model of 
the channel representing the palmitoyl groups (white dots) oriented away from the 
inhibitory site on the Bdel2 subunit. The inhibitory site is occupied by exogenous 
palmitic acid (purple dots). (C) Summary of inhibition by SP in the presence of 10 μM 
palmitic acid *p<0.05 compared to current amplitude prior to SP (n=7) or compared to 
the presence of palmitic acid alone (n=6). **p<0.05 % inhibition by SP compared to % 
inhibition by PA+SP. Individual traces taken before and 2 mins following application of 
5 nM SP (D) alone or (E) in the presence of 10 μM palmitic acid. 
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CHAPTER V: 
Orientation of Cavβ to Gβγ is critical for membrane-
delimited inhibition of Cav2.2 by dopamine D2 
receptors 
Abstract 
Voltage-dependent CaV2.2 (N-) channels undergo inhibition by different G-
protein coupled receptors via a membrane-delimited, voltage-dependent pathway. This 
type of modulation involves interaction of Gβγ with multiple regions of CaV2.2. CaVβ 
acts as a competitive antagonist of Gβγ for binding to the N-channel’s I-II linker. While 
Gβγ displaces CaVβ to inhibit N-channel activity, CaVβ in turn displaces Gβγ during a 
depolarizing pulse to relieve inhibition. As with Gβγ, CaVβ interacts with multiple sites 
on CaV2.2; however its interaction with the I-II linker controls the “off rate” of Gβγ 
during a depolarization. Previously, we examined the gating properties of CaV2.2 mutants 
lacking one or two amino acids in the IS6-AID segment, a rigid, region distal to IS6 and 
proximal to CaVβ's AID binding site on the I-II linker, and found that a specific 
orientation of CaVβ2a is required for normal gating. The mutations result in inefficient 
coupling between voltage sensor movement and channel opening, apparently by altering 
CaVβ's orientation relative to CaV2.2. Here we tested whether the mutant N-channels 
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support voltage-dependent inhibition following D2 dopamine receptor activation by 
quinpirole. A single amino acid deletion abolished N-current inhibition. In contrast, 
deletion of two amino acids restored inhibition; however, inhibition now was voltage-
independent. Gβγ maintained a close association with CaVβ in mutant channels, as 
confirmed by bimolecular fluorescence complementation measurements. We conclude 
that the relative orientation of CaVβ to CaV2.2 is critical for relief of voltage-dependent 
inhibition. These findings are consistent with the IS6-AID segment serving a role in 
coordinating CaVβ movements to promote channel opening.  
 INTRODUCTION 
N-channels affect numerous physiological processes by regulating the influx of 
calcium ions. G-protein coupled receptors (GPCRs) modulate N-channels by both 
voltage-dependent and voltage-independent mechanisms (Hille, 1994). Voltage-
dependent inhibition, also referred to as membrane-delimited inhibition, occurs when 
activated Gα release Gβγ dimers that then bind N-channels (Herlitze et al., 1996; Ikeda, 
1996; De Waard et al., 1997; Zamponi et al., 1997). Gβγ  binding delays the opening of 
N-channels in response to positive voltages, resulting in decreased current amplitude and 
slowed activation kinetics, termed reluctant gating (Bean, 1989). During voltage steps to 
depolarizing potentials, N-current inhibition is relieved due to apparent dissociation of 
Gβγ. Reversal is transient; upon repolarization to negative potentials Gβγ rebinds so that 
N-current exhibits reluctant gating during a subsequent depolarizing voltage step (Elmslie 
et al., 1990; Ikeda, 1991). In certain primary neurons under basal conditions (Barrett and 
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Rittenhouse, 2000) or conditions that favor high tonic G protein activity (Ikeda, 1991, 
1996), prepulses also relieve tonic inhibition, i.e., reluctant gating in the absence of 
transmitter.  
Prepulse facilitation of transmitter-stimulated or tonic reluctant gating requires the 
presence of the CaVβ subunit (Meir et al., 2000). In CaVβ’s presence, slowed activation 
kinetics, a rightward shift in voltage-dependence of activation and changes in inactivation 
are more pronounced. These findings suggested that CaVβ’s and Gβγ’s interactions at the 
I-II linker reversibly shift channel activity between two biophysical profiles. When 
CaV2.2 is coexpressed with a CaVβ, its voltage sensitivity increases compared to 
expression of CaV2.2 alone; both activation and inactivation profiles shift in the negative 
direction. Mean open time also increases (Dolphin, 2003). In contrast, following 
membrane-delimited inhibition currents exhibit the reverse trend, similar to N-channel 
gating in the absence of a CaVβ. These findings suggest that inhibition by Gβγ is due to 
the displacement of CaVβ binding (De Waard et al., 2005). 
Their molecular interactions support this possibility. N-channels consist of the 
pore-forming CaV2.2 subunit, which is organized in four transmembrane domains (I-IV) 
interconnected by intracellular linkers. CaVβ binds CaV2.2 with high affinity at the alpha-
interacting domain (AID) of the I-II linker (Fig 5.1A) (Pragnell et al., 1994) while Gβγ 
binding partially overlaps with the AID region (Chen et al., 2004; Opatowsky et al., 
2004; Van Petegem et al., 2004). The overlap results in competition such that Gβγ 
displaces CaVβ for binding to the AID region (Hummer et al., 2003; Sandoz et al., 2004). 
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In turn, positive voltages allow CaVβ to displace Gβγ (Canti et al., 2000; Sandoz et al., 
2004). Thus it is the dynamic nature of their competition at the I-II linker that gives rise 
to voltage-dependent inhibition (Lopez and Brown, 1991; Bourinet et al., 1996; Zamponi 
and Snutch, 1998; Sandoz et al., 2004). However, how CaVβ disturbs Gβγ binding during 
prepulses and prolonged depolarization remains poorly understood. 
Therefore, in the present study we have tested CaVβ’s role in relieving voltage-
dependent membrane-delimited inhibition of N-current by one such GPCR, the dopamine 
D2 receptor (D2R). D2Rs belong to the D2-like subfamily that couples to pertussis toxin 
(PTX)-sensitive Gi/o, and can stimulate membrane-delimited inhibition of recombinant N-
current (Senogles et al., 1987; Page et al., 1998; Stephens et al., 1998; Canti et al., 1999). 
Other studies show that D2Rs activate PLA2 at least partially via a PTX-insensitive G 
protein and its activation releases free AA (Kanterman et al., 1991; Caccavelli et al., 
1992; Schinelli et al., 1994). Moreover, exogenous AA modulates N-current by a 
different mechanism than membrane-delimited inhibition (Liu et al., 2001). Here we first 
show that with coexpression of CaVβ2a, inhibition of CaV2.2 by the D2R agonist 
quinpirole (quin) occurs via a BAPTA-insensitive, voltage-dependent pathway (Fig 
5.1B), confirming D2Rs mediate N-current inhibition by the membrane-delimited 
pathway.  
Second, we asked whether a specific orientation of CaVβ and Gβγ relative to 
CaV2.2 confers prepulse facilitation. We used mutant N-channels with one or two amino 
acids deleted in the region between the last transmembrane segment (S6) of domain I 
(IS6) and the AID, termed the IS6-AID segment (Vitko et al., submitted; Fig 5.1C). Since 
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the IS6-AID segment is a rigid helical region (Arias et al., 2005), one or two amino acid 
deletions should orient CaVβ2a and Gβγ to a different face of the helix, thus positioning 
them differently relative to CaV2.2 (Vitko et al., submitted). We show that mere 
association of CaVβ with CaV2.2 is insufficient for the voltage-dependence of membrane-
delimited inhibition, but rather a specific orientation of CaVβ2a is required to relieve 
reluctant gating and facilitate current amplitude.  
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MATERIAL AND METHODS 
Site directed mutagenesis 
The cDNA encoding the rat brain CaV2.2 (GenBank entry #AF055477) was 
cloned into the plasmid vector pcDNA6 (Lin et al., 1997). A 1.5 kb fragment was 
subcloned into pCR2.1-TOPO (Invitrogen, Carlsbad, CA), then mutated using the 
Quikchange protocol and Pfu Ultra DNA polymerase (Stratagene, La Jolla, CA). 
Oligonucleotide primers were obtained from Invitrogen and used without purification. 
All restriction enzymes were purchased from New England Biolabs (Ipswich, MA). The 
full-length cDNA was reassembled in the original plasmid vector that was cut with AscI 
and BsiWI by ligating the following fragments: AscI(32)/BlpI(355), BlpI/SacI (1407), and 
SacI/BsiWI (2991). The Bdel1 and Bdel2 amino acid mutations were contained in the 
BlpI/SacI fragment, and the sequence of this fragment was verified for each mutant by 
automated sequencing at the University of Virginia Biomolecular Research Facility. 
Transfection 
 Human embryonic kidney (HEK) cells with a stably transfected M1R (HEK-M1) 
were grown at 37°C with 5% CO2 in Dulbecco’s MEM (DMEM)/F12 supplemented with 
10% FBS, 1% G418, 0.1% Gentamicin and 1% HT supplement (Gibco Life 
Technologies, Grand Island, NY). For transfection, cells were plated in 12-well plates at 
50-80% confluency. Cells were transiently transfected using Lipofectamine and PLUS 
reagents (Invitrogen, Carlsbad, CA) as per the manufacturer’s instruction. The 
transfection mixture consisted of plasmids encoding wt or mutant Cav2.2 e[a10, ∆18a, 
® 
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Δ24a, 31a, 37b, 46] (#AF055477; Vitko et al., submitted; Fig 5.1C), α2δ−1 (#AF286488) 
and either CaVβ2a (#M80545) or CaVβ3 (#M88751) at a 1:1:1 molar ratio. 32 ng/well of 
D2R (#NM_000795; UMR cDNA Resource Center, University of Missouri, Rolla, MO) 
and enhanced green fluorescent protein cDNA (used at less than 10% of total cDNA), 
were also included in the transfection medium. Cells were plated on poly-L-lysine coated 
coverslips 24-72 hours post transfection. However, currents elicited from Bdel1 and 
Bdel2 mutants were not detectable using the above-mentioned transfection protocol. To 
boost mutant expression by increasing transcription, 80 ng of plasmid containing the 
SV40 T antigen was included during transfection. Currents were recorded between 24 
and 76 hours post transfection.  
 
Electrophysiology 
a2+ currents were recorded at room temperature (20-24°C) using a  Whole-cell B
Dagan 3900a patch clamp amplifier (Dagan Instruments Inc., Minneapolis, MN). 
Currents were filtered at 1-5 kHz using the amplifier’s four-pole low-pass Bessel filter 
and digitized at 20 kHz with a CED micro1401 interface [Cambridge Electronic Design, 
(CED) Cambridge, UK]. Data were collected using the Signal 2.16 software (CED) and 
stored on a personal computer. Prior to analysis, capacitive and leak currents were 
subtracted using a scaled-up hyperpolarizing test pulse to -100 mV. For all recordings, 
cells were held at -90 mV and given either a 24 or 100 ms depolarization to the test pulse 
indicated. Unless mentioned, the protocol was repeated every 4 sec. For prepulse 
experiments, a 24 ms depolarization was followed 250 ms later by a step depolarization 
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to +120 mV for 25 ms, then followed 30 ms later by another 24 ms depolarization (see 
Fig 5.2B) and repeated every 10 sec. Electrodes were pulled from borosilicate glass 
capillary tubes. Each electrode was fire-polished to ~1μm to yield a pipette resistance of 
2-3 MΩ. The external solution contained (in mM): 125 N-methyl glucamine (NMG)- 
aspartate, 10 HEPES and 5 or 20 barium (Ba2+) acetate; the pH was adjusted to 7.5 with 
CsOH. When the Ba2+ concentration was lowered from 20 mM to 5 mM (for recording 
wt Cav2.2 currents), 135 NMG-aspartate was substituted for Ba2+. The internal solution 
of the pipette consisted of (in mM): 135 Cs-aspartate, 10 HEPES, 0.1 1, 2-bis(O-amino-
phenoxy)ethane-N,N,N’,N’-tetraacetic acid (BAPTA), 5 MgCl2, 4 ATP, and 0.4 GTP; the 
pH was adjusted to 7.5 with CsOH. When 20 mM BAPTA was included in the pipette 
solution, the Cs-aspartate concentration was lowered accordingly in the internal solution.  
 
Pharmacology 
 prepared as a 3 mM stock solution in double-distilled water and stored 
at -20°
 complementation (BIFC) 
Quin was
C. To make a working concentration of 300 nM, the stock solution was serially 
diluted with bath solution daily. Bovine serum album (BSA; fraction V, heat shock, fatty 
acid ultra-free; Roche Applied Science, Indianapolis, IN) was dissolved directly in the 
bath solution and diluted further to make a final concentration of 1mg/ml. All chemicals 
were obtained from Sigma-Aldrich Inc. (St. Louis, MO) except where noted. Drugs were 
applied with a gravity-driven bath perfusion system and complete bath exchange was 
achieved within 10-14 s.  
Bimolecular fluorescence
 
 126
BIFC imaging was carried out as per methods earlier described (Vitko et al., 
submitted). Briefly, a small C-terminal (a.a. 159-238) sequence of cyan fluorescent 
protein (CFP) was fused to the C-terminus of full length β3 or β3 core (Chen et al., 
2004). The big N-terminal fragment of CFP (a.a. 1-158) was fused to the N-terminus of G 
protein gamma 2 (Gγ2). Gγ2 plasmid was bicistronic with mCherry using the internal 
ribosome entry signal from IRES-2 (Clontech). This red signal was used for both 
selection of transfected cells and calculation of the cyan BiFC to red ratio. Plasmids 
encoding CaV2.2, Bdel1 or Bdel2 (250 ng), α2δ-1 (250 ng), full length β3 or β3 core (100 
ng), Gβ2 (250 ng) and Gγ2-mCherry (100 ng) were transiently transfected into HEK-293 
cells. After 18 hrs the cells were plated onto polylysine-treated glass bottom dishes 
(Fluorodish, World Precision Instruments, Saratoga, FL). Transfected cells were 
identified by their red fluorescence. Their red and cyan fluorescence signals were 
collected using the Olympus microscope (40x objective, 2x2 binning) described below. 
Digital images were background subtracted using a region devoid of cells, and the ratio 
of cyan to red signal for each cell was calculated. Following the method of Shyu et al. 
(Shyu et al., 2006), BiFC specificity was determined using the median of the CFP/RFP 
signal for each condition. Images of live cells were collected using a Cooke Sensicam QE 
(Romulus, MI) mounted on an Olympus BX61WI equipped with an Olympus confocal 
spinning disk unit (Melville, NY).  
 
ata analysis 
 
D
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After the onset of the test pulse, maximal whole-cell inward current amplitude 
was measured using Signal 2.16 (CED). Percent change in current amplitude was 
measured as [(I-I’)/I]*100 where I is the average amplitude of peak current measured 
from 5 current traces prior to drug application and I’ is the average current amplitude 
measured from 5 current traces at least 90 s after application of quin. BiFC data were 
acquired and analyzed using IPLab 4.0 (Scanalytics, Fairfax, VA) as described previously 
(Vitko et al., 2007). 
 are presented as mean ± s.e.m (standard error of the mean). 
Average current amplitude before and after application of quin was compared using a  
two-tailed paired t-test. Two means were compared using a two-way Student’s t-test. 
Statistical significance was set at p<0.05 or p<0.01. Data were analyzed using Excel 
(Microsoft, Seattle, WA) and Origin (OriginLab, Northampton, MA). Statistical analysis 
of fluorescent images was performed using one-way ANOVA with the Kruskal-Wallis 
post test using GraphPad Prism. 
 
Statistical Analysis 
 Summary data
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RESULTS 
 
Quin inhibits wt CaV2.2 current via a voltage-dependent pathway. 
 
We hypothesized that a specific orientation of CaVβ2a relative to CaV2.2 (Fig 
5.2A) is critical not only for regulating the channel’s gating properties (Vitko et al., 
submitted) but also for voltage-dependent modulation of N-current. To first recapitulate 
voltage-dependent inhibition of N-current by D2R activation, we applied 300 nM quin to 
HEK-M1 cells transfected with CaV2.2, α2δ-1and CaVβ2a. Application of quin inhibited 
the CaV2.2/β2a currents by 53 ± 12% (n=4; p<0.05; Fig 5.2B & C). Inhibition was 
significantly relieved following a depolarizing prepulse (p<0.01). To rule out any 
possibility of a Ca2+-sensitive diffusible second messenger pathway mediating inhibition 
of CaV2.2/β2a currents, we dialyzed cells with a high concentration of BAPTA (20 mM) 
to chelate intracellular Ca2+ (Beech et al., 1991). In the presence of 20 mM BAPTA, quin 
still inhibited currents by 60 ± 4% (n=4; p<0.05; Fig 5.2E & F). Moreover, with 20 mM 
BAPTA, inhibition was significantly relieved following a prepulse (p<0.05).  
One of the hallmarks of N-current inhibition by the membrane-delimited pathway 
is a slowed rate of current activation. As with membrane-delimited inhibition, the slowed 
activation kinetics are abolished with a strong depolarization (Bean, 1989). To confirm 
that N-current inhibition by quin occurs via a membrane-delimited pathway similar to 
previous observations (Page et al., 1998; Stephens et al., 1998; Canti et al., 1999), we 
tested whether N-current inhibition involves a decrease in activation kinetics, detected as 
a change in time to peak inward current (TTP). As shown in Fig 5.2D, following 
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application of quin, there is an upward trend for TTP. However, with a strong 
depolarizing pulse, TTP significantly decreased (p<0.05; n=6). The above properties of 
N-current modulation are consistent with D2Rs inhibiting CaV2.2/β2a currents via a 
membrane-delimited, voltage-dependent pathway.  
 
Relief of tonic inhibition is disrupted with deletions in the IS6-AID segment. 
 The orientation of CaVβ relative to CaV2.2 subunit was earlier shown to be critical 
for CaVβ to regulate activity of CaV2.2 channels (Vitko et al., submitted). They found that 
with one or two amino acid deletions in the IS6-AID segment, CaVβ's ability to increase 
the open probability of the channels was lost; so was the ability to regulate the channel’s 
activation and inactivation kinetics. While CaVβ is thought to regulate the movement of 
the IS6 with voltage thereby regulating the channel’s inactivation (Hering, 2002), an 
altered orientation of CaVβ was proposed to affect the coupling between movements of 
the voltage sensor of IS4 to movements of IS6 thereby affecting how CaVβ modulates the 
channel’s voltage sensitivity (Vitko et al., submitted). Since Gβγ increases the latency to 
N-channel opening (Dolphin, 2003), we wondered whether the relative orientation of 
CaVβ is also critical for voltage-dependent relief of tonic Gβγ-mediated inhibition of 
CaV2.2. To determine the optimal relation between prepulse voltage and facilitation, we 
measured CaV2.2/β2a currents after varying the prepulse voltage from -40 mV to +120 
mV in 20 mV increments (Fig 5.3A). We compared the profile of CaV2.2 with Bdel1 and 
Bdel2 mutants, each co-expressed with CaVβ2a and α2δ-1. A depolarizing step to 0 mV 
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(P2) produced facilitation of wt CaV2.2 currents (P1) that steadily increased with voltage 
before reaching a maximum prepulse value of +120 mV. In contrast, Bdel1 and Bdel2 
currents showed no prepulse facilitation (Fig 5.3B). We also tested the dependence of 
facilitation on test pulse voltage by varying the test pulse voltage from -20 to +20 mV in 
10 mV increments (Fig 5.3C). Facilitation of wt CaV2.2 currents was apparent over the 
voltage range -20 to +20 mV. In contrast, the dependence of facilitation on test pulse 
potential was lost for both Bdel1 and Bdel2 currents (Fig 5.3D, 5.4).  
 
Deletion mutants retain Gβγ binding to the CaVβ subunit. 
 To determine whether the loss in facilitation was due to a loss of the close 
association of Gβγ and CaVβ at the AID in Bdel mutants, we used bimolecular 
fluorescence complementation (BiFC) analysis to detect interactions between Gβγ and 
either CaVβ3 core or the full length CaVβ3. Our results show that significant fluorescence 
occurs when wt CaV2.2, Bdel1 or Bdel2 is present while little fluorescence occurs in the 
absence of an α1 subunit (Fig 5.5). Experiments where either CaVβ3 core or full length 
CaVβ3 are expressed with different α1 subunits show similar fluorescence profiles, 
consistent with our observation that the close association between Gβγ and CaVβ is 
retained in the deletion mutants.  
 
Deletion mutants disrupt voltage-dependent modulation by D2 receptors. 
Since Bdel1 and Bdel2 exhibited disruption in relief from tonic inhibition, we 
tested whether voltage-dependent modulation by quin was similarly disrupted. We 
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predicted that by disrupting the relative orientation of the CaVβ subunit, Bdel1 and Bdel2 
would no longer show voltage-dependent inhibition by quin, matching the profile 
observed with tonic prepulse facilitation. We found that Bdel1 and Bdel2 show disrupted 
current modulation as well as disrupted relief of tonic Gβγ inhibition (Fig 5.6 and 5.7). 
Co-expression of Bdel1 with CaVβ2a (Bdel1/β2a) yielded currents that rapidly 
inactivated and showed no prepulse facilitation (Figs 5.6A, B & F). Application of quin 
elicited no current inhibition (Fig 5.6A & B). To confirm that the loss of inhibition was 
not due to disruption in the interaction of Bdel1 specifically with CaVβ2a, we co-
expressed Bdel1 with CaVβ3. Again, application of quin caused little prepulse facilitation 
(Fig 5.6D-F) or inhibition (Fig 5.6D, E) of N-current.  
 To determine whether a further change in the orientation of CaVβ (Fig 5.7A) 
would recover current modulation, we tested the Bdel2 mutant. Application of quin 
strongly inhibited the current (Fig 5.7B, C); however, depolarizing prepulses did not 
relive the inhibition (Fig 5.7C, D).  
 
Inhibition of Bdel2 currents by quin is voltage-independent and not mediated by the 
slow, diffusible second messenger pathway. 
Inhibition of native or recombinant N-current by two other GPCRs, the tachykinin 
NK-1 and M1 muscarinic receptor involves a voltage-independent, lipid-dependent 
pathway often referred to as the slow pathway (Chapters II, III and IV; (Shapiro and 
Hille, 1993; Liu and Rittenhouse, 2003b, 2003a; Bannister et al., 2004). We hypothesized 
that the voltage-independent inhibition of Bdel2 currents described in Fig 5.7 might 
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involve a similar lipid-dependent pathway. To test this possibility, we employed two 
different strategies. First, we applied quin in the presence of BSA, which will scavenge 
any free fatty acid that may be released after receptor activation (Liu and Rittenhouse, 
2003a).  Second, we dialyzed 20 mM BAPTA into cells to chelate intracellular Ca2+ and 
minimize N-current modulation by the slow pathway. In the presence of BSA or 20 mM 
BAPTA, application of quin still inhibited Bdel2 currents (59 ± 5% and 54 ± 3% 
respectively (Fig 5.8).  
DISCUSSION 
Inhibition of CaV2.2 channels by D2R involves a membrane-delimited pathway 
Here using a mammalian cell line, we show that in HEKM1 cells, inhibition of 
CaV2.2/β2a currents by D2R stimulation occurs via a voltage-dependent pathway that 
does not involve a Ca2+-sensitive diffusible second messenger pathway. These findings 
are similar to previous studies performed by the Dolphin lab where they found that co-
expression of CaV2.2 with CaVβ2a along with α2δ and D2R resulted in inhibition of N-
currents by quin in Xenopus oocytes. Inhibition was voltage-dependent and relieved by a 
large depolarizing prepulse (Page et al., 1998; Stephens et al., 1998; Canti et al., 1999). In 
contrast, D2R activation by quin inhibits N-currents in neostriatal neurons via a 
membrane-delimited pathway; this inhibition is voltage-independent and not relieved by 
a depolarizing prepulse (Yan et al., 1997). D2R activation causes release of AA in 
neurons (Kanterman et al., 1991; Caccavelli et al., 1992; Schinelli et al., 1994). These 
observations suggest that D2Rs may also couple to Gq proteins and their activation 
stimulates a lipid-dependent pathway similar to other GqPCRs such as M1 muscarinic and 
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NK-1Rs (Chapters II, III; Liu and Rittenhouse, 2003a). However modulation of 
recombinant CaV2.2 channel activity by D2Rs does not appear to involve a BAPTA-
sensitive, lipid signaling pathway (Page et al., 1998; Stephens et al., 1998; Canti et al., 
1999) (unpublished data from Mandy Roberts-Crowley). Consistent with recombinant 
data dialyzing a high concentration of BAPTA (20 mM) into striatal neurons to chelate 
intracellular Ca2+ did not affect inhibition of peak currents elicited from non-L-type 
channels (Hernandez-Lopez et al., 2000). These findings suggest that different Gβγ 
subunits may interact with native N-channels to mediate a BAPTA-insensitive, 
membrane-delimited pathway since earlier studies demonstrated that the amount of N-
current facilitation observed is dependent on not only the CaVβ subunit expressed but also 
which Gβγ subunits were present (Meir et al., 2000; Feng et al., 2001). 
 
Changing the relative orientation of CaVβ affects Gβγ-mediated inhibition as well as 
prepulse relief of the inhibition 
 Having shown that D2R modulation of N-current is membrane-delimited, we 
tested the role of CaVβ2a in regulating the properties of membrane-delimited inhibition. 
Previous studies have shown that CaVβ and Gβγ compete with each other for binding to 
α1 subunits (Tedford and Zamponi, 2006). The presence of a CaVβ subunit increases the 
peak current as well as causes a hyperpolarizing shift both in channel activation and 
inactivation. On the contrary, the presence of a Gβγ subunit decreases peak current and 
causes a depolarizing shift in the activation curve (De Waard et al., 2005; Tedford and 
Zamponi, 2006). In the absence of CaVβ, channels undergo increased G-protein mediated 
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inhibition as if the absence of a competing CaVβ facilitates Gβγ binding to the AID 
(Campbell et al., 1995; Roche et al., 1995; Bourinet et al., 1996). However, conflicting 
evidence also showed that the presence of CaVβ, in fact, promotes Gβγ-mediated 
inhibition (Meir et al., 2000). Because this study was done in a different expression 
system as compared to the other studies, it is difficult to reconcile the latter data with 
previous evidence. While a number of possibilities, such as displacement or steric 
hindrance of CaVβ by Gβγ, could account for the observation it is clear that a competition 
exists between CaVβ and Gβγ for binding to the AID region (De Waard et al., 2005; 
Tedford and Zamponi, 2006).  
Additionally, the role of CaVβ in prepulse-induced relief of Gβγ-mediated 
inhibition is well documented (Tedford and Zamponi, 2006) where with depolarization, 
CaVβ seems to compete with Gβγ and regain its binding to the AID. The presence of 
CaVβ subunits not only  increases the rate of prepulse facilitation, but depending on the 
subtype of CaVβ and Gβγ subunits that are co-expressed, the “off” rate for Gβγ also 
varies (Roche and Treistman, 1998; Canti et al., 2000; Meir et al., 2000; Feng et al., 
2001). These data further support the theory of competition between CaVβ and Gβγ in 
prepulse relief of membrane-delimited inhibition. 
Our data support that a model where competition existing between Gβγ and 
CaVβ2a for binding to the AID region may underlie voltage-dependent modulation of N-
current by GPCRs. Specifically, the disruption in the relative orientation of CaVβ2a to 
CaV2.2 disrupts the competitive relationship between Gβγ and CaVβ. In the presence of 
quinpirole, currents elicited from wt CaV2.2/β2a channels show inhibition that can be 
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relieved by a prepulse, while Bdel2/β2a currents show inhibition which is not relieved by 
a prepulse. Imaging data in Chapter IV indicate that CaVβ maintains close proximity to 
both Bdel2 and Gβγ at the plasma membrane. This finding rules out the possibility that 
the loss of prepulse facilitation arises from dissociation of CaVβ from Bdel2. It is possible 
that with a change in orientation, CaVβ loses a key interaction site with Bdel2 and is thus 
incapable of sensing the electric field and displacing Gβγ during a depolarizing prepulse. 
Alternatively, it is also possible that new constraints imposed upon CaVβ from its 
palmitoyl groups tethered to the plasma membrane, while assuming a different 
orientation relative to Bdel2, restricts CaVβ from displacing Gβγ.  
The palmitoyl groups of CaVβ2a contribute to the slowed inactivation kinetics of 
wt CaV2.2 currents (Olcese et al., 1994; Qin et al., 1998) possibly by interacting with the 
inactivation machinery (Hering, 2002). This interaction appears disrupted in Bdel1 and 
Bdel2 since the currents inactivate more rapidly than CaV2.2/β2a currents (Vitko et al., 
submitted). The palmitoyl groups require a specific orientation for modulating N-channel 
activity (Chapter IV) and possibly also for regulating channel inactivation (Vitko et al., 
submitted). Thus, the mutations in Bdel1 and Bdel2 cause CaVβ2a’s palmitoyl groups to 
orient differently and hence the profiles of fast inactivation are also strongly affected. 
With the Bdel1 mutant channels, the lack of inhibition that accompanies changes 
in inactivation may be another manifestation of competition between CaVβ and Gβγ. 
Imaging data in Fig 5.5 confirm that CaVβ and Gβγ are in close proximity. This proximity 
depends on the presence of CaV2.2 thereby ruling out the possibility that inhibition does 
not occur because Gβγ cannot come in close proximity with Bdel1 or CaVβ due to the 
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changed orientation arising from the mutation. There could be multiple explanations for 
the lack of inhibition of Bdel1/CaVβ2a currents. First, the amino acid deletion in Bdel1 
may cause a reorganization of the helical structure of the AID that disrupts CaVβ’s ability 
to couple with AID and increase channel open probability (Po) (Vitko et al. submitted). 
Hence, with low Po, N-channels are already effectively “inhibited” and Gβγ can no longer 
confer inhibition when quinpirole is applied. Second, it is possible that due to a change in 
the orientation of CaVβ2a, it no longer competes with Gβγ for binding to the AID. Hence 
tonic inhibition is never relieved with a prepulse and because it is not relieved, no further 
inhibition occurs. Third, due to the mutation in the IS6-AID segment, the Gβγ that binds 
to the AID may reside in closer proximity to its higher affinity interaction sites such as 
the carboxy terminus (De Waard et al., 2005). As a consequence, the increased strength 
of interaction between Gβγ and Bdel2 no longer allows Gβγ to be displaced by CaVβ2a 
during a prepulse. 
 
Voltage-independent inhibition of Bdel2/β2a currents does not involve the slow 
pathway 
Inhibition of Bdel2/β2a currents is BAPTA-insensitive and was unaffected by the 
presence of BSA, indicating that this form of inhibition is distinct from the slow pathway 
inhibition that was earlier characterized for N-current in neurons (Beech et al., 1991; 
Bernheim et al., 1991; Mathie et al., 1992; Liu and Rittenhouse, 2003a). Voltage-
independent inhibition of N-channel activity by GPCRs couple to PTX-insensitive G 
proteins such as Gq (Hille et al., 1995), G13 (Wilk-Blaszczak et al., 1994), Gs or Golf  
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(Surmeier et al., 1995). This rules out the possiblity that keeping all other conditions 
unchanged, by deleting the two amino acids in the AID region, there is a switch to a 
different G-protein isoform, such as Gq, that mediates the inhibition. Thus, we conclude 
that the resulting change in orientation of CaVβ2a that arises from the mutations in Bdel2 
is sufficient to place CaVβ2a out of the electric field and render it incapable of 
participating in prepulse-relief of inhibition. 
Previously we showed that CaVβ2a assumes a specific orientation relative to 
CaV2.2 so that the palmitoyl groups may interact with an inhibitory site on the channel to 
block voltage-independent inhibition by the slow pathway (Chapter IV). The orientation 
of the palmitoyl groups may also be critical for enabling CaVβ2a to interact with regions 
of the N-channel that slow inactivation (Qin et al., 1998). Moreover, palmitoylation may 
orient low-affinity interaction sites of CaVβ2a to facilitate their interaction with the 
channel; these low-affinity interaction sites may facilitate movement of CaVβ during 
depolarization (He et al., 2007). By deleting one or two amino acids, as in Bdel1 and 
Bdel2, the disruption in voltage-dependent modulation could disrupt a) the interaction of 
the palmitoyl groups of CaVβ2a with the α1 subunit b) interaction of the low affinity sites 
on CaVβ2a with the α1 subunit c) the competitive relationship between Gβγ and CaVβ2a 
for binding to the AID.  
 In summary, our data support previous observations that CaVβ is necessary for 
voltage-dependent inhibition of N-current. Although, the exact role of CaVβ in voltage-
dependent inhibition remains incompletely elucidated, we conclude that the precise 
orientation of CaVβ at the AID region allows rapid voltage-dependent inhibition and its 
 
 138
relief by a prepulse. Voltage-dependent, membrane-delimited inhibition of presynaptic 
N-channels by GPCRs, such as the opioid receptor, regulates Ca2+ entry into nerve 
terminals thus providing relief from pain (Altier et al., 2006). While channel subtypes, 
accessory subunit composition and membrane potential contribute to regulating 
membrane-delimited inhibition (Tedford and Zamponi, 2006), our study raises the 
possibility that N-channel mutations may underlie disrupted structural and functional 
properties of voltage-dependent modulation when no other discrepancy in receptor, 
ligand or signaling pathway is clinically obvious. Dysfunction of Ca2+ channels underlies 
several neuronal diseases such as migraine and epilepsy. It is possible that mutations that 
change the structure of key regions of the Ca2+ channels, such as in the AID, may cause 
more subtle changes in channel function, but could severely impact the channel’s 
response to agonists released during neural activity. 
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Figure 5.1 Membrane-delimited modulation involves Gβγ binding to CaV2.2 (A) 
Schematic representation of Gβγ binding to CaV2.2 following D2R activation. The I-II 
linker connects domain I and II of the N-channel. The CaVβ and Gβγ bind to overlapping 
sites at the AID region. (B) Flowchart showing the signaling cascades by which 
quinpirole may modulate CaV2.2. (C) I-II linker sequences for wt CaV2.2, Bdel 1 and 
Bdel 2 show where the amino acid deletions were made within the IS6-AID segment. 
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Figure 5.2 D2R inhibits recombinant CaV2.2 currents via a voltage-dependent pathway. 
HEK cells were transiently transfected with wt CaV2.2, α2δ−1, β2a and D2R. (A) 
Working model of the Cav2.2 channel with an associated β2a subunit.  β2a’s palmitoyl 
groups are shown as two white dots. (B, E) Individual traces taken before (con) and after 
application of 300 nM quin using (B) 0.1 mM or (E) 20 mM BAPTA. P1 represents 
current before a prepulse and P2 represents current measured after a prepulse. Scale bars 
always represent 200 pA on the Y-axis and 0.024 s on the X-axis. (C, F) Summary of the 
inhibition due to quin before and after prepulse in the presence of (C) 0.1 mM BAPTA 
(n=4; **p<0.01) and (F) 20 mM BAPTA (n=4; **p<0.01). (D) Summary of TTP before 
and after application of quinpirole (n=6, *p<0.05). 
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Figure 5.3 Deletions in the IS6-AID segment disrupt voltage-dependence of current 
facilitation. (A) Voltage protocol to determine dependence of facilitation on prepulse 
potential. The depolarizing pulse was increased from -40 mV to +120 mV with 20 mV 
increments. Individual sweeps representing P1 and P2 obtained by stepping to indicated 
test potentials. Dashed line represents sweep following a prepulse to -40 mV; solid line 
represents sweep following a prepulse to +120 mV. (B) Facilitation ratio (P2/P1) was 
plotted against prepulse potential for wt (○), Bdel1 (◊) and Bdel2 (▲). (C) Voltage 
protocol to determine dependence of facilitation on test potential. The test potential was 
increased from -20 mV to +40 mV with 10 mV increments. (D) Facilitation ratio for each 
prepulse was plotted against test pulse potential for wt (○), Bdel1 (◊) and Bdel2 (▲).  
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Figure 5.4 Tonic facilitation of currents is lost as observed in current voltage profiles (A) 
CaV2.2/β2a (○) (B) Bdel/ β2a (◊) (C) Bdel2/ β2a (▲). P1 indicated by closed symbols, 
P2 indicated by open symbols; n-3-4 per group. 
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Figure 5.5 Interaction of Gβγ and CaVβ is dependent on α1 subunit expression. (A, D) 
Images of representative cells obtained with bimolecular fluorescence complementation 
(BIFC) assay illustrate the close association of Gβγ with (A) β3 core or (C) full length β3 
with no α1 or in the presence of wt CaV2.2, Bdel1 or Bdel2. (B, E) Histogram 
representing CFP/RFP ratio for wt CaV2.2, Bdel1 and Bdel2 in the presence of (B) β3 
core or (E) full length β3. Summary of BIFC specificities obtained with (C) β3 core or 
(F) full length β3. n=94-138.  
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Figure 5.6 A single amino acid deletion in the IS6-AID segment disrupts inhibition and 
its relief by a prepulse. HEK-M1 cells were transiently transfected with D2R, Bdel1, 
α2δ−1, β2a (B, C) or β3 (E, F). (A) Working model where the single amino acid deletion 
in CaV2.2 (Bdel1) disrupts the orientation of β2a relative to Bdel1. (B, E) Individual 
sweeps taken before (con) and after application of 300 nM quin. (C, F) Summary of 
current inhibition by quin before and after a prepulse (n=5-6; NS denotes not significant). 
(D) Summary of facilitation ratio for wt with β2a (●), Bdel1 with either β2a (■) or β3 
(**p<0.01; n=4-6 per group). 
 
  
147
0
20
40
60
80
 
P2%
 In
hi
bi
tio
n 
by
 q
ui
n
P1
0
20
40
60
80
 
P2
%
 e
nh
an
ce
m
en
t b
y 
qu
in
P1
D.
B. E.
C. F.
100°
β2a
Bdel1
A.
β2a
con
quin
P1 P2
+120
-90
0 mV 0 mV
β3
quin
con
P1 P2
+120
-90
0 mV 0 mV
0.0
0.5
1.0
1.5
2.0
P
2/
P
1 
ra
tio
NS
NS
** **
%
 In
hi
bi
tio
n 
by
 q
ui
n
%
 e
nh
an
ce
m
en
t b
y 
qu
in
P
2/
P
1 
ra
tio
P
2/
P
1 
ra
tio
 
 148
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-80
-60
-40
-20
0
20
 
%
 c
ha
ng
e 
by
 q
ui
n
0
20
40
60
80
P2
%
 In
hi
bi
tio
n 
by
 q
ui
n
P1
* **
A.
B. D.
200°
Bdel2
β2a
C.
con
quin
P1 P2
+120
-90
0 mV 0 mV
%
 c
ha
ng
e 
by
 q
ui
n
%
 In
hi
bi
tio
n 
by
 q
ui
n
 
 
 
Figure 5.7 Current modulation by D2Rs is partially restored in Bdel2 channels. (A) 
Working model of Bdel2 where the orientation of β2a relative to Bdel2 is partially 
restored. β2a’s palmitoyl groups are indicated by the two white dots. (B) Individual 
traces taken before (con) and after application of 300 nM quin. (C) Summary of N-
current inhibition by quin before and after a prepulse. D) Summary of N-current 
inhibition before (filled) and after (open) a prepulse for wt (●), Bdel1 (■) and Bdel2 (▲); 
n=4-6 per group. *p < 0.05, **p< 0.01. 
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Figure 5.8 Inhibition of Bdel2 current by quin is voltage-independent but not mediated 
by a free fatty acid. (A) Individual traces taken after preincubation with BSA in the 
before (solid) and after (dashed) application of 300 nM quin. (B) Summary of current 
inhibition due to quin in the presence of BSA before (P1) and after (P2) a prepulse (n = 5 
per group; *p < 0.05 compared to control current amplitude before and after a prepulse). 
(C) Example traces and (D) summary of mean current inhibition by quin with 20 mM 
BAPTA in the pipette solution (n = 5 pergroup, *p<0.05 compared to control peak 
currents before and after a prepulse). 
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CHAPTER VI: 
 
Discussion 
 
 
In this thesis, I have studied the modulation of N-channels by NK-1R and the role 
of CaVβ subunits in determining which form of modulation dominates. I have used a 
recombinant system to study N-channels in isolation without having to pharmacologically 
block other channels. I have summarized my key findings and discussed their functional 
implications at the cellular and molecular level and where appropriate, in terms of pain 
therapy. I have also discussed key outstanding questions that remain and what 
experiments I would do in the future to try to answer them. Lastly, I summarize my 
vision of how I could imagine CaVβs serving as a therapeutic target for treating 
neuropathic pain.   
 
1) The slow pathway mediates N-current modulation by SP 
 
Rapid turnover of phospholipids upon stimulation of pancreatic slices by 
acetylcholine was first observed in the 1950s (Hokin and Hokin, 1953). Although it is 
well known that prostaglandins and other metabolites of AA released during pain and 
inflammation are important inter- and intracellular signaling molecules (Hannun and 
Obeid, 2008), the role of AA as a signaling molecule mediating N-current modulation has 
not been readily accepted (Delmas et al., 2005; Michailidis et al., 2007). Consequently 
the actions of AA on neuronal calcium channel functioning are not understood 
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mechanistically. Therefore, as my first question, I used a pharmacological approach in 
Chapter II to examine whether inhibition of N-current by SP involves phospholipid 
breakdown by the slow pathway. I tested antagonists against components that appear to 
participate in slow pathway modulation of N-channel activity by other GPCRs such as 
the M1R (Liu and Rittenhouse, 2003). My findings are consistent with ERK1/2, PLA2 and 
a free fatty acid, most likely AA, participating in N-current inhibition by NK-1Rs (Fig 
6.1). These findings link SP and the inflammatory signaling that normally occurs during 
pain  to N-channel modulation. Recently, the enzyme diacylglycerol lipase was shown to 
be necessary for modulation of N-current by M1R (Liu et al., 2008) in addition to PLC 
and PLA2 (Liu and Rittenhouse, 2003a). Hence it is possible that this lipase and other 
enzymes are also involved in modulation of N-current by NK-1Rs. The data in Chapters 
II-IV indicate that as with M1R signaling, NK-1Rs utilize the same signaling cascade to 
modulate N-current. 
The requirement of several phospholipases for N-current inhibition (Liu and 
Rittenhouse, 2003a; Gamper et al., 2004) suggests that N-channel modulation arises from 
a coordinated breakdown of phospholipids occurring in close proximity to the channel. A 
proximal location of the enzymes and precursors could provide specificity and efficiency 
of signaling. An example of enzyme location optimizing function is diacylglycerol lipase, 
which synthesizes 2-arachidonoyl-glycerol from diacylglycerol (Bisogno et al., 2003). 
Diacylglycerol lipase is specifically targeted to the neck and not the body of postsynaptic 
spines in cerebellar Purkinje neurons. Its location ensures that diacylglycerol in spines 
can activate protein kinase C sufficiently before its rising concentration reaches the neck 
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of the spine and undergoes metabolism to yield 2-arachidonoyl-glycerol (2AG). Once 
synthesized, 2AG will diffuse into the synaptic cleft away from the postsynaptic 
membrane where it rapidly binds to presynaptic cannabinoid receptors ensuring efficient 
retrograde signaling (Yoshida et al., 2006).  
The involvement of phospholipid metabolism in N-current modulation by SP 
comes as no surprise, given the role of the enzymes phospholipase A2, C and D in pain 
and inflammation (Steed and Chow, 2001; Svensson and Yaksh, 2002; Drdla and 
Sandkuhler, 2008). However, identifying the specific components of this Gq signaling 
pathway that act on N-channels is an important step forward in understanding the 
possible molecular changes occurring during pain transmission because, given the 
diversity of signaling molecules, not all GPCRs modulate ion channels the same way. For 
example, bradykinin is a key mediator of inflammatory responses and its receptor 
activation leads to activation of PLC, PLA2 and release of diacylglycerol (Farmer and 
Burch, 1992). Yet, bradykinin modulates Ca2+ currents by a pathway distinct from M1Rs 
or NK-1Rs (Wilk-Blaszczak et al., 1994; Delmas et al., 2002; Gamper et al., 2004).  
Interestingly, despite overlapping downstream signaling molecules with muscarinic 
agonists and SP, bradykinin’s receptor couples to a G13-coupled receptor (Wilk-
Blaszczak et al., 1994). These findings suggest that perhaps the G-protein is critical in 
creating signaling microdomains that then determine the enzymes contained within it. My 
studies predict that other receptors, which couple to Gq, also should utilize the same 
pathway to modulate N-current. This possibility is supported by findings that angiotensin 
II also inhibits N-current in SCG neurons via a diffusible messenger (Shapiro et al., 
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1994b). Moreover, these GPCRs should not only modulate N-current in peripheral and 
spinal neurons but also in the brain wherever Gq-coupled receptors are found (Stewart et 
al., 1999).   
 
Future Direction: What is the role of cPLA2 in shaping an action potential in dorsal 
horn neurons?  
My findings were collected using recombinant N-channels. Could one of the 
enzymes, for example cPLA2, discussed in Chapter II participate in modulation of Ca2+ 
currents when SP is released onto the dorsal horn neurons? Moreover, how would the 
modulation of Ca2+ currents affect the shape of the action potentials in the dorsal horn? 
To answer these questions, I would generate action potentials by injecting current into 
dorsal horn neurons before and after applying SP. I would then compare the action 
potential profiles from wild-type neurons with similar recordings from dorsal horn 
neurons isolated from cPLA2-/- mice. I would expect cPLA2 to be important in 
modulation of Ca2+ currents in the dorsal horn neurons. I would predict that while SP 
application in the neurons from wt mice would affect the action potential duration and/or 
frequency of action potentials, these parameters would be unaffected in neurons from 
cPLA2-/- mice. Unpublished data from Dr. Liwang Liu indicates that SCG neurons from 
the cPLA2-/- mice display unanticipated hyperexcitability in control conditions. Whether 
adding back cPLA2 would restore the membrane excitability remains untested.  
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2) CaVβ subunit expression determines whether enhancement or inhibition 
dominates N-current modulation 
In Chapter III, I extended the observation made by Dr. John Heneghan in his 
thesis that modulation of N-channels by M1R changes from inhibition to enhancement 
depending on which CaVβ subunit is co-expressed, by testing whether a similar profile of 
modulation is observed when stimulating NK-1Rs with SP. Whereas inhibition is 
observed with CaVβ3, I found that N-current enhancement occurs when the palmitoylated 
CaVβ2a is present (Fig 6.1). Additionally, I advanced our understanding of how CaVβ2a 
appears to block inhibition to reveal enhancement. From studies with mutated and 
chimeric CaVβ subunits we showed that block of inhibition required palmitoylation of 
CaVβ2a and I discovered that free palmitic acid is sufficient to block N-current inhibition 
by SP. These findings suggest that the palmitic acids are necessary and sufficient for 
blocking inhibition. 
While the role of CaVβ was earlier conceived as being confined to regulating the 
channel’s expression and kinetic properties, separation of inhibition and enhancement 
based on the subtype of CaVβ that is co-expressed with CaV2.2 identified a new role for 
CaVβ in channel modulation by the slow pathway. Biophysical and biochemical studies, 
presented in Chapter V, indicate that N-current enhancement occurs via the same 
pathway that mediates inhibition, but it is not clear whether enhancement occurs via a site 
that is located on the channel or on the CaVβ subunit.  
While direct interaction of AA with specific sites on N-channels has been 
proposed as a mechanism for channel modulation, this direct interaction could occur at an 
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extracellular site, an intracellular site or within transmembrane regions (Meves, 2008). N-
current enhancement by exogenous AA occurs faster than inhibition, indicating two 
different sites of action (Barrett et al., 2001). In the presence of BSA in the bath, both N-
current inhibition and enhancement by Oxo-M are lost (Liu and Rittenhouse, 2003a). 
Internal dialysis of SCG neurons with BSA eliminates inhibition when Oxo-M is applied 
and application of arachidonoyl coenzyme AA, an AA analog that cannot cross the cell 
membrane, mimics enhancement but not inhibition (Barrett et al., 2001). These four 
experiments suggest that enhancement occurs extracellularly or within the outer leaflet of 
the membrane while inhibition occurs intracellularly or within the inner leaflet. Alterna-
tively the enhancement site could be within the inner leaflet, but exhibit higher affinity 
for AA such that residual AA that remains in the presence of BSA or that accompanies 
the arachidonyl CoA, but crosses the cell membrane, can act at the internal site.  
Both internal and external sites of action have been observed for K+ channel 
modulation by AA (Ordway et al., 1991).  For example, in a study examining the effects 
of AA on the transient K-current IA, an internal inhibitory site was proposed since 
intracellular application of a low concentration of AA (1pM) inhibited IA while a 106-fold 
increase in AA concentration was required when applied extracellularly (Bittner and 
Muller, 1999). An explanation for this observation is that, when a higher concentration of 
AA was applied extracellularly, the AA must cross the cell membrane to interact with the 
inhibitory site for inhibition to occur. The existence of an inhibitory site for AA on N-
channels is further revealed in the finding that exogenous palmitic acid can block this 
inhibition (Chapter III), most likely by occupying this same site. Determining the exact 
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location of the regions of N-channels that confer enhancement and inhibition should 
provide a detailed, molecular understanding of how the modulation occurs. 
 
Future direction: Is the interaction of CaVβ subunits with CaV2.2 subunits dynamic? 
I would be very interested in determining whether the distribution of CaVβ2a and 
CaVβ3 subunits changes during conditions of neuropathic pain. The ratios of CaVβ 
subunits expressed in individual neurons have not been studied in any brain region. By 
performing immunocytochemistry on dorsal horn tissue samples from animals before and 
after nerve injury, a change in the subunit ratio could be measured acutely and over a 
period of days. The findings should be quite relevant to pain management because the 
CaVβ expression pattern should determine whether inhibition or enhancement of N-
current occurs in the presence of SP. In turn the change in N-current is predicted to alter 
neuronal firing; in other words, CaVβ subunit expression should affect membrane 
excitability. The possible contributions of the two different CaVβ subunits to membrane 
excitability will be discussed below in a later section.  
 
3) Role of palmitoylation in N-channel modulation 
From the studies in Chapter III, I realized that by further understanding the role of 
palmitoylation in N-channel modulation, I could gain mechanistic insight on how NK-
1Rs inhibit N-current. Therefore in Chapter IV, I tried to determine whether the palmitic 
acids might be interacting with CaV2.2 to somehow disrupt N-current inhibition by SP. I 
tested mutant N-channels where CaVβ2a associates with CaV2.2 in a different orientation 
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(Vitko et al., submitted). I found that while current enhancement occurs with CaVβ2a 
expression with wt channels, deletions in the IS6-AID segment that change CaVβ2a’s 
orientation in relation to CaV2.2, result in current inhibition by the slow pathway. While 
changing CaVβ2a’s orientation still allows it to bind to mutant N-channels, the data seem 
to indicate that with a sufficient change in orientation, the palmitoyl groups acquire a new 
position whereby they no longer block N-current inhibition when SP is applied. Thus, 
inhibition dominates N-current modulation. I cannot yet claim to completely understand 
what causes current enhancement. However, the data in Chapter IV give an image of a 
missing key, palmitic acid in this case, which when absent (as in CaVβ3) or displaced 
(when CaVβ2a associates with Bdel2), allows current inhibition, and when added back in 
the form of free palmitic acid can block inhibition. The data also show for the first time 
that in addition to the subtype of CaVβ subunit that associates with N-channels, it is also 
the orientation of the CaVβ subunit that determines the form of modulation observed 
following exposure to SP. When SP is applied, Bdel2/CaVβ2a currents do not show 
current enhancement even when palmitic acid is added back, hence it is possible that the 
determinants of current enhancement (discussed below) are present in CaVβ2a; however 
since its orientation is changed compared to when it is associated with wt CaV2.2, the 
enhancement site(s) also is not available.  
The novel role of palmitoylation as an antagonist of lipid signaling raises 
questions about an unanticipated role for palmitoylation in the pain pathway. While 
palmitoylation of CaVβ2a is a dynamic process (Hurley et al., 2000), inhibiting palmitoyl 
acyltransferases by the nucleoside antibiotic, tunicamycin, causes neuronal growth cones 
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to collapse within 10 mins of application (Patterson and Skene, 1994). This effect can be 
reversed by application of exogenous palmitic acid indicating a role for palmitoylation in 
neurite extension and axon regeneration. This leads one to wonder whether the palmitoyl 
acyltransferase could be specifically up- or down-regulated during neuropathic pain. 
Regulation of palmitoyl acyltransferases may be a mechanism to regulate neuronal 
excitability by changing the levels of palmitoylated proteins including Cavβ2a. 
Preliminary experiments indicate that besides N-channels, dorsal horn neurons also 
express CaVβ2a and CaVβ3 subunits as early as postnatal day 3 (Fig 6.2). Could a 
toggling of N-channel modulation by dynamic palmitoylation of CaVβ subunits be 
observed at this stage of development? Answers to these questions await future studies. 
 
Future Direction: Where are the enhancement and inhibitory sites located? 
While the sites for current modulation are still not known, two potential sites are 
along the S6 segments of CaV2.2, which line the channel’s pore forming an inverted 
tepee, and the variable D2 region of CaVβs- both of which have been implicated in 
regulating channel inactivation. I am interested in this question because finding an 
inhibitory site would not only help in better understanding the modulation of CaV2.2, but 
it would also establish CaV2.2 as a lipid-binding protein. Mutating residues in the S6 
region possesses the risk of destabilizing the tepee but careful amino acid substitutions 
may help in overcoming the challenge. Of particular interest is a key asparagine residue 
in the S6 region that is conserved among NaV and CaV channel families (Fig 6.3a). This 
N406S mutation is a mutation in NaV1.5  that contributes to aberrant electrocardiograph 
 
 159
patterns in Brugada syndrome, also known as Sudden Unexpected Death Syndrome 
(Brugada et al., 2005). The asparagine residue is part of a sequence of amino acid 
residues that is highly conserved in both Na+ and Ca2+ channel families (Fig 6.3b). 
Mutation of this residue to serine in the cardiac voltage-gated Na+ channel, NaV1.5, 
accelerates inactivation kinetics. Compared to wt channels, in the presence of a fatty acid, 
the mutant channels show faster recovery from inactivation, less current inhibition and 
enhancement of current (Xiao et al., 2001; Itoh et al., 2005; Itoh et al., 2007). Hence it 
seems that while the S6 region is important for inactivation (Hering et al., 2000), it could 
also be important for current inhibition by fatty acids. 
I am particularly curious about the role of CaVβ2a in current enhancement. If the 
palmitoylated CaVβ2a blocks inhibition revealing latent enhancement, is there a structural 
component of the CaVβ subunit that promotes enhancement? As pointed out earlier, a 
determinant of N-current enhancement could be present in the CaVβ2a subunit. One 
region of interest  that could be easily tested is a variable D3 region which is longest in 
CaVβ2a compared to CaVβ1b, CaVβ3 and CaVβ4 (Birnbaumer et al., 1998). This D3 
region, also referred to as the HOOK region (Fig 6.4) connects the two highly conserved 
SH3 and guanylate kinase (GK) domains of the CaVβ subunits and is usually involved in 
interaction of membrane-associated guanylate kinases with other proteins (Chien et al., 
1998; Hanlon et al., 1999; Chen et al., 2004; Opatowsky et al., 2004; Van Petegem et al., 
2004). Coincidentally, enhancement of current was observed with a peptide containing 
the SH3-HOOK-GK region (De Waard et al., 1994). But since an artificial peptide 
generated from a shift in the reading-frame of the SH3-HOOK-GK region when dialyzed 
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into Xenopus oocytes also caused current enhancement, the enhancement was considered 
to be a non-specific effect due to lack of a mechanistic explanation (Chen et al., 2004) . 
However, increase in current was also seen when a peptide containing CaVβ’s GK 
domain but not when the SH3 and GK regions from PSD95 were co-expressed in the 
oocytes (Chen et al., 2004). With careful analysis, it is possible that the HOOK region by 
itself or together with the SH3 and GK domains indeed contributes to current 
enhancement.  
One way to test the involvement of the SH3-HOOK-GK region is to use the 
recently published CaVβ2a mutants that lack the SH3, GK or the connecting HOOK 
region (Dresviannikov et al., 2008). If enhancement of CaV2.2 current is lost in the 
presence of one of these mutant CaVβ2a subunits, one could focus on the deleted 
sequence as a potential site for enhancement. It would be interesting to see whether all 
the CaVβ subunits share the same sequence or if the site is unique to CaVβ2a. In any case, 
discovery of a site on CaVβ2a that contributes to current enhancement would be a key 
finding since most studies tend to focus on N-current inhibition. Yet, current 
enhancement at sub-zero membrane potentials is crucial when cells undergo short 
depolarizations during a postsynaptic potential or an action potential, such as during 
transmission of nociceptive information. On the other hand, if the inhibitory site for AA 
can be identified, it would potentially offer opportunities to develop novel strategies to 
manage pain, injury and stroke, where the impetus would be on developing drugs that 
target the inhibitory site to prevent uncontrolled modulation by AA.  
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4) Moving CaVβ2a’s orientation alters membrane-delimited inhibition 
In chapter V, I have shown that CaVβ’s normal orientation to CaV2.2 is necessary 
to observe both membrane-delimited inhibition and relief of this inhibition following a 
depolarizing pulse. The data in this chapter serve as a control for the data in Chapter IV 
because it shows that CaVβ2a’s orientation is not only important for modulation via the 
slow pathway but also for a different form of modulation of N-current, the membrane-
delimited inhibition. These findings suggest that CaVβ’s orientation with the wt CaV2.2 
allows it to move with the electric field during a step depolarization. This movement 
serves to displace Gβγ and thereby relieve N-current inhibition. When CaVβ’s orientation 
to CaV2.2 is changed as with Bdel1 or Bdel2, CaVβ can no longer harness the kinetic 
energy of CaV2.2’s movements or the electrical field across the cell membrane to 
“budge” Gβγ and hence inhibition is maintained. What the data in this chapter does not 
clarify is how the altered orientation alters the voltage-dependence of inhibition; but it 
does provide the insight that altered orientation of CaVβ disrupts CaVβ’s ability to 
dislodge Gβγ during positive test pulses. As with Chapter IV, the way to move this 
forward conceptually would be to determine whether the palmitic acids of CaVβ2a 
directly interact with CaV2.2 as described above. Tethering CaVβ2a to CaV2.2 may 
efficiently couple CaVβ-subunit movement to positive shifts in voltage. Indeed, when 
comparing the effectiveness of CaVβ subunits, the greatest prepulse facilitation of 
inhibited current is observed with CaVβ2a (De Waard, 2005).   
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Final comments on the role of SP and Ca2+ channel in neuropathic pain  
Neuropathic pain arises from damage to nerve fibres which are located either 
peripherally or in the dorsal root (Zieglgansberger et al., 2005) and may occur following 
disease or surgery. In animal pain models, peripheral neurons show increased membrane 
excitability after nerve injury that results in hyperalgesia (intense pain) or allodynia 
(increased response to normally innocuous stimuli) (Hogan, 2007). DRG neurons show 
prolonged action potential duration, decreased amplitude and duration of 
afterhyperpolarization and decreases in high-voltage activated Ca2+ currents following 
nerve injury.  
Influx of Ca2+ is tightly coupled to Ca2+-sensitive K+ channels, which generate 
IK(Ca2+) that underlies the afterhyperpolarization in many neurons (Fig 6.5a). Thus loss of 
Ca2+ currents, which could arise from inhibition of Ca2+ currents by SP, following nerve 
injury causes decreased outward IK(Ca2+) and reduces the amplitude and duration of 
afterhyperpolarization (Fig 6.5b). These changes would be predicted to increase neuronal 
firing rates. A prolonged action potential is likely to release more neurotransmitter (such 
as SP) at the synapse between DRG and dorsal horn neurons while reduced afterhyper-
polarization increases membrane excitability and burst firing. Increased rate of firing of 
dorsal horn neurons in response to nociceptive inputs is one of the mechanisms that leads 
to central sensitization of neurons that causes hyperalgesia (Campbell and Meyer, 2006). 
Increased burst firing increases nociceptive transmission via secondary neurons in the 
dorsal horn. However, after peripheral nerve injury, a reduction in SP immunoreactivity 
and an increase in NK-1R immunoreactivity in dorsal horn neurons (Malmberg and 
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Basbaum, 1998) could be an indication of increased downstream signaling leading to 
increase in ion channel modulation. Thus if the expression of CaVβ2a subunits can be 
increased in spinal cord neurons pharmacologically or by gene manipulation, the released 
SP might elicit larger Ca2+ currents that will restore IK(Ca2+) and reduce membrane 
excitability (Fig 6.5c).  
While expression of ion channels changes with neuropathic pain, targeting 
individual CaVβ subunits may be unrealistic and pose a challenge for therapeutic 
management. Anti-convulsive drugs such as gabapentin and pregabalin, aimed at the α2δ-
1 subunit, are currently used to treat neuropathic pain (Galluzzi, 2007) despite uncertainty 
surrounding their exact mechanism of action. With the advent of RNAi technology, such 
selective targeting of CaVβ subunits could be used to restore membrane excitability and 
provide relief from neuropathic pain. Thus, future experiments using genetic knockout 
mice, such as cPLA2-/- (Bonventre et al., 1997) combined with cellular, molecular and 
pharmacological techniques will provide crucial answers regarding the role of N-current 
modulation by phospholipids, such as AA, in health and disease. 
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Figure 6.1 A working model of the signaling pathway involved in modulation of N-
channels by SP. SP either enhances or inhibits N-current depending on the CaVβ subunit 
that is co-expressed. The studies in this thesis indicate involvement of ERK1/2, cPLA2 
and free AA in N-current modulation by SP. The presence of a CaVβ2a subunit blocks 
inhibition when SP is applied and the net effect is enhancement of current. On the 
contrary, when a CaVβ3 subunit is present, inhibition predominates over enhancement. 
 
 165
 
Figure 6.2 Postnatal day 3 dorsal horn (DH) neurons express CaVβ2a as well as CaVβ3 in 
addition to CaV2.2 and NK-1R. Homogenized tissue samples were lysed in 0.8 ml TRIzol 
reagent (Invitrogen). After separating RNA from DNA using phenol-chloroform phase 
separation, RNA was precipitated using isopropyl alcohol and washed with 75% ethanol. 
After drying, the RNA pellet was dissolved in RNase-free water. Subsequently, reverse 
transcription was carried out using 1.0 μl 10X buffer RT, 1.0 μl dNTP mix (5 mM each 
dNTP), 1.0 μl Oligo-dT primer (0.5 mg/ml), 0.125 μl RNase inhibitor (40 U/μl, 
Promega), 0.5 μl Omniscript Reverse Transcriptase and RNase-free water to make up a 
total volume of 10 μl (all reagents from QIAGEN, Valencia, CA unless otherwise noted). 
The mixture was incubated at 37ºC for 1 h. The mixture was then heated at 93ºC for 5 
min followed by cooling on ice to rapidly inactivate the transcriptase. Aliquots of RT-
PCR product were amplified by PCR using the following primers: α1B: 5’-CAC ATG 
CCA ACG CCA GCG AAT G-3’ and 5’-GAC AGG CCT CCA GGA GCT TGG TG-3’ 
(633 bp product) (Lin et al., 1996), NK-1R: 5’-AGG ACA GTG ACC AAT TAT TTC 
CTG G-3’ and 5’-CTG CTG GAT GAA CTT CTT-3’ (668 bp product) (Goto et al., 
2007) and β2a:  5’- ATA ACC ACA GAG AGG AGA GCC ACA-3’ and 5’-TAT ACA 
TCC CTG TTC CAC TCG CCA-3’ (258 bp product) and β3 5’- TCC CTG GAC TTC 
AGA ACC AGC AG-3’ and 5’- TTG TGG TCA TGC TCC GAG TCC TG-3’ (368 bp) 
(Lin et al., 1996). Reaction mixtures for PCR contained 2 μl template cDNA, 2.5 μl 10X 
Buffer, 0.5 μl dNTP mix, 2 μl each of forward and reverse primer and made up in 
distilled water to a final volume of 25 μl. The protocol for amplification was 94°C for 4 
mins, followed by 33 cycles of 94 °C for 45 secs, 60 °C for 45 secs, 72 °C for 1 min and 
held at 72 °C for 10 mins for last extension. PCR products were run on 1.8% agarose gel 
stained with ethidium bromide along with 1000 bp DNA ladder (Fermentas Life 
Sciences). Postnatal day 3 SCG neurons serve as a positive control for the presence of 
NK-1R, CaV2.2 and CaVβ2a.  
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LILAVVA  415 (N406)
rCav1.2  411  PWVYFVSLVIFGSFFVL LVLGVLS  435 (N428)
rCav1.3  382  PWVYFVSLIILGSFFVL LVLGVLS  406 (N399)
hCav1.4  348  PWVYFVSLVIFGSFFVL LVLGVLS  372 (N365)
rCav2.1  338  NWLYFIPLIIIGSFFML LVLGVLS  362 (N355)
rCav2.2  332  NWLYFIPLIIIGSFFML LVLGVLS  356 (N349)
rCav2.3  278  NWLYFIPLIIIGSFFVL LVLGVLS  302 (N295)
rCav3.1  371  NFIYFILLIIVGSFFMI LCLVVIA  395 (N388)
rCav3.2  395  NFIYFILLIIMGSFFMI LCLVVIA  419 (N412)
rCav3.3  372  NFIYFILLIIVGSFFMI LCLVVIA  396 (N389)
B.
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Itoh et al., J Cardiovasc Electrophysiol. 2005 Apr;16(4):378-83.  
 
Figure 6.3 The S6 region is an important site for channel modulation based on sequence 
comparison across Na+ and Ca2+ channels. (A) Schematic representation of the location of 
the human point mutation in the gene SCN5A that encodes the pore-forming α subunit of 
NaV1.5 channels. (B) A comparison of the homologous sequences from domain I S6 
region of NaV1.5 and CaV families. The conserved sequence of amino acids including 
asparagine could be a key site that mediates current inhibition by AA release during 
stimulation of the slow pathway since this residue confers fatty acid sensitivity to NaV1.5.    
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Adapted from Chen et al., Nature 2004 June; 429:675-680  
 
Figure 6.4 Schematic representation of the structural organization of CaVβ subunits. 
CaVβ subunits all share the homologous D2 and D4 domains that are placed inter-
mediately between the variable D1, D3 and D5 domains. 
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Figure 6.5 Schematic representation of altered membrane excitability that could occur in 
the presence of different CaVβ subunits. (A) Under normal conditions, influx of Ca2+ 
gives rise to an outward Ca2+-activated K+ current that contributes to the after-hyperpo-
larization following an action potential. (B) Upon nociceptive stimuli, released SP would 
modulate Ca2+ channel activity in the dorsal horn neurons by the slow pathway. If 
inhibition of Ca2+ currents occur due to the presence of CaVβ3 subunit expression, a 
decrease in Ca2+-activated K+ currents would shorten the afterhyperpolarization, lead to 
an increased rate of firing, and contribute towards hyperalgesia. This could explain the 
hyperexcitability that occurs in neuropathic pain. (C) Following treatment, if expression 
of CaVβ2a became predominant, the resultant N-current enhancement following release 
of SP would increase the Ca2+-activated K+ current, restore the afterhyperpolarization, 
and bring membrane excitability to pre-injury levels. 
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Adapted from Hogan Croat Med J. 2007;48:9-21  
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